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ABSTRACT

Today, in modem farming practices veterinary drugs are given to food-producing
animals. The generic term "veterinary drugs" covers a broad variety of classes of
chemical compounds and the list of drugs is enormous and it is a significant analytical
challenge in regulatory control to provide monitoring programmes. The major concerns
in veterinary drug usage are the presence of harmful residues that may be introduced into
the human food chain. The aim of this research is the development of analytical methods
capable of screening and confirming increased numbers of these residues in target
matrices by Gas Chromatography Tandem Mass Spectrometry (GC-MS/MS) and Liquid
Chromatography Tandem Mass Spectrometry (LC-MS/MS). The focus is on NonSteroidal Anti Inflammatory Drugs (NSAIDs) residues in food of animal origin. The
research resulted in the development and validation of methods for the analysis of
NSAIDs in milk. The second topic under investigation was in the field of post-mortem
forensic toxicology. Forensic toxicological activities are important in society and great
efforts to implement rapid analytical procedures in a forensically credible manner is
continuous across the globe. The main objectives of the research work in post-mortem
forensic toxicology were to address the issues concerning the availability of rapid novel
unequivocal confirmatory analytical methodologies for forensically important drugs. The
aim of this work was to develop single fast, simple and reliable sample preparation
procedures in blood and urine with detection by hybrid LC-MS as analytical strategies in
a forensic laboratory for the determination of drugs of abuse in this study which were
previously not available. All analytical methodologies developed in blood, milk and urine
matrices were validated in accordance with EU legislation; Commission Decision
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2002/657/EC. This validation legislation is concerned with the interpretation of results

and the performance of analytical methods. Validation criteria were examined using
protocols laid down in this legislation. These included specificity, accuracy, precision,
repeatability, reproducibility, decision limits (CCa), detection capabilities

(CC~)

and in

addition measurement uncertainty (MU). The methods developed for the NSAIDs
residues in milk had accuracies ranging from 73-109 % and the precision for all analytes
ranged from 2-30%. The CCa and the CC~ values ranged from 0.46-0.79 ng mL- 1 and
the MU ranged from 9-90%. The methods developed for the forensically important drugs
in blood and urine had accuracies ranging from 80-113% and the precision for all
analytes ranged from 4-22%. The CCa and the

CC~

values ranged from 0.005-0.05 ug

mL- 1 and the MU ranged from 13-47%. To ensure that methods were suitable for purpose
the methods were evaluated in international proficiency testing schemes and results were
satisfactory. In addition some of the methods were accredited in accordance with
IS017025 guidelines. A number of different analysts were trained on the new
methodologies developed in this work thus providing further evidence of the
development of rugged analytical methods and satisfactory results were obtained using
quality control material. In addition the methods have replaced previous methods in The
State Laboratory for the monitoring ofNSAIDs and are used routinely at present in the
Republic of Ireland in national monitoring programmes. The methods developed for
blood and urine in the forensic toxicology section of this thesis have replaced previous
methods in national forensic toxicology monitoring programmes in the past number of
years at The State Laboratory and are used in toxicology testing for the law courts in
forensic and Coroner's cases in Ireland. The method in this thesis for forensic drugs in
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blood is submitted for accreditation in 2012 as satisfactory results were obtained using
quality control and international proficiency test samples in the past number of years.
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CHAPTER 1: INTRODUCTION

1.1 Aims, Objectives and Relevance of this Research Work

1.1.1

Introduction

This research was carried out in The State Laboratory, Ireland. The role of the State
Laboratory is to provide expert scientific advice to government departments and other
clients. The laboratory is well equipped with advanced instrumentation to meet the
laboratories wide client base. A trend in the laboratory has been to introduce modem
techniques to replace current ones in order to introduce better efficiency. The efficiencies
gained can come in several different areas as the more modem technology may offer
greater sensitivity, allow for the use of more simplified extraction procedures, or
increases in sensitivity which may allow for detection of compounds not previously
detectable, allow for wider ranges of substances to be analysed in a single detection
protocol and in addition modem instruments will have computerised data systems which
can be integrated with laboratory information management systems (LIMs) sample
management technology. This can improve data transfer in order to speed up calculations
and improve sample reporting efficiencies to improve turn around times for clients. The
laboratory is also a National Reference Laboratory for Veterinary Drug Residues and
gives advice to the Department of Agriculture and other national laboratories performing
analysis on the National Veterinary Residue Control Plan. The research in this thesis was
carried out on the topic of non-steroidal anti-inflammatory drugs (NSAIDs) as the State
Laboratory is a National Reference Laboratory for these classes of veterinary drugs.
Therefore the thesis covers the veterinary drug residues field as the first topic for
investigation in order to improve monitoring at the laboratory for these drugs in Ireland.
As milk is a matrix that is directly consumed by the general public, careful consideration
should be given in .food safety to the possibility of veterinary drug residues.
The food safety issues concerning edible matrices and NSAIDs were studied.
-It was the purpose of the work carried out in this thesis to develop analytical strategies for
NSAIDs residues that were previously not available to meet legislative requirements.
The main objectives of the research work on veterinary drug residues described in four
separate chapters in this thesis were to address food safety concerning NSAIDS and
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edible matrices by developing new analytical strategies for the analysis of these
substances that were previously not available to regulatory laboratories and included;
•

The development of quantitative confirmatory Gas Chromatography Tandem
Mass Spectrometry method that meets EU target limits set for the analysis of
ibuprofen (lBP), ketoprofen (KPF), diclofenac (DCF) and phenylbutazone (PBZ)
in milk.

•

The development of a quantitative confirmatory method for the analysis of
firocoxib (FIRO) in milk using Rapid Resolution Liquid Chromatography
Tandem Mass Spectrometry.

•

The development of a rapid quantitative confirmatory method for the
determination of carprofen (CPF), diclofenac (DCF), mefenamic acid (MFN),
niflumic

(NIFLU),

naproxen

(NAP),

oxyphenylbutazone

(OXYPHEN),

phenylbutazone (PBZ) and suxibuzone (SUXI) in milk using Rapid Resolution
Liquid Chromatography Tandem Mass Spectrometry.
•

The development of an analytical strategy for the determination of six NSAIDs in
bovine plasma and an improved analytical strategy for the simultaneous
determination of authorised and non authorised residues of ten NSAIDs in milk
by liquid chromatography tandem mass spectrometry.

•

To adopt the criteria governing method validation for these substances according
to Commission Decision 2002/657IEC.

•

To apply these methodologies to routine analysis and implement into the National
Reference Laboratory in Ireland for NSAIDs.

The thesis covers the field of post-mortem forensic toxicology as the second topic for
investigation in order to improve monitoring at the laboratory for forensically important
drugs. The State Laboratory provides a toxicological service to the Coroner's of Ireland.
The work described in this thesis involved developing new methods in order to improve
the toxicological service to the Coroner's of Ireland. Work was undertaken in order to
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evaluate newer technology to improve overall analysis time in the laboratory and expand
the classes of drugs for analysis. The second topic in this thesis covers the improvement
of toxicological analyses in the post-mortem forensic toxicological field to give
confirmatory results on the absence or presence of drugs and their metabolites. To help
address the issues of obtaining rapid post-mortem forensic toxicology analytical results,
the development of rapid analytical methods in blood and urine matrices in particular was
focused on as the subject matter of this thesis targeting opioids, cocaines and
amphetamine drugs. The availability of such analytical strategies would allow results to
be given to Irish Court system, An Garda Siochana and families of the deceased more
efficiently. Forensic toxicological activities are important in society and great efforts to
'implement rapid analytical procedures in a forensically credible manner is continuous
across the globe. The main objectives of the research work on post-mortem forensic
toxicology were to address the issues concerning the availability of rapid, novel,
unequivocal confirmatory analytical methodologies for forensically important drugs. The
'aim of this work was to develop single fast, simple and reliable sample preparation
procedures in blood and urine with detection by hybrid LC-MS as analytical strategies in
a forensic laboratory for the determination of drugs of abuse which were previously not
available. Areas focused on were the following;

•

To adopt the criteria governing method validation for forensically important
substances according to Commission Decision 2002/657/EC as an alternative
validation protocoL

•

To develop a hybrid liquid chromatography mass spectrometry strategy in a
forensic laboratory for opioid, cocaine and amphetamine classes in human
unne.
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•

To develop a new mixed mode solid phase extraction strategy for the
determination of opioids, cocaines, amphetamines and adulterants in human
blood.

•

To apply these methodologies to routine analysis and implement into the
National Confirmatory Laboratory in Ireland for Post-Mortem Forensic
Toxicology in Ireland to replace traditionally used GC-MS techniques.

•

The methods will be used routinely to establish the cause of death based on
requests from the medical examiner, the coroner or the pathologists in Ireland.

1.2 Veterinary Drug Residue Issues in Foods for Human Consumption

1.2.1

Introduction

Today, in modern farming practices veterinary drugs are given to food-producing
·animals. The generic term "veterinary drugs" covers a broad variety of classes of
chemical compounds and among these, for example include non-steroidal antiinflammatory drugs (NSAIDs) quinolones,

p-Iactams, macrolides, lincosamides,

sulphonamides, tetracyclines, antiparasitic agents such as anthelmintics or coccidiostats,
p-agonists, nitrofurans and nitroimidazoles. However the list is enormous and it is a
significant analytical challenge in regulatory control to provide monitoring programmes.
The presence of pharmacologically active chemicals in a food-producing animal can give
rise to the occurrence of residues in food. This is an important issue in the food safety
area. The major concerns in veterinary drug usage are the presence of harmful residues
that may be introduced into the human food chain. In addition ingestion of antibiotic
.drugs could cause residues that aid the development of antibiotic resistant pathogens. In
the ED this food safety problem has been dealt with by providing legislation for
veterinary drug residues in food. [Mitchell et aI., 1998]. The inability to meet legislative
requirements in relation to levels of residues in food could have severe results for the
nation concerned. There is also on-going public interest in relation to drug residues in
food worldwide due to more intense methods of animal husbandry. There is concern over
the environmental impact of the agricultural practices and concern over animal welfare.
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The global demand for animal products is projected to increase considerably due mainly
to the increase in population. Predictions for the future growth of the population vary but
a United Nations report in 2008 states that the world population will exceed 9 billion in
2050 UN 2008 [UN 2008].

In 2009 the Food and Agriculture Organisation (FAO)

released a report entitled "The State of Food and Agriculture" which highlights that since
the 1960's consumption of milk per capita in the developing countries has almost
doubled, meat consumption more than tripled and egg consumption increased by a factor
of five [FAO 2009]. Trends showed that developing countries have responded to growing
demand for livestock products by rapidly increasing production. Between 1961 and 2007,
the greatest growth in meat production occurred in East and Southeast Asia, followed by
Latin America and the Caribbean and most of the expansion in egg production was in
East and Southeast Asia, while Southeast Asia dominated milk production [FAO 2009].
The increase in productivity has been as a result of a combination of factors such as
advanced breeding and feeding technology, the use of hybridisation and artificial
insemination accelerating the progress of genetic improvement, improvements in feed
technology and improvements in animal health technology including the use of vaccines
and antibiotics. The bulk of livestock produce is consumed generally within a country of
production and does not enter international trade but for some countries livestock produce
exports are important. Contamination of livestock products nationally and internationally
from Asia and Latin America with veterinary drug residues can be the cause of
·international trade interventions leading to a loss of revenue for the exporting countries
[Mitchell et aI., 1998].
Veterinary therapeutic products are generally used in livestock production for one of
three purposes [National Research Council 1999].

1. Therapeutic treatment of active infection.
2. Vaccination or prophylactic medication to prevent or to minimise infection.
3. Production enhancement-growth promotion and improvement of feed
conversion efficieRcy with antimicrobial drugs and hormones.

6

1.2.2

Improper or illegal use of veterinary drugs

The incidence of residues in food, in violation of the levels set down in legislation, can
occur in a variety of circumstances. These infringements result from either the
inappropriate use of licensed products or the illegal use of unlicensed and prohibited
substances [Kennedy et aI., 2000]. A number of situations contribute to the improper use
of licensed products, including, poor treatment records or failure to recognise treated
animals and use of a drug other than as described on the product label. Residues occur
chiefly by not observing sufficient withdrawal periods before slaughter of animals. As
long as a licensed drug is used in accordance with its product licence and as long as the
drug withdrawal periods are respected by farmers, drug residues should not occur in
human food at concentrations exceeding the maximum residue limits (MRLs).
Deliberate use of prohibited drugs can occur for the following number of reasons which
includes: the use of certain banned compounds that can be very efficient at controlling
particular infections eg nitrofurans or banned compounds that can be very cheap and
readily available e.g. phenylbutazone (PBZ) and the use of growth promoting hormones
in order to enhance the weight of animals. Prohibited compounds such as PBZ which
were once authorised but now banned. PBZ is widely used in the equine industry making
it readily available [Dodman et aI., 2010].
Cross contamination in feed mills is also another circumstance in which high levels of
residues could potentially occur in food [Kennedy et aI., 2000]. Trace quantities of
medicated feed may be retained at various points along the production line,
contaminating subsequent batches of feed as they are processed. The electrostatic
properties, especially those of some drugs in powder form, exaggerate the problem,
making it more complicated to purge the equipment between batches. Manufacturers
·have produced granular formulations with reduced electrostatic properties in reaction to
this. The electrostatic properties of the drug nicarbazin (NCB) caused problems during
the manufacture ofNCB-free feeds, since NCB powder is strongly electrostatic and could
not be removed from feed milling equipment. [Canavan et aI., 2000]. NCB is a widely
used coccidiostat drug, which is licensed as a feed additive for broiler chickens, but not
Jor laying hens. There is a predicament in many countries world-wide with the incidence
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of NCB residues in poultry tissues and eggs. Canavan et aI., [2000] have reported a
proportional relationship between the concentration of 4,4'-dinitrocarbanilide (DNC) and
4,6-dimethyl-3-hydroxypyrimidine (DHP) in eggs, the two marker residues for NCB, and
the feed levels. Feed contaminated with NCB at concentrations higher than 2 mg kg

-I

gave rise to residue concentrations ofDNC in eggs higher than 100 Ilg.kg-I. Yakkundi et
aI., [2002] designed an experiment to establish the relationship between halofuginone
(HFG) in contaminated feed and HFG residues in eggs. HFG is used to treat coccidiosis
also and has been registered as an anticoccidial feed additive for broiler hens and turkeys.
In general the HFG concentration was much lower than those seen in similar studies on
NCB. However comparison of the HFG concentrations measured in eggs and the MRL
for HFG in bovine muscle suggested that feed contamination could give rise to
potentially significant HFG residues in eggs. The study also showed that depletion of
HFG from eggs was slower compared to NCB and lasalocid [Yakkundi et aI., 2002].

1.2.3

Environmental contamination

Commercial fish fanning could be another source of potential contamination where
veterinary drugs or other contaminants, which have been given as feed additives,
accumulate in sediments and may become ingested by marine species in the vicinity of
farms [Kennedy et aI., 2000]. The presence of drug residues may pose a health risk, if
these wild species are harvested for human consumption. Murata et aI., [2011] carried
out a nationwide monitoring study of antibiotics in Japan. The antibiotics targeted in the
study were sulphonamides, trimethoprim and macrolides. The results showed that the
signals of the veterinary antibiotics were overwhelmed by those of human antibiotics in
the lower reaches of most rivers. The concentrations were higher in urban rivers and were
dominated by macrolides which were derived mainly from urban sewage although larger
amounts of veterinary antibiotics are used in livestock. The authors postulate that lower
concentrations of livestock antibiotics were found as livestock derived waste is unlikely
to be readily discharged directly to surface waters. Nonetheless the threat posed by these
residues is unknown. Other groups have found livestock waste caused antibiotic
.contamination of water supplies with veterinary drugs [Yang et aI., 2003, Lissemore et
aI., 2006 and Wei et aI., 2011].
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1.2.4

Animal-to-animal transfer

Recycling of drugs due to ingestion of faeces and/or urine considerably contributes to the
levels and persistence of residues in porcine tissues, poultry tissues and eggs [Kennedy
et aI., 2000, Cannavan et aI., 2000]. Short-lived contact of unmedicated animals to the
excretions of medicated animals in improperly cleaned accommodations during transport
or in the slaughter house can result in high residues levels.
Canavan et aI., [2000] identified tenfold higher NCB values in the liver of broiler
chickens treated with this drug and accommodated on flooring where litter can collect
compared with those housed on wire flooring. Total exchange of the litter was the only
way to stop the recycling by the birds.

1.3 The Risks to Human Health

1.3.1

Toxicity and allergenicity

A huge number of antibiotic and anthelmintic drugs administered in therapeutic and subtherapeutic forms to domesticated species are also approved for use in humans. Acute and
chronic toxicity studies have been evaluated and shown these drugs to be reasonably safe
.[National Research Council, 1999]. The possibility of acute toxicity from veterinary
drugs and their metabolites derived from animal tissues is exceptionally small. On the
other hand the likelihood of chronic toxicity expressed in long-term, collective allergenic,
mutagenic, teratogenic or carcinogenic effects is not easy to assess.
As a result veterinary drugs with a high probability to cause one or more of these toxic
effects were banned by the EC for veterinary use in order to protect human health.
Phenylbutazone (PBZ) is a NSAID that was authorised for administration in the United
States for the treatment of rheumatoid arthritis and gout in 1952. Severe and often fatal
adverse effects such as aplastic anemia and agranulocytosis appeared in the literature
within a period of three years of its usage [Benjamin et aI., 1981, Bottiger et aI., 1973,
Cameron et aI., 1966, Chaplin 1986, Br Med J. 1952, Dunn et aI., 1972, Etess et aI.,
1953, Hale et aI., 1960, Leonard et aI., 1953, Mauer et aI., 1955, McCombs et aI., 1958,
Nelson et aI., 1995, Ramsey et aI., 1976, Steinberg et aI., 1953]. Due to the bone marrow
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toxicity of PBZ, the Food and Drug Administration (FDA) set no safe levels for PBZ in
animals intended for food.
Chloramphenicol is another such compound which also causes toxic aplastic anaemia
that does not correspond to dosage. Residues of tetracycline can reversibly slow down the
growth of the skeleton and irreversibly tarnish the teeth of children younger than 8 years
as tetracyclines are deposited in bones and teeth. Sulfonamides have caused increasing
concern over their carcinogenic and mutagenic potential. Initially they had been used
widely at sub-therapeutic and therapeutic concentrations in food-animal production but
concerns have lead to decreased usage, longer withdrawal times and more intensive
residue monitoring.
There is potential for toxicity from benzimidazole anthelmintic drugs [DelatoUf et aI.,
1986]. Certain benzimidazoles are mutagenic, however the effect is low in mammals
even at high doses. A general property of benzimidazoles is teratogenicity and
teratogenic metabolites have been identified and quantified in animal products such as
milk, eggs and meat. For levamisole, the most significant of the adverse effects, which
are rare, were agranulocytosis and neutropenia [Heitzman et aI., 1998].
Therefore to protect human health, the EU has set up maximum residue limits (MRLs)
for residues of licensed veterinary drugs in animal tissues entering the human food chain.
The MRL may be defined as the maximum concentration of marker residue (e.g. parent
compound, metabolites etc) resulting from the use of a veterinary drug, expressed as
mg/kg, that is legally permitted or recognised as acceptable in or on a food [Mitchell et
aI., 1998]. The MRL is associated with the acceptable daily intake (ADI). This is an
estimate of the amount of a substance in food and/or drinking water, expressed on a body
weight basis that can be ingested daily over a lifetime without appreciable health risk to
the consumer on the basis of all the known facts at the time of the evaluation. It is
typically shown in milligrams of the chemical per kilogram of body weight. The ADI is
calculated from the no-observable-effect level (NOEL) taking into account a safety factor
(usually 100) [Grein et aI., 2000]. The NOEL is the greatest concentration or amount of a
substance, found by observation or experiment, which causes no detectable effect. The
maximum acceptable total residue level (TRL) is calculated from the ADI considering the
consumption pattern. The MRL is the detectable proportion of the marker residue that
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.corresponds to the TRL value. The MRL value refers to the permissible level for the
marker residue.
Besides conventional toxicological effects, other issues such as the effects of drugs on the
immune system and pharmacological effects together with specific effects of residues of
veterinary antibiotics on the human gut flora, should be evaluated when considering safe
residue levels [Boisseau et aI., 1993].
Besides toxicological problems, hypersensitive reactions from rJ-lactam (e.g penicillin)
antibiotic residues in milk and meat [Mitchell et aI., 1998, National Research Council,
1999] in sensitive individuals can occur.
Nonetheless, the risk to human health due to residues of veterinary drugs in foodstuffs
must be taken in perspective. Microbial contamination of food is a major health problem
worldwide. Infections of poultry products with Salmonella and Campylobacter are
greater risks to public health than are residues of veterinary drugs in food. An emerging
problem worldwide is the increasing prevalence of multi-drug resistant salmonella and
resistance to clinically important antimicrobial agents such as fluoroquinolones and third
generation cephalosporins [Brands et aI., 2005, Chao et aI., 2007, Chen et aI., 2007,
'Gebreyes et al 2005].
The public risks of antibiotics and their metabolites are difficult to define, and the
presence of high levels in food is illegal and subject to financial penalties in many
countries.

.1.3.2

Antibiotic resistance

Antibiotic resistance is a well documented major health threat around the world that has
been given high priority by many health agencies. A particular example is the Definitive
type 104 (DTI04) which was first recognised in the UK in 1984 [Threlfall et aI., 1996].
This phage has commonly exhibited resistance to five anti-microbial agents namely
ampicillin, chloramphenicol, streptomycin, sulfamethoxazole and tetracycline [Gebreyes
et aI., 2004, Rayamajhi et aI., 2008] Fluoroquinolones and third generation
cephalosporins are recommended for use where microorganisms are resistant to these
antibiotics [Hooper et aI., 19?1, Jacobson et aI., 1989, Karczmarcz et aI., 2010]. Recent
research has identified that this phage and other stereotypes can acquire additional
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resistance to fluoroquinolones and higher generation cephalosporins [easin et aI., 1999,
Fey et aI., 2000, Hsueh et aI., 2004, Weill et aI., 2006, Winokur et aI., 2000].
The widespread use of anti-microbial agents in the treatment of humans and animals and
also as growth promoting agents in livestock production has greatly promoted the
appearance of anti-microbial resistant bacteria [Araque., 2009, Gonsia et aI., 2011, Hur et
aI., 2011, Singh et aI., 2010]. In addition, the potential exists for

animal-to-human

transfer of the resistance.
Animals fed with low (prophylactic) levels of antibiotics may give rise to bacteria with
evolving resistance to these or other drugs. Humans may be exposed to these bacteria
through consumption of food. In order to ensure cautious use of antimicrobials in
livestock in the major production countries these nations have set up their own national
monitoring system such as European Antimicrobial Resistance Monitoring

system

[EARS-Net 2010], National Antimicrobial Resistance Monitoring System in the United
States [FDA 2010] and the Japanese Veterinary Anti-microbial Resistance Monitoring
system [JVARM 2009].

1.3.3

Technological problems

The preliminary worry in relation to antimicrobial residues in food were not expressed by
consumers but by dairy processors who identified that contaminated milk was inhibiting
the starter cultures used in the manufacture of fermented milk commodities as well as
'interfering with the dye reduction tests used for milk quality [Mitchell et aI., 1998].
Penicillin though not intrinsically toxic, can inhibit the fermentation process employed by
the dairy industry if the concentrations exceed the MRL [Tamime et aI., 1999]. Grunwald
et aI., [2003] showed that the presence of penicillin negatively affected yogurt
production. The sensitivity of thermophilic and mesophilic starter cultures for
manufacturing high-value fermented products such as cheese, yogurt, butter or raw
sausages, requires biotechnologically safe raw supplies.
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1.3.4 Effect of processing on residues
Most foods of animal origin are cooked (except milk and honey) before consumption but
none of the required studies for .licensed drugs evaluate the effect of processing on
residues. Infonnation about this influence is necessary to obtain more accurate estimates
of consumer exposure to residues or possible breakdown products. Several drug residues
during nonnal cooking and processing procedures were evaluated by Rose et al.,[1997].
Residues of levamisole were identified as being stable to heating, but a fraction was lost
from the meat into the juice. Studies also showed oxfendazole instability in boiling water
was found after 3 hours and heating of samples with incurred residues of oxfendazole
destroys the drug residues. Moats et al., [1999] reported that ordinary cooking procedures
for meat, even to "well-done" must not be depended upon to break the more heat
sensitive compounds such as penicillins and tetracyclines. Tarbin et aI., [2005] evaluated
the change in concentration of marker compound for the anti-coccidial drug nicarbazin,
N,N'-bis(4-nitrophenyl)urea (dinitrocarbanilide) (DNC), in model oil, aqueous solutions
and in chicken and egg. DNC residues in eggs were stable to microwave cooking and
residues in chicken muscle were stable to stewing and microwave procedures. Other
cooking procedures lead to a decreased amount of DNC and only minor amounts of
residues leached into juices. Javadi et aI., [2011] evaluated the effects of different
cooking processes such as boiling, roasting and microwaving on enrofloxacin (ENF)
residues in chicken muscle, liver and gizzard tissue from broiler chickens. The study
showed that ENF was reduced after different cooking processes. In cooked meat and
gizzard the most reduced levels of the residue were due to the boiling method. Cooked
liver residue levels were the most depleted due to the roasting process. The highest
residue levels remained after microwave cooking/heating. The relevance in food safety is
unknown as the nature of the degradation products is uncertain generally. The identity of
these degradation products should be established and their toxicity assessed. It would be
useful if data generated from surveillance of raw tissue for dietary intake calculations and
consumer exposure estimates be considered in the light of the effect of cooking on
veterinary drug residues.
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1.4

Legislative Aspects

1.4.1

Overview of EC Decisions, Council regulations and guidelines

The incidence of residues of veterinary drugs in food is an international dilemma. Foodproducing animals and animal products are transported within EU countries and between
EU countries and Third Countries. Much time and funds are spent by the EU to monitor
residues and harmonise European legislation in the control of residues. The inspection of
animals and of fresh meat for the presence of veterinary drug residues and specific
contaminants was regulated by the European Commission by Council Directive

86/469/EEC [1986]. Current national surveillance schemes monitor residues under
Council Directive 96/23/EC [1996] on measures to monitor certain substances and
residues thereof in animal products and under Commission Decision 97/747 IEC [1997]
which lays down l€?vels and frequencies of sampling in order to monitor some substances
and residues thereof in certain animal products. The EU Decision details the number of
samples to be analysed for each drug residue group. This directive gives an efficient and
reliable approach for the monitoring and control of illegal substances or inaccurate use of
authorised substances in animal products intended for human consumption within the EU.
With the purpose of enabling this harmonised approach a number of particular
requirements are noted in the text, these include:

1. Requirements related to the establishment and safeguarding of a network of EU
and national (Member State) reference laboratories.
2. Enforcement methods to be taken by Member States in the case of noncompliant
results.
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3. Designed sampling and analysis strategies, usually addressed as residue
monitoring according to national control plans.
4. Requirements related to the authorisation of imports of food of animal origin from
Third Countries that could contain residues.

Quality criteria for laboratory residue analyses are outlined in Commission Decision
93/256/EEC [1993] which states the methods to be used for detecting residues of
substances having a hormonal or thyrostatic action. Reference methods for the list of
National Reference Laboratories for detection of residues are outlined in Commission
Decision 93/257/EEC [1993].
The two decisions are revised on a regular basis in order to take into account the current
scientific information and the latest technological advances. A revised edition was
submitted by the Directorate General for Agriculture as a draft Commission Decision
SANCO/1805/2000 [2000] laying down performance criteria for the analytical methods
to be used for certain substances and residues thereof in live animals and animal products
according to Council Directive 96/23/EC [1996]. This draft article was revised and
enacted as Commission Decision 2002/657IEC [2002] implementing Council Directive
96/23/EC [1996] concerning the performance of analytical methods and the interpretation
of results. The establishment of MRLs in the EU is governed by Council Regulation
EEC/23 77/90 [1990] amended by several EC Regulations. This regulation establishes
details of compounds that have a fixed MRL (Annex 1), that need no MRL (Annex 11), or
that have a provisional MRL (Annex Ill).

Annex IV of this regulation is a list of

.compounds that are forbidden for use in livestock production. Annex V provides
information and the data needed to determine the MRL values. Annex 1 of this regulation
gives a list of substances that should be monitored in each EU member state. This
catalogue of substances is broken into two separate sections: Category A substances and
Category B substances. Category A substances are those whose use are partly or entirely
illegal in food producing animals, whereas Category B substances are those products that
are legal for use in food producing animals.
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In addition to the protection of consumers from the potential risk of harmful residues,
MRLs are also essential to smooth the progress of international trade. However, the
introduction of the MRL has a severe impact on the availability of veterinary medicinal
products. The data that must be generated is very complex requiring a huge number of
experiments and the costs involved must be borne by the pharmaceutical company. This
is because pharmaceutical companies that want to market their products must surrender
full dossiers to regulatory authorities so MRLs can be set. These dossiers outline
pharmacological and toxicological properties of their product. Most companies are wary
of carrying out such trials because of the financial implications of preparing and carrying
out such trials. Therefore compounds that may have been used in the past are now no
longer available. This may be forcing the use of un-licensed products. Since some
veterinary drugs are licensed for use in particular species only, farmers may use the
products in an off label manner by treating a different species. The danger of the
occurrence of residues in food when food producing animals are treated with un-licensed
products or with products used in an off-label manner, is substantial. As the risks
associated with this phenomenon potentially increase then consumer protection must be
the highest priority. The European Commission issued a precautionary principle based on
the Treaty of Amsterdam (Treaty of Amsterdam, 1997). A definition of this principle is
stated by Fisher et al 2006 "Where, following an assessment of available scientific
information, there are reasonable grounds for concern for the possibility of adverse
effects but scientific uncertainty persists, provisional risk management measures based on
a broad costlbenefit analysis whereby priority will be given to human health and the
environment, necessary to ensure the chosen high level of protection in the Community
and proportionate to this level of protection, may be adopted, pending further scientific
information for a more comprehensive risk assessment, without having to wait until the
·reality and seriousness of those adverse effects become fully apparent". In order for any
regulatory agencies internationally to be in a situation to implement consumer protection
a number of important factors need to be measured. A risk analysis needs to be carried
out on the types and concentration of residues occurring, reliable data on the consumption
of food types needs to be tabulated. In order to achieve reliable data and gain this
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information rapid, sensitive and rugged analytical methodologies need to be developed
and implemented in National Monitoring Plans in each nation.

1.5 Determination of Veterinary Drug Residues

1.5.1

Introduction

Analytical methods can be divided into screening, quantitative and confirmatory
procedures. In the case of screening methodologies, they should ideally be rapid, simple
to use and offer a positive or negative result for the test compound at a specified level.
Screening tools include rapid test kits such as microbial receptor, receptor binding, radio
or enzyme immunoassays used to monitor for veterinary residues. Screening
methodologies can present some difficulties as they are not always sensitive at the
required concentration (e.g. MRL), are often drug class and not compound specific and
do not give quantitative information. Therefore supplementary analytical tests are
required to determine if a sample is actually violative for an animal drug residue. Some
tests, such as immunoassays, provide semi-quantitative results.
Quantitative methods are designed to separate, quantify and provide some qualitative
information on the analyte of interest. Most gas and liquid chromatographic methods
would fall into this category. Quantitative assays classify samples as positive or negative
relative to specific drug concentration.
.Confirmatory methods provide unambiguous identification of the drug residue being
targeted. Due to its sensitivity and specificity, mass spectrometry is the preferred method
for confirmation of drug residues.

1.5.2

Screening assays

A screening assay makes a division between compliant and suspect samples i.e. samples
containing residues over an allowed limit. The most important requirement for a
screening assay is that it

yields very few false negatives, in essence the p-error

(possibility of false negative ~esult or a risk for the consumer) should be lower than 5%;
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some false positives are acceptable as these will show a negative result when a
confirmatory assay is performed.
The most basic methods used for detection of antimicrobial residues in food were based
on the detection of growth inhibition of various sensitive bacterial strains [Mitchell et al.,
1998]. The major disadvantages of these assays are that (i) they are not very definite for
identification purposes, (ii)

they are not quantitative and (iii) they have a limited

detection level for many antimicrobials. Besides, they are lengthy requiring several hours
before results are obtained. However they are cheap, easy to carry out, flexible for
screening large numbers of samples and they have a reasonably broad antimicrobial
detection spectrum.
The specificity of the immune system is demonstrated by its ability to distinguish subtle
differences between antigens. Immunoassays exploit this and examples of such tests are
enzyme-linked immunosorbent assays (ELlSA) and radioimmunoassays (RIA). Neogen
Corporation developed an ELISA Kit for ibuprofen [Biocompare.com]. Saini et al.,
[2012] analysed diclofenac using ELISA in liver samples from livestock carcasses.
FedMedco

developed

a

MaxSignal

Ketoprofen

ELISA

Kit

for

ketoprofen

[FedMedco.com]. Jackman et aI., [1996] described class specific enzyme immunoassays
for the determination of most benzimidazole drugs. For thiabendazole a compound
·specific ELISA had to be developed. Wang et al., [2011] developed an ELISA for the
determination of nitroimidazole in food products. Enzyme immunoassays are influential
tools for evaluating food products for the occurrence of veterinary drug residues. The
paybacks are high through-put of samples and low costs compared to instrumental
methods, however commercial kits can be expensive. Van der Made et aI., [2004] altered
·the sample preparation step of an enzyme immunoassay (RIDASCREEN ™
Acetylgestagene EIA of R-Biopharm) to provide an easier and quicker assay for the
detection of medroxyprogesterone acetate (MPA) in kidney fat. Another commercial kit
was tested (MPA ELISA of Euro-Diagnostica RV) in addition which showed poorer
sensitivity for MP A. The results identified that screening using the former kit in
.combination with a simplified extraction procedure gave rise to a reliable screening
method for the determination of MPA in kidney fat of pigs. With this test it was shown
that 30 samples could be analysed per day by one analyst. Ferguson et al., [2005]
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detected chloramphenicol and chloramphenicol glucuronide residues in poultry muscle,
honey, prawn and milk using a surface plasmon resonance biosensor and Qflex kit
chloramphenicol. Traynor et aI., [2003] detected multi-p-agonist residues in liver matrix
using surface plasma resonance biosensor. Peippo et al., [2004] described an easy and
rapid time-resolved fluoro immunoassay (TR-FIA) for the screening of narasin in poultry
plasma. Noot et al., [2004] described a surface plasmon resonance (SPR) based
immunoassay using the Biacore Q ™ SPR biosensor for multi-sulfonamide detection in
porcine muscle. Following a simple preparation, results for 40 samples are available in
just over five hours.

1.5.3

Confirmatory methods

1.5.3.1 Introduction
After samples have been analysed by a screening procedure and when certain samples
screen positive further

analys~s

by a confirmatory analytical method is required in order

to be unambiguously declared positive. Chromatographic methodologies play an
important role in the confirmatory tests for residues of veterinary drugs and
contaminants. There are numerous types of chromatographic methods currently in use for
residue analysis. These are categorised under thin layer chromatography (TLC), gas
chromatography (GC) and high performance liquid chromatography (HPLC). TLC has
been used, generally for screening or qualitative assays only. Most veterinary drugs are
non-volatile, polar, heat sensitive and or difficult to derivatise for GC. Therefore the
most widely used analytical technique in residue analysis is HPLC. For confirmatory
analysis chromatography with selective detectors is used commonly. Mass spectrometry
(MS) is the favoured detection method for confirmation. Hyphenated techniques such as
gas chromatography-tandem mass spectrometry (GC-MS-MS) and liquid
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chromatography-tandem mass spectrometry (LC-MS-MS) are the most authoritative
analytical tools in the analytical laboratory. On top of the general performance
requirements, supplementary stipulations are essential for confirmatory methods. These
comprise of the introduction of the concepts of identification points, defining criteria for
relative ion intensities and the setting of limits for relative retention times. For a method
to be deemed confirmatory, an exact number of identification points must be attained. For
confirming the presence of compounds categorised within Group A; at least four
identification points are required. For confirmation of substances within Group B; at least
three identification points are required. The number of identification points obtained by a
particular method depends on the determination technique employed. Tandem mass
spectrometry using a number of different triple quadrupole mass spectrometers operated
in multi reaction monitoring mode was used as the determination step for all veterinary
drug residue methods developed within the research carried as part of this thesis. This
technique is classified within 2002/657/EC [Commission Decision 2002] as being lowresolution mass spectrometry, when operated in multi reaction monitoring mode; it gains
one identification point for each precursor ion and 1.5 identification points for each
product ion monitored. So if two product ions are monitored; which result from one
precursor ion a total of 4 identification points are earned.
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1.6 Validation Of Analytical Methods For Use In Veterinary Drug Residue
Determination

1.6.1

Introduction

Within the EU, each member state is developing their own surveillance methods for
veterinary drug residues and these methodologies have to be validated to demonstrate
their reliability. The validation parameters to be considered for these analytical strategies
are described in: Commission Decision 2002/657/EC [2002] and they are: specificity,
linearity, trueness, precision, recovery, analytical limits, stability and ruggedness. The
criteria laid down in this

deci~ion

were followed during the validation procedures carried

out in this thesis. The legislation outlines how these parameters can be determined,
however it does not make it compulsory for labs to use these approaches; as outlined in
the document "Other approaches to demonstrate that the analytical method complies with
performance criteria for the performance characteristics may be used, provided that they
achieve the same level and quality of information".

1.6.2

Validation parameters

1.6.2.1 Specificity
The specificity describes the ability of the method to measure the analyte of interest in
the presence of other substances such as other analytes, metabolites and interferences in
the sample matrix.

1.6.2.2 Linearity
The mathematical relationship between the response and the concentration of the analyte
in the matrix must .be established.

.1.6.2.3 Trueness
This is a component of accuracy and is defined as the closeness of agreement between the
mean value measured for an analyte from a large series of test results in a CRM and its
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certified value, expressed as a percentage of its value. If no CRM is available, relevant
parameters may be evaluated using fortified sample material.

1.6.2.4 Precision
The precision, another accuracy component, is the closeness of agreement between the
results obtained by applying the experimental procedure several times under prescribed
conditions and covers repeatability, within laboratory reproducibility and inter-laboratory
reproducibility. The measure of precision is computed as standard deviation of the test
result.

1.6.2.5 Recovery
Matrix effects in biological samples can cause reduced signal of analyte during the
analytical procedure and can affect .the recovery or extraction efficiency. Non matrixrelated losses can occur due to the analytical procedure. If there is no CRM available to
calculate trueness, the recovery has to be determined by experiments using fortified blank
material. Whenever possible, incurred residue matrix material has to be used to optimise
the method to recover as much incurred material as possible.

·1.6.2.6 Analytical limits
The two analytical limits defined in Commission Decision 2002/657/EC [2002] are the
decision limit (CCa) and the detection capability (CCP)· The decision limit is the value
from which it can be concluded that a sample is truly violative with an error probability
of a. The a-error, which is the probability that the tested sample is not truly violative,
·even though a violative measurement has been obtained (false positive decision) shall be
1% or 5% or lower for banned and MRL compounds, respectively. In the case of banned
substances, CCa is the minimum concentration level at which a method can discriminate
with a statistical certainty of 1- a whether the identified compound is present. For
substances with an established MRL, CCa is the concentration above which it can be
·decided with a statistical certainty of I-a that the identified compound content is truly
greater than the MRL.
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The detection capability is the smallest content of a substance that may be detected,
identified and quantified in a sample with an error probability of p. The p-error, stated as
the probability that the tested sample is truly violative, even though a non-violative
measurement has been obtained (false negative decision), should be less than or equal to
5 %. In the case of banned substances, CCp is the minimum concentration at which a
method is able to truly detect residues in samples with a statistical certainty of I-p. For
substances with an established MRL, CCp is the concentration level at which the method
is able to distinguish MRL concentrations with a statistical certainty of I -po

SubslJnces for which no pemlined limit has been esrablished
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1,64 s.
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Standard Deviation of the contaminated sample

a

Rate of false non-compliant results

P

Rate of false compliant results

CCa

Response with a given a -error and 50% p-error
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CC~

Response with a very small a-error and ~-error

Figure 1-1: Illustrating CCa and CC~ taken from Commission Decision 2002/657/EC

1.6.2.7 Stability

The validation process should always include a study of the stability of the analyte or
matrix constituents in the sample matrix as well as the stability of the standard analyte in
solution. Whenever possible, incurred samples should be used to evaluate the stability in
the matrix material.

1.6.2.8 Ruggedness

Ruggedness is tested by a separate systematic experimental strategy. Pre-investigation
studies have to be carried out by selecting factors in the sample pre-treatment stage,
clean-up stage, instrument stage and analysis, which may control the measured results
·obtained. Such factors may include the operator, the reagents, the instruments and the
laboratory circumstances. The ruggedness of the method can be tested during
determination of the within-laboratory reproducibility as part of the method validation.

1.6.3

Residue monitoring

.Residue monitoring or surveillance strategies require the analysis of a huge number of
samples. Conventionally screening techniques, such as inhibitory substance tests and
irnmunoassays are used in residue laboratories. However multi-residue screening
methods are more useful. Screening methods reduce the quantity of samples requiring
more detailed analysis. Screening assays are an important part of the integrated approach
to residue monitoring. It is necessary to combine different methods in an incorporated
system in which a number of different tests are applied successively depending on the
targets or objectives of the analysis. For regulatory purposes such a strategy should
include at least two or more independent methods.
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•

Screening with a method optimised to prevent false negative results and with an
acceptable number of false positive results at a low cost (e.g microbial growth
inhibition tests).

•

Intermediate tests to identify the residue category.

•

Quantitative confirmation with an independent method optimised to prevent false
positive results.

1.7

Post-mortem forensic toxicology drug monitoring

1. 7.1

Introduction

The thorough investigation of the cause or sudden causes of death is a very significant
civic responsibility. Establishing the cause of death is based on the medical examiner, the
coroner or the pathologist arriving at an accurate conclusion which may depend on the
combined effort of the pathologist and the toxicologist utilising sound analytical
strategies. The cause of death in a poisoning cannot be proved beyond debate without
toxicological analysis that establishes the presence of the toxicant in the tissues and body
fluids. It is important to note that many drugs do not produce pathological lesions and
therefore their presence in the body can only be demonstrated by chemical methods of
isolation and identification. Frequently the issues surrounding the cause of death or
'criminal activity must be resolved by the judicial system. Forensic toxicology
laboratories analyse specimens using a variety of analytical procedures. GC/MS and LCMS are the most widely used methodologies for confirmation providing unequivocal
identification. There is a need for rapid turnaround times, expansion of the number of
chemicals measured in a specific test and to make methods, trained personnel and
·equipment available for instant response to toxicological emergencies.
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1.8.

Legislative Aspects

1.8.1

Overview

The possession of controlled substances is illegal. Drugs in Ireland are restricted by
several different statutes of Irish Law; The Misuse of Drugs Act, 1977 is the main
national legislation [1977] covering the forensically important drugs studied in this thesis
and gives details of the list of controlled drugs. The Misuse of Drugs Act 1977 is divided
into 43 sections. For example, in section 2 definition of a controlled drug is given. In
this Act controlled drug mea~s "any substance, product or preparation (other than a
substance, product or preparation specified in an order under subsection (3) ofthis
section which is for the time being in force) which is either specified in the Schedule to
this Act or is for the time being declared pursuant to subsection (2) ofthis section to be a
controlled drugfor the purposes ofthis Act". In sections 3 and 4, the Act describes the
restrictions on possession of controlled drugs. In section 15 of the Act supplying of
controlled drugs is detailed. In Section 17 unlawful cultivation of the opium poppy and
plants of the genus Cannabis is described. In section 19 details are given in relation to
occupier or owners of premises to be used for controlled substance cultivation, drug
taking, manufacture or importation which is recognized as an offence. The Misuse of
'Drugs Act is a substantial document and has been amended regularly. In 1984 The
Misuse of Drugs Act 1984 was brought into force in order to extend the law in relation to
certain dangerous drugs [1984]. The Misuse of Drugs Act 1984 is divided into 16
sections. Section 2 gives a more comprehensive definition of "cannabis" and "opium
poppy" plants. In section 10 the document details requirement for evidence by certificate
as follows the production ofa certificate purporting to be signed by an officer ofthe
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Forensic Science Laboratory ofthe Department ofJustice and relating to an
examination, inspection, test or analysis, as the case may be, specified in the certificate of
a controlled drug or other substance, product or preparation so specified shall, until the
contrary is proved, be evidence ofany fact thereby certified without proofofany
signature thereon or that any such signature is that ofsuch an officer". Generally the
Misuse of Drugs Act 1977 and 1984 are quoted together when describing controlled
substances. In 1987 the Misuse of Drugs Act, 1977 (Controlled Drugs) (Declaration)
Order 1987 came into effect [1987]. The purpose of this order was to declare certain
substances, products and preparations be controlled for the purposes of the Misuse of
Drugs Act, 1977. This Declaration Order added Buprenorphine to the controlled drugs
.list. In 1993 the Misuse of Drugs Act, 1977 (Controlled Drugs) (Declaration) Order 1993
was published [1993]. Likewise the purpose was to declare certain substances, products
and preparations be controlled for the purposes of the Misuse of Drugs Act, 1977. This
Declaration Order added a number of other drugs e.g Ephedrine. In 1999 the Criminal
·Justice Act 1999 was brought into law [1999]. The Act contains 42 Sections. This
legislation relates to the penalties for drug trafficking, providing evidence by certificate
in relation to exhibits in court and in addition to other legal matters such as providing
video evidence. In 2010 a huge departure was taken in Irish legislation with the
'pub1ication of the Criminal Justice (Psychoactive Substances) Act 2010 which no longer
followed the Misuse of Drugs Act format for legislation [2010]. This Act was divided
into 26 sections. It is an act in order to prevent the misuse of dangerous or harmful
psychoactive substances and provides for offences relating to the sale and importation,
'exportation or advertisement of these substances. In this Act a psychoactive substance
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means "a substance, product, preparation, plant fungus or natural organism, which has
when consumed by a person, the capacity to-raj produce stimulation or depression ofthe
central nervous system ofthe person, resulting in hallucinations or a significant
disturbance in, or significant change to motor function, thinking, behaviour, perception,
awareness or mood or, (b) cause a state ofdependence including physical or
psychological addiction. As a result of this legislation the Act brought into effect the

removal of headshop drug products over the counter and shut down premises of this type.
The Criminal Justice (Psychoactive Substances) Act 2010 listed substances such as
synthetic cannibinoids, benzylpiperazine and piperazine derivatives, mephedrone and
gamma butyrolactone (GBL) for example.
The above legislation is utilised in cases where laboratories find substances that are
illegal and thus severe penalties are enforced through the legal system based on the drug
identified. In the post-mortem forensic toxicology area however there is a more of an
emphasis on understanding the cause of a sudden or unexplained death. Although the
Mis-Use of Drugs Act legislation described above may become relevant within this
investigation if any of the controlled substances are detected. The principal legislation
affecting the State Laboratory Post-Mortem Forensic Toxicology work carried out in this
thesis is based on the Coroner's Act 1962 [1962] and The Coroner's (Amendment) Act
2005 in Ireland [2005].
The Human Toxicology section based in the State Laboratory, Ireland provides a
toxicological service to the Coroner's of Ireland. The post-mortem toxicology work in
this thesis was carried out within this section at the State Laboratory. A Coroner in
Ireland is an autonomous official with legal responsibility for the investigation of sudden
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and unexplained deaths. The function of the Coroner is to enquire into the circumstances
of unexpected, mysterious, violent and unusual deaths. This may require a post-mortem
examination sometimes followed by an inquest. The post-mortem is carried out by a
pathologist, who acts as the Coroner's agent for this purpose. The Coroner's examination
initially is concerned with establishing whether or not the death was due to natural
causes. If a death is due to natural causes then an inquest must be held by law. A postmortem (or autopsy) is a procedure to establish the cause of death. If the cause of death
cannot be determined beforehand, the Coroner will arrange for a post-mortem
examination to be carried out. During this post-mortem examination samples such as
blood and urine are sent for toxicological analysis. The State Laboratory performs
toxicological analyses on these samples to give confirmatory results on the absence or
presence of drugs and their metabolites. In addition chemicals such as ethanol, other
volatile substances, carbon monoxide and other gases as well as toxic chemicals are
monitored to identify if prese~t in human fluids and tissues.

1.9

Determination of forensically important drug residues

The analysis of drug residues in the veterinary drug residue and post-mortem forensic
toxicology fields' is very similar. Analytical methodologies include screening,
quantitative and confirmatory procedures also. In the case of screening methods, they
should ideally be quick, simple to use and give a positive or negative result for the test
compound at a specified level. Screening tools include rapid test kits such as microbial
receptor, receptor binding, radio or enzyme immunoassays used to screen for drug
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residues. Drawbacks of screenmg tests are mentioned below. Therefore additional
analytical tests are needed to determine if a sample is actually positive for a drug residue.
Quantitative methods are likewise designed to separate, quantify and provide some
qualitative information on the analyte of interest. Most gas and liquid chromatographic
methods would fall into this category. Quantitative assays classify samples as positive or
negative relative to specific drug concentration.

1.9.1

Screening assays

In this thesis the requirements according to Commission Decision 2002/657/EC [2002]
for veterinary drug residues were utilised as an alternative procedure in the post-mortem
forensic toxicology field. The most important requirement for a screening assay is that it
yields very few false negatives, in essence the ~-error (possibility of false negative result)
should be lower than 5%; some false positives are acceptable as these will show a
negative result when a confirmatory assay is performed. Screening assays are developed
to detect opioids, cocaines and amphetamine drugs or classes of drugs by utilising an
immunologically based reaction coupled with a variety of detection techniques. Major
advantages of these techniques include small sample volumes, inexpensive, high sample
throughput, rapid turnaround times and long shelf lives. They are also popular due to
their ease of use, potential for automation and their adaptability for use with blood and
urine samples [Perrigo et aI., 1995]. A disadvantage of immunoassay is their cross
reactivity with substances that have similarities with the abused drug, yielding false
positive results. Another disadvantage is that false negative results can occur if the
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concentration of the drug is below the assay cut-off, if the urine sample is collected prior
to the drug's window of detection or if the sample has been diluted or adulterated
[Eskridge et aI., 1997, Lee et aI., 2004, Ateshkadi et aI., 1996]. There are a number of
immunoassays available, for example the enzyme multiplied immunoassay technique
(EMIT), the cloned enzyme donor immunoassay (CEDIA), fluorescence -polarisation
immunoassay (FPIA),

kinetic interaction of microparticles in solution (KIMs), the

radioimmunoassay (RIA) and the enzyme-linked immunosorbent assay (ELISA). In the
analysis of amphetamine substances (brand name shown in brackets)) such as
amantadine/(Symmetrel) [Lee et aI., 2004], benzathine salt forms [Berthier et aI., 1995],
brompheniramine, chloroquine/(Aralen), desipramine/(Norpramin) [Lee et aI., 2004],
doxepin/(Sinequan) [Merrigan et aI., 1993] and levomethamphetamine/(Vick's Nasal
Inhaler) [Eskridge et aI., 1997] to name just a few that have been illustrated in the
literature as produCing false positives. In the analysis of opioids substances doxylamine
[Berthier et aI., 1995], fluoroquinolones [Hauseman et aI., 1983], gatifloxacin/(Tequin)
[Baden et aI., 2001], poppy seeds (foods) [Eskridge et aI., 1997, Lee et aI., 2004] and
rifampin /(Rifadin) [Lee et aI., 2004] have given false positive results. In the analysis of
cocaines false positive results can occur if tolmetin /(Tolectin) [Young et aI., 2004] or
.coca tea [Mayor et aI., 2006] are present. In immunoassays substances causing false
negative results for amphetamines can be aspirin based [Wagener et aI., 1994, Linder et
aI., 1994]. Substances that give false negatives in analysis of opioids are salicylates
[Merrigan et aI., 1993, Wagener et aI., 1994, Stout et aI., 2004] and substances such as
.aspirin [Wagener et aI., 1994, Linder et aI., 1994]. Ascorbic acid, fluconazole/(Diflucan),
mefenamic acid/(ponstel) [Young et aI., 2004] can give false negative results for cocaine.
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A study by Herring et aI., [2001] gives comprehensive information on interferences with
drug screens in urine testing. Therefore due to cross-reactivity the immunoassay tests are
not specific enough to confirm the identity of the drugs and stand up in a court of law and
a second specific test is carried out by a confirmatory method for either blood or urine
matrices obtained from the deceased. Confirmatory methods provide unmistakable
identification of the drug residue in question. Due to its sensitivity and specificity, mass
spectrometry is the preferred method for confirmation of drug residues in the forensic
toxicology field .

.1.9.2

Confirmatory methods

Samples that screen positive need to be further analysed by a confirmatory analytical
method in order to be unambiguously declared positive. The same chromatographic
techniques play an important role in the confirmatory tests for residues of veterinary
drugs and drug residues in the forensic toxicology area. There are a number of
chromatographic methods currently in use for residue analysis. These include thin layer
chromatography (TLC), gas chromatography (GC) and high performance liquid
chromatography (HPLC). TLC has found some use, generally for screening or qualitative
assays only. Some drugs are polar, non-volatile, heat sensitive and or difficult to
derivatise for GC. Therefore HPLC is the most commonly used analytical technique for
residue analysis. For confirmatory analysis chromatography with selective detectors is
used widely. Mass spectrometry (MS) is the preferred detection method for confirmation.
Hyphenated techniques such as gas chromatography-tandem mass spectrometry (GC-MS)
and liquid chromatography-mass spectrometry (LC-MS) are the most powerful analytical
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tools in the analytical laboratory. The approach for validation and general method
performance parameter requirements are outlined in Commission Decision 2002/657/EC
[2002]. The requirements for confirmation relating to identification points, defining
criteria for relative ion intensities and setting limits for relative retention times were
utilised in the veterinary drug residue field according to Commission Decision
2002/657/EC. For a method to be deemed confirmatory, a specific number of

identification points must be attained. Group A substances are substances that are banned
for use as veterinary drug residues. Opioids, cocaines, amphetamines and adulterants
were treated as Group A substances in this thesis under veterinary drug residue legislative
requirements. For confirming the presence of compounds categorised within Group A; at
least four identification points are required. Tandem mass spectrometry using a number
of different triple quadrupole mass spectrometers operated in multi reaction monitoring
mode was used as the determination step for the veterinary drug residue methods
developed (NSAIDs in milk and plasma) within the research carried out as part of this
thesis. This technique is classified within Commission Decision 2002/657lEe [2002] as
being low-resolution mass spectrometry. When operated in multi reaction monitoring
mode it gains one identification point for each precursor ion and 1.5 identification points
for each product ion monitored. So if two product ions are monitored; which result from
one precursor ion then a total of 4 identification points are earned. For confirming the
presence of opioids, cocaines and amphetamines hybrid mass spectrometry was used.
Hybrid mass spectrometry is a device that consists of two or more m/z separation
devices. The QTRAP is a hybrid triple quadrupole-linear ion trap operated in multiple
reaction monitoring mode and enhanced product ion mode as the determination step. So
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4 identification points are obtained when two product ions are monitored as detailed
above. In addition a full scan enhanced product ion spectrum is obtained for each drug
thus giving a combination 4 identification and additional identification points for full
scan spectra providing more data for confirmation. The QTRAP was used as the
determination step for the opioids, cocaines, amphetamines and adulterants residues in
blood and urine in post-mortem samples in the research carried out as part of this thesis in
the post-mortem forensic toxicology field.

1.10

Validation Of Analytical Methods For Use In Post-Mortem Forensic

Toxicology Residue Determinations

National regulatory laboratories throughout the world develop their own inspection
methods for post-mortem forensic toxicology drug residues. These methods have to be
validated to demonstrate they can be used in a court of law. The method performance
parameters outlined in Commission Decision 2002/657EC [2002] in the veterinary drug
residue field were adopted in post-mortem forensic toxicology studies in this work.
Validation param~ters to be evaluated for analytical methods are described in:
Commission Decision 2002/657/EC [2002] and they are: specificity, linearity, trueness,
precision, recovery, analytical limits, stability and ruggedness. The criteria laid down in
this decision were followed during the validation procedures carried out in this thesis.
The individual validation parameters are defined earlier in the veterinary drug residue
section of the thesis.
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Chapter 2: Literature Review
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2.1 Introduction

This chapter will give an overview in relation to NSAIDs in veterinary drug residue
analysis and also in relation to the forensically important drugs in post-mortem forensic
toxicology being targeted by the State Laboratory for transfer to LC-MS technology. The
chapter will also deal with issues in relation to analytical method development and
legislation requirements for the drugs targeted. The chapter comprises of the following:

•

Background information on NSAIDs, pharmacokinetics, metabolism, uses and
risks to consumers

•

Background information on forensically important drugs such as

-Opioid drugs and their pharmacokinetics, metabolism, uses and risks to the
consumers.
-Cocaine and its pharmacokinetics, metabolism, uses and risks to the consumers.
-Amphetamine drugs and their pharmacokinetics, metabolism and risks to the
consumers.
-Piperazine drugs and their pharmacokinetics, metabolism and risks to the consumers.
-Ketamine and its pharmacokinetics, metabolism, uses and risks to the consumers.
-Adulterant drugs
•

Extraction and purification procedures

•

Specific biological matrices available for testing

-Veterinary drug residues monitoring
- Forensic toxicology drug monitoring
•

Overview of mass spectrometry

2.2 Overview of Veterinary Drugs Studied

2.2.1 Non-Steroidal Anti-Inflammatory Drugs
The chapters 3 to 6 of this thesis are based on work carried out on non-steroidal antiinflammatory drug's (NSAIDs) as part of the veterinary drug residue section of the thesis
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focusing on the detection of these substances in milk and plasma matrices. NSAIDs are
defined as "compounds that are not steroidal and that suppress inflammation" [Booth et
aI., 2001]. NSAIDs compose an important class of drugs with therapeutic applications
that have spanned several centuries in veterinary and human medicine. Historically, the
discovery of certain plants and their extracts being applied for the relief of pain, fever and
inflammation gave rise to the development of anti-inflammatory drugs. Salicylates were
discovered in the 19th century to be the active components of Willow spp such as Salix

alba in the treatment of fever, pain and inflammation [Rainsford., 2004]. Scientific
advances in the 19th _20 th cent~y led to the development of the NSAIDs. The discovery of
aspirin in 1946 (although this has been readdressed in article published by Sneader
[2000]) followed subsequently by PBZ was the beginning of the NSAID revolution. PBZ
was in the beginning employed as a combination with antipyrine in the assumption it
would enhance the' actions of the latter. In the 1950's ibuprofen was the second drug to be
available as an over the counter medication along with aspirin.
The general chemical classification of the NSAIDs gives rise to four classes. The four
classes are Carboxylic acid, Carboxamides or Oxicams, Sulphonanilides and Diarylsubstituted Pyrazoles/Furanones [Rainsford 2007]. The list ofNSAIDs is outlined in
Figure 2-1.
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Table 2-1. Chemical classification of the NSAIDs, taken from Rainsford [2004]
There are a number of diverse molecular structures and a more exhaustive list ofNSAIDs
outlined by Gupta [2007] and all of which share a common mechanism of action:
Salicylic acid derivatives (e.g. Acetylsalicylic acid, Diflusinal, Salicylates)
Oxicam Derivatives (e.g. Meloxicam, Piroxicam, Tenoxicam)
Fenamates/Anthranilic Acid Derivatives (e.g. Diclofenac, Aclofenac, Ibufenac,
Melcofenamic Acid, Mefenamic Acid, Niflumic Acid, Tolfenamic Acid)
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Propionic Acid Derivatives (e.g. Benoxaprofen, Carprofen, Ibuprofen, Fenbufen,
Fenoprofen, Flurbiprofen, Ketoprofen, Suprofen, Tiaprofenic Acid)
P-Aminophenol derivatives (e.g. Acetaminophen)
Indolacetic acids (e.g. Etodolac, Indomethacin, Sulindac, Tolmetin, Zomepirac)
Aminonicotinic Acid Derivatives (e.g Flunixin meglumine)
Pyrazolone Derivatives (e.g. Dipyrone, Isopyrine, Phenylbutazone,Oxyphenylbutazone)
Quinolone Derivatives (e.g. Cinchopen)
The above is an incomplete list of all the

SAIDs available [Gupta 2007]. An example of

the molecular structure of a representative of each of these listed above is detailed in
Figure 2.1. The NSAIDs licensed for use in veterinary medicine in the EU for use in food
producing animals is outlined in Table 2-2.
The mode of action ofNSAIDs hinders one or more steps in the metabolism of
arachidonic acid (AA). NSAIDs act chiefly to decrease the biosynthesis of prostaglandins
(PG) by inhibiting 'cyclooxygenase (COX). The discovery of two isoforms of COX
(COX-I and COX-2) has advanced the knowledge of the mechanism of action and the
possible side effects ofNSAIDs. COX-I, expressed in almost all tissues of the body,
catalyses the creation of constitutive PG which aids a variety of normal physiologic
effects including GI mucosal protection, hemostasis and protection of the kidney from
hypotensive insult. By difference, COX-2 is activated in inflamed or injured tissues and
catalyzes the development of inducible PG, including PGE2, associated with intensifying
the inflammatory reaction. COX-2 can also be implicated in thermoregulation and the
pain reaction to inJury. It is postulated that antipyretic, analgesic and anti-inflammatory
actions ofNSAIDs is due to the COX-2 inhibition. In addition simultaneous inhibition of
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COX-l may give rise to many of the undesirable effects ofNSAIDs including gastric
ulceration and renal toxicity [Merck Manual, Ninth Edition]. NSAIDs can vary in their
capability to inhibit COX isoforms and any drug that is capable of inhibiting COX-2 at a
lower concentration than that required to inhibit COX-l could be classified by experts as
a safer option. This has been the basis for the COX-2 selective NSAIDs and research has
focused on development of these [Merck Manual, Ninth Edition].
NSAID drugs studied in this thesis which are licensed for use in food producing animals
were carprofen (CPF), diclofenac (DCF), firocoxib (FIRO), flunixin (FLU) and its
metabolite hydroxy-flunixin (FLU-OH), meloxicam (MLX) and tolfenamic acid (TLF).
Carprofen is administered orally or as an intravenous injection [EMENMRL/914/04Final]. Diclofenac is administered intramuscularly [EMEA/CVMP/6742112009].
Firocoxib is administered either orally or by intravenous route [EMENCVMP/383063Final]. Flunixin is administered intravenously, orally and by intramuscular routes. In
veterinary medicine flunixin is administered with meglumine as a solubiliser
[EMENMRL/744/00-Final]. Tolfenamic acid can be administered orally or
intramuscularly [EMENMRL/183/97-Final]. Meloxicam is administered subcutaneously
or intravenously [EMENCVMP/152255/2006-Final]. Ketoprofen is administered by
intravenous or intramuscular routes and it is of no risk [EMENMRL/020/95]. NSAIDs
that are not licensed for use in food producing animals were also studied in this work and
these included ibuprofen (IBP), mefenamic acid (MFN), niflumic acid (NIFLU),
naproxen (NAP), PBZ, oxyphen (OXYPHEN) and suxibuzone (SUXI). In addition
ketoprofen (KPF) was studied.
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2.2.1.1 Pharmacokinetics/Metabolism of NSAIDs

The NSAIDs are weak organic acids that are well absorbed. It has been noted that food
can affect the oral absorption of some NSAIDs e.g (flunixin meglumine and PBZ)
[Merck Manual, Ninth Edition]. These drugs are available as parenteral formulations.
Upon absorption NSAIDs are comprehensively bound (99 %) to plasma proteins with
only a small percentage of unbound drug accessible and active in tissue. Most of the
NSAID class are biotransformed in the liver to dormant metabolites and are excreted
from the liver to inactive metabolites by the kidney via glomerular filtration and tubular
secretion. The biotransformation and elimination half-lives vary significantly by species
therefore it is difficult to extrapolate dosages from one species to another [Merck Manual,
Ninth Edition].

2.2.1.2 Uses of NSAIDs

NSAIDs are extensively used as veterinary medicinal substances for therapeutic uses as
the NSAIDs can relieve pain and inflammation without the immunosuppressive and
metabolic side effects associated with corticosteroids. Generally NSAIDs give only
indicative release from pain and inflammation and do not alter the course of pathologic
damage. As analgesics, NSAIDs are less powerful than opioids so more functional for
mild to moderate pain [Merck Manual, Ninth Edition]. NSAIDs are routinely used for
the relief of pain from osteoarthritis, colic, navicular disease, laminitis, perioperative pain
[Merck Manual, Ninth Edition], mastitis, metritis, agalactia [EMEA/MRL/744/00-Final]
and respiratory disease [EMEAlMRL/183/97-Final]. They can also be used in
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cells and blood vessels and promoting ulceration and gastritis [Merck Manual, Ninth
Edition].
Food with residues ofNSAIDs can have serious health effects for the consumer.
Longterm exposure to NSAIDs has caused kidney turnors in mice and liver turnors in rats
[Kari et aI., 1995]. It has been reported in recent years also that the COX- II inhibitor
class ofNSAIDs are implicated in cardiovascular damage in humans [Debabrata 200&~

Staa et al., 2008). Other potential side effects include gastrointestinal disorders, aplastic
anaemia and agranulocytosis [Goodman and Oilman 1990J and changes in renal function
[Goodman and Gilman 1992J. These drugs can also be used in an off-label manner where
they are utilised in species in which they are not licensed leading to residues which could
Potentially have ill health effects if consumed. Due to little data being available in
relation to residues of these substances in unlicensed species these could lead to
s·Iglll·fi!Cant risk to the consumer.
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Table 2-2: MRL listings for non-steroidal anti-inflammatory drugs
Drug

Marker Residue

Animal Species

MRL

Target Tissue

(~g/kg)

Carprofen

Sum ofCPF and CPF glucuronide

Bovine, equine

500
1000

Diclofenac

Firocoxib

DCF

FIRO

1000

Liver

1000

Kidney

Bovine

allowed

Milk

Bovine, porcine

5

Muscle

I

Fat+skin

5

Liver

10

Kidney

Bovine

0.1"

Milk

Equine

10

Muscle
Fat

15

Flunixin
Flunixin

Flunixin

Flunixin

Meloxicam

Metamlzole

Kidney
Milk

Bovine

40

Bovine

20

Muscle

30

Fat

FLU

FLU

MLX

Equine

Porcine

Equine, Porcine, Bovine

TLF

Bovine and porcine

VEDA

As marker 4-MAA

Equine

Bovine, porcine, equine

Bovine
Acetylsalcylic acid
SOdiUm
•

Liver

10

FLU

Bovine
.Vedaprofen

60

As marker FLU-OH

Bovine
Tolfenamic Acid

Muscle
Fat

Bovine, chicken

300

Liver

100

Kidney

10
15

Muscle
Fat

60

Liver

10

Kidney

50

Muscle

10

Skin+fat

200

Liver

30

Kidney

20

Muscle

65

Liver

65

Kidney

15

Milk

50

Muscle

400

Liver

100

Kidney
Milk

50
50
20

Muscle
Fat

100

Liver

1000

Kidney

100
100

Muscle
Fat

100

Liver

100

Kidney
Milk

50
Not

Milk

allowed

Eggs

acetylsalicylate,
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(viii)

(ix)

OH

F'
Igure 2-1: Molecular tructure of different types of NSAIDs: (i) Acetlysalicyclic
A.cid, (ii) Meloxicam, (iii) Diclofenac, (iv) Ibuprofen, (v) Acetaminophen, (vi)
Etodol ac , (vii) Flunixin, (viii) Phenylbutazone and (xi) Cinchophen
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.semi-synthetic opiates like heroin and methadone. Opioids can produce intense euphoria
and a sense of well being. Cocaine and amphetamines are stimulant drugs. Crack cocaine
IS a smokable form of cocaine which is formulated by chemically altering cocaine
Powder to form crystals and the term crack is utilised because it makes a crackling sound
When burnt. Users of cocaine can feel more alert, confident and have an increased sex
.
drive U .
, sers of amphetamme drugs can have more energy, feel confident, exhIlarated and
reqUire less sleep and food. The drugs of abuse can render users severely physically or
Psychologically addicted and lead to severe withdrawal symptoms and social problems.
'Controlled drug testing involves screening by immunoassay and confirmation by
Chromatography (GC or LC) in an array of biological fluids. This thesis focuses on the
development of analytical strategies for these substances in blood and urine in a
regulatory laboratory.

2.310 ..
. Plold Drugs
2.3.1 1 T
. ypes of Opioid Drug
In 1803

, a German chemist Frederick Serturner, purified opium and isolated morphine
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d W d
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developed in Germany in the second World War when Germany was unable to acquire
opiates for medical uses. Its pharmacological activity is quite close to morphine. It is
often used orally due to its reduced potency to suppress withdrawal symptoms and used
Widely in drug addiction programs e.g oral methadone substituted for injectable heroin.
However methadone can produce marked sedative effects with repeated administration as
a result of drug accumulation. Buprenorphine is a semisynthetic, highly lipophilic opioid
derived from thebaine and possesses analgesic and opioid antagonist properties. [Baselt
2008;190]. It is 25 to 50 times more potent than morphine. In addition the drug can be
administered as high dose tablets for the maintenance therapy of opiate addicts.
An opioid drug is a drug that binds to opioid receptors which are found mainly in the
central and peripheral nervous system. The term opiate is often utilised as a synonym for
.opioid. Opiate should refer to the natural alkaloids found in the resin of the opium poppy

(Papaver somniferum). Poppy seed, a common food ingredient contains morphine and
may contribute to high oral morphine doses. It has been noted in the literature that the
presence of thebaine, present in poppy seeds but not in illicit or pharmaceutical dosage
forms could be used to identify dietary sources versus intentional drug use [Casella et aI.,
2006].
There are a number of classes of opioids and examples of molecular structure of each
class

are given below in Figure 2-2.

·Opioids can be classified as follows:
(i) Natural Opiates (e.g. resin of opium poppy, morphine, codeine, thebaine, leaves

of mitragyna speciosa, salvinorin A)
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(ii) Semi-synthetic Opioids (e.g. Heroin, Hydromorphone, Hydrocodone,
Buprenorphine)
(iii) FUlly synthetic Opioids (e.g Fentanyl, Methadone)
(iv)Endogeneous Opioid peptides (e.g. Endorphins, Dynorphins, Endomorphins)

2.3.1.2 PharmacokineticsIMetabolism of Opioids
Morphine can be taken orally or by alternative routes. Morphine is N-demethylated to
normorphine (5%) which is less active and normorpine is a urinary metabolite available
in free (1 o/r)
d
.
h
..
f d "
d
.
o an conjugated (4%) forms. However t e maJonty 0 a mlmstere morphme
is inactivated by conversion to morphine-3-glucuronide in urine [Baselt 2008: 1057]. Free
morphine, morphine-6-glucuronide, morphine-3-ethereal sulphate and morphine-3,6odigl ucu

'd
. .
rOm e are present in urine also. Morphine-6-glucuromde IS a powerful analgesic

but has less side effects compared to morphine and might be a useful alternative in postoperative pain relief [Binning et aI., 2011]. Blood levels of morphine are less than those
achieved boo
ak
Low b'IOaval'1 a b'I'
YInjectIOn when morphine is orally ten.
I Ity 0 f morp h"me IS
0

due to large quantities becoming metabolised while crossing the liver. If the drug is
injected into a vein in the arm large amounts reach the nervous system. In addition
o

0

Plates can be absorbed through smoke inhalation. Crossing the blood-brain barrier is
' IS
. Iess polar thus
difficult fIor morphine due to polarity of its two hydroxy I groups. H
erom
croSses the blood brain barrier easily and is 2.5 times more potent than morphine [Fenton
2002] .
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Use of morphine or heroin. T9 distinguish if heroin or morphine, it is important to
establish the presence of 6-monoacetylmorphine, the intermediary metabolite of heroin,
in blood

d'
.
an unne whIch can only arise from heroin. Another issue is that codeine can be

partly demethylated to morphine. A urinary morphine result could be due to codeine
ll1ed' ,
ICatlOn. If codeine medication was ingested then only small amounts of morphine
would be present. It has also been reported that drinking 240 mL of Papaveris fructis
herbal tea c

t"
I
h"
on aInmg 10-32 mg L- produced urinary morp me concentratIOns of 1-7 mg

L"
[Thuyne et aI., 2003]. Morphine can also be a metabolite of codeine, ethylmorphine,
her'

Om and pholcodine [BaseIt 2008: 1057] which can complicate morphine analysis. The

half-life of morphine is 1.3-6.7 hours [Baselt 2008: 1057]. Codeine is transformed in
'
. '
.
,
humans v· 0 d
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,
.
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.)
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,
"
. ~
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d
.
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'
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.
,
. 16'm d"d
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m
IVI uaIs w h
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I
' I
loods were generally less than 1 mg L' however total morphme evels were
uSUalI '
Y m the range 1-10 mg L -I [Thevis et aI., 2003]. In humans codeine is well
absorbed ~
101I0wing intramuscular or oral administration [Adler et aI., 1955]. Vree et aI.,
[1992] sh

_)
OWed that an oral 30 mg dose achieved average plasma levels of 67 IJ.g L for

COd'
. eme, 968 /lg L- 1 for codeine-6-glucuronide and 54 IJ.g L- 1 morphine-3-glucuronide
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.
natIon half-lives in the study for these three species at 1.5,2.8 and 1.7 hours
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respectively [Sasaki T.A. 2007]. Forensic toxicology widens net for drugs of abuse:
Codeine has a half-life of 1.2-3.9 hours [Baselt 2008:355]. Dihydrocodeine undergoes the
same biotransformation steps in urine involving N- and O-dealkylation with glucuronide
or sulphate conjugation at the 3- and 6- hydroxyl positions encountered. The plasma halflife for dihydrocodeine is 3.4-4.5 hours [Baselt 2008:465]. Heroin (diacetylmorphine,
diamorphine) is rapidly deacetylated in whole blood to 6-acetylmorphine catalysed by
blood esterases, and 6-acetylmorphine is further hydrolysed to morphine in the liver
[Baselt 2008:730]. It was reported in the literature that 6-Acetylmorphine is present in
urine in 64-73% of all heroin ~ases studied, averaging approximately 0.8 mg L- 1 up to 10
1

mg L- • [Fehn et aI., 1985; Derks et aI., 1986]. Papaverine metabolites are found in a high
percentage of urine specimens from heroin users [Paterson et aI., 2006] but also can be
present in urine following poppy seed consumption [Trafkowski et aI., 2006]. The plasma
half-life of heroin is 2-6 min, the plasma half-life of 6-monoacetylmorphine is 6-25 min
and the plasma half-life of morphine is 2-3 hours [Baselt 2008;730]. Methadone is
metabolised in urine by mono- and di-N-demethylation, resulting in formation of2ethylidene_l ,5-dimethyl-3,3- diphenylpyrrolidine (EDDP) and 2-ethyl-5-methyl-3,3diphenylpyrroline (EMDP) [Pohland et aI., 1971]. The blood plasma half-life of
.methadone is 15-55 hours. [Baselt 2008 :941]. Buprenorphine is metabolised mainly by
the N-dealkylation to form norbuprenorphine which is pharmacologically active and
glUcuronide conjugation of both buprenorphine and norbuprenorphine [Cone et aI.,
1985]. The half-life of buprenorphine in plasma is 2-4 hour (parenteral) and 18-49 hour
.(sublingual).
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2.3.1.3 Uses of opioids

O· .
PlOlds are a group of drugs that are used to treat moderate to severe pain after
Operations and in the treatment of cancer and rheumatoid arthritis. However the drugs
should be used cautiously. The drugs act on opioid receptors. Within the spinal cord, the
brain and other organs opioid receptors exist. These bind endogenous and natural
compounds known as beta endorphins or endorphin peptide transmitters. The endorphins
bind to the °PIOI
"d receptors thus reducing the perceptIOn
. 0 fpam.
' D rugs suc h as morphme
.
Or heroin increase the opioid receptor response by stimulating these receptors like that of
the natural endorphin compounds. [Fenton 2002]. Codeine is not as potent an analgesic as
morphine but is a very effective antitussive. Heroin has no accepted medical use,
Methado'
.
.
b
ne IS used m narcotic maintenance programs, Buprenorphme can e
administered as high dose tablets for the maintenance therapy of opiate addicts.
Transde

1
'
nna patches supplying buprenorphine have also become aVaIlable for the

treatme
.
nt of moderate to severe chronic pain.

2.3·1.4 Risks t o I n d'IVI'd ua Is I ngestmg
' 0plOl
. 'd s
Addiction to these .drugs develops due to opioid receptors m
. the bram
. , s I'Im b'IC system
(drug d
.
ependence region) binding to these drugs. There has been a cause for concern as

the Use of

"
.
d' h
'b
h
°PIOlds has risen dramatically in control of pam an mlg t contn ute to t e

problem f .
,
o opIate addiction [Okie 2010]. Opioids are generally used recreatlOnally due to
their ab'l'
I Ity to produce euphoria and addiction occurs as a result of
PhYsical!
Psychological dependence. It has been noted that psychological addiction to
°Pioids is mor lik Iy ifth drug i taken recreationally [Doy Ie et a I., 2004] ' W'It hd rawa I
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sYmptoms include sweating, nausea, depression, severe fatigue, pain and vomiting.
Eliminating the ingestion of opioids slowly over time (days/weeks) will reduce
Withdra

I
.
wa symptoms. [Doyle et aI., 2004]. Adverse effects due to morphme usage

include Constipation pupillary constriction, nausea, vomiting, hypothermia, depression to
name but a few. Adverse effects due to codeine in addition include miosis, respiratory
depression. Adverse reactions to dihydrocodeine include dizziness, drowiness,

I'
Ightheadedness, nausea and constipation. The severity of withdrawal symptoms depends
On the half-life of the opioid. Heroin and morphine withdrawal occur quickly but are
more severe than methadone but methadone takes longer. Complications arising from
'her'

Om usage can re ult in liver disease [Edland 1972 ; Stimmel et aI., 1972; Force et aI.,

1974], PUlmonary hypertyension [Kurtzman, ]970] and peripheral nerve lesions [Ricter et
aI., 1973]. The symptoms of opioid withdrawal can also be treated with other medications
ho weve th
.
d.
r ey are not very effective. Ventricular arrhythmia has been reporte m
methadone maintenance patients receiving an average daily dose of 400 mg [Krantz et
aI.,2002].
(i)

(iii)

(ii)

re

~CH2Mecoo

. . . Me

"
e
Me~\N'M
Ph

MeCOO'"

EtCO

Ph

Figure 2 2
- : Molecular tructure of different cia se of opiates/opioids: (i)
l\torphin

e,

(..)
11

Heroin and (Hi) Methadone
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2.3.2

ocaine

Cocaine i a drug that I' JnJamou
. Co
r 'It potentIa
. I fior recreat'IOna I a b
Jor
u ed
an 'IS extremely
Popular.

Coca
In th
COcain

ocain i n tan w drug on the market.

la b gan liminating
cain
highl addicti

Id

r act d

cain from the recipe,
er th c unter until 1916. By the turn of the 20

qualiti

COcain ,th free b

ocaine i a natural substance found

th

century

w r well known, Th re are two chemical form of
all. Th free ba e refer to the drug not

ith n

all. Thi free ba e i

rn kabl , The p d r fi rm fain i th hydrochl ride alt and can b di olv d in
r intr na al. It ann t be moked b cau e of the high
III

Itin) and

ilin) pint· f

ain hydr chi rid .
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2.3.2.1 Pharmacokin tic and

Th pharma kin ti

In

etaboJi m of ocaine

i d p nd nt n a numb r f factor

admini trati n, ph i
g n tic, h half-li

n urr nt u

with oth r drug and

fain i fr m 0,7-1.5 h ur and mo t of the drug i eliminated

In a fI W h ur [KI

aI., 200 ; K Ibri h

uch a rout of

ikin tal., 2008; Ba It 2008:247-253; Hoffman et
t I,,2

],

aine und rg

m tab li m through diffl rent

et al.. 20 8' eikin et aI., 2008; Ba It
tal., 2007' latlow
nv rt d t th maj r metabolite
in human liv r and can be detect d 1-4

h Ur

tal.,2008J. PIa ma
ith

C

nin m th

f! rm
t\i· maJ r in ctiv m tab lit

nd e

1

nin meth

J

'st r arc appr

2007).

al. 2

t r. B nzoyl cg nin and
fc

ain. h h Iflif!

imat Iy 5-6 h ur

of

tal.,

I ngcr h If-lif! than c cain [ ap 11 -Pi r

].

t

-d mcthylati n f c cain
in 'imult ne u I 11atl w 1993] a thi

th hi Ih but re ult

In

a thl ne f( rmati n whi h i a tran c t rift ati n
ff! t· bl

cffe t
ould be d .

Ith e

f

d pre' 'ure. heart rat and
ainc and al

hIt gcth r

rat . in indi

nn
t

al. I

., I '

'J.

'

Ih len has an climinati n h If-lif'

f

150 minut

wher a with cocaine it i approximately 90 minutes [Boghdadi et aI., 1997].

In addition the formation of coca thylen lead to the reduced metabolism of cocaine and
is frequ ntly n t d in pati nt with concurrent cocaine and ethanol u e [Jatlow 1993].
When crack cocain i

mok d m tabolite

uch a anhydroecgonine methyl ester

(AEM } m thyl cgonin and carbomethoxycycloheptatriene derivatives [Klasco et aI.,
2008; Ba It 2008'247-253' Hoffman 2006' Ko1brich et aI., 2006; Boghdadi et aI., ]997;
Cone et al. 1998] can b id ntifi d. Th pyroly i products of cocaine, anhydroecgonine

g nin m th I

and anhydr

u d to identify crack cocaine" smokers

although it i worth n ting that th

product can a1

0

appear in GC-M analysis as

thermal d gradati n pr duct of c ca thylen [ onzalez tal., 1995].

2.3.2.2

e of ocain

Cocaine h

a numb r f acc pt d m dical u e . It can be utili ed a a topical anaesthetic

and p .
nph ral a

n tri t r, it ha b n employ d in urg rie of the ear, eye, no e and

rnOuth ~ r d ad . [

a rt t al.,: Mu 11 r tal., 2005]. Popularity of cocaine u e in a

clinical

uniqu ability t induce local an the ia and limit epistaxi .

ttin i du

[Pithini t al.,:V n

2.3.2.3 Ri

I

r t I., 2 00].

to Indi idual Ing. ting ocain

ocain

t m and cardi va ular t

icity. In the central nervou

f cl p mine, n repin phrin and erotonin [ hanti et
I., 2

re ult .

In. ci/urc

].

nd . n b impli

tivity i incr a d th n thi can
t cl in th . clclicti n [fe t

f

caine rLa on tal.,
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2001; O'Dell et aI., 2000; Shanti et aI., 2003; Knuepfer et aI., 2003]. It is thought that the
abundance f d '
. .
.
o opamme causes the majorIty of effects. Overuse of cocame causes
depletion of dopamine stores and can cause intense longing for the drug which is called

"

Washed out" syndrome [Shanti et aI., 2003; Hoffman et aI., 2006]. Washed out

sYndrome causes difficulty with muscle movement, causes lethargy and anhedonia
[Boffman

' .
et al 2006]. The drug also affects heat regulatIOn and can cause hypothermIa

[Boffman et aI., 2006]. The cardiovascular effects of cocaine are as a result of its ability
to block

d'
so lUrn channels and is a type I antidysrhythmic agent [Shanti et aI., 2003;

HOffman et al 2006]. The drug also affects hypertension as a result of its ability to cause
vasOConst' .
.
.
.
fICtIon, cardIac ischemia, and end organ and tIssue mfarcts.

(i)
(ii)

~
/

0

OH

0\

/\

or \ J

Pi

'

gUre 2-3·• M 0 Iecular structures of (i) Cocame
. an d (..)
B enzoy Iecgonme
.
1I

2.3.3

A

lllphetamine Drug

t\rnPheta .
.
h .
mIne have sympathomimetic activity (stImulate the sympat etIc nervous
sYstem) to

. I'
Am h
.
gether with strong central nervous system (eNS) stImu atIOn.
p etammes

'are a Sub
group of the ub titut d phenethylamine class of compounds. There are a
nUmber ofd

.
.
d' d' h' h .
rug In thi cat gory. Only an overVIew of the members stu le In t IS t eSIS

will be .

gIven. The member con idered include amphetamine, methamphetamine,
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pseudo phedrin , 3,4-m thyl n dioxyamphetamin (MDA) and 3,4methylen dioxym thamph tamine (MDMA). timulants drugs can heighten mood,
Increa e al rtn

and d cr a

Or simultan ou Iy

fatigue. Inge tion of amphetamine type drugs either alone

ith oth r drug

Amphetamin

uch a cannabis and alcohol is widespread.

ynth i d in

rmany in 1887 but not until 1927 were its

Physiological em ct d crib d. In 1927 the drug wa investigated as an artificial
replac rn nt for ph drin . In 1933 the volatile ba e form of the drug was sold as an
inhal r or ad
utili ed to

ng tanto [Ra mu

n 2006]. During World War II amphetamine wa

mbat fatigu . Amph tamine b cam wid Iy abu ed recreationally and in

order to Contr I

ight gain. M thamphetamine wa fir t ynthesi ed in Japan in 1893

and wa wid Iy u d in World War IJ by the G rman' . Today homemade manufacture of
metharnph tamin and c n urr nt abu e i wide pread. P eudoephedrine occur naturally
a d-i rn r in ari u Ephedra pe i

in c njunction with I-ephedrine. The drug i

adrnini t r d r 11 a ana al d c nge tant and bronchodilator but can be found in nonpre cription c Id r m di

h drug can be u ed a a tarting material in manufacture of

metharnph tamin . MD

MDMA'

1

i a ynth tic ub tance commonly known a ecstasy.

)cn r 11 tak n in tablet fl rm although if powdered could be snorted, injected

Or inhal d. M

nth i d in 1914. In the late 1980' MDMA u e in the
id pread. MDA i a p ych tr pic amphetamine which ha

imi1ar

rally and intrav nou Iy. MDA wa fir t
Ynth i' d'In )
In

1960 and

P

ibl h II

)

D

\i

S

pa t ntcd a
I in th

u

.

In )

n in Ire cl'

[Thic

ugh uppr

ant in 1958, a an ataractic

. MDA i primarily a c ntral timulant and a
n tal., 197 ]. It i u ed ill gaIly by
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recreational drug users, Amphetamines acts on neurons in both the central nervous
sYstem and the peripheral nervou system that employ dopamine, norepinephrine and/or
serotonin . Th e pecI' IC
f actiOn
i ' of amphetamme
, ,IS to enter vesicles
,
that store
, .mto th e synaptlc
'"JunctiOn,
neurotransmitters an d pro duce Ieakage 0 f the neurotransmitter
The nerve cell then tran mits its message but in a way which is extreme and not related to
standard phy iological reaction,

2.3.3.1 Pharm

The resp
stereoch

ki
.
.
aco nehc and Metabohsm

On e to amphetamine drugs is dose dependent and also depends on the

'
emlcal nature of the drug. Amphetamine may be ingested or snorted and less

often injected. The a ymmetric a-carbon atom of amphetamine can give rise to two
enan '
homer. [ M DDA urope]. Amphetamine is available in d or I isomeric form with
the d~i

.
omer havmg 3-4 time mor activity. The plasma half-life is 7-34 hours but is

dependent on urinary pH [Ba It 2008:83-84]. An alkaline pH decreases elimination
Wherea

. , .
an aCidic pH increa e it. Analysis of amphetamine in urine is complicated

becaus ' ,
.
e It I a m tab lit of m thamph tamine and other drugs such as fenethyllme,
fenpro

porex [B elt 2008:83-84]. A major metabolite is phenylacetone subsequently

oxidised

to b nzoic acid and

cr ted a conjugate. A mall amount is converted by

oxidaf
Ion to nor ph drin and thi and it parent are p-hydroxylated, [Baselt 2008:83-84].
Blood

conc ntrati n

f d- and 1_ amphetamin developed steady-state peak plasma

concentrati n a raging 7 mg .) fI r d-amphetamine and 22 mg L-) for I-amphetamine;
elirn'
Ination half-li
rnay b

ra d 11-14 hour

r

lau en et aI., 2005]. Methamphetamine

ften m ked or inj cted. It can exi t as d- and 1-
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ISomer. Th d-i m rh

trong r c ntral timulant action but le Speriph raJ

Ympathomim ti a ti it th n th I-i

m r. D-M thamph tamine undergoe

ome N-

d rnethylati n t amph tamin , it maj r activ metabolite. D-m thamphetamine urine

concentration

f 0.5-4 m

b rv d in 24 hour after taking 10 mg dose.

-I

[Lebi h tal., 197 ]. In a id urin up t 7 % par nt drug i found and 7% amphetamin

r

njugat d p-hydr xy-methamphetamin wherea
iI und aft r amphetamin admini tration

oth r minor m tab lit
[ aldw II tal., 1 72; him
con ntrati n

t 1.,200 ]. A tudy by lIeu ti et al howed p ak urine

r )in 4 m) -I r ng , 1.9-6.0) at 14 hour for methamph tamin and
7-1.

t 17h ur iI ramphetamin aft radmini trationof20mg.

. h I -I'I
7J . rm
4 J.

for amph t min [Kim t I..

w r 23 h ur iI r m thamphetamine and 22 hour
I d c nc ntrati n wh n methamphetamine wa

.125 m) kg-I h w d th pia ma liminati n half-lifl of
10 h

Ur [

hOur buti
to fI 11

I'r
'le,' . t

b
Pr

k t 1.,1

2). 'lh h If-life fd-m thamph tamin wa b tw en 6-15

urin pI! d p nd nt [

th

It 2

47- 49].

th d-i m r but m re I wly. L-

nl I-m th mphctaminc may

- t I - 1 hr I

a re ult

-m thamph tamin i b liev d

th u

'
Cnpti n m th- rn h t'min

1nh-1 r. I r s nee

d-m thamph tamin indi at

r th illi it dru ) pr pared b redu ti n f I-cph drin

r

d-pseudoephedrine. Presence of racemate is due to illicit drug synthesis from phenyl-2propanone [Fitzgerald et al., 1988; Cody et al., 1993, Hornbeck et al., 1993]. Blood
eliminar h I '
.
Ion a f-lIves for the plasma species are approxImately 10 and 33 hours
resp .
ectIvely [Mendelson et al., 2006 ].
Methamph t .
.
h h
e amme has a higher potency than amphetamme. T e alf-life is
approximately 9 hours [EMCDDAlMethamp]. The major metabolites are 4hYdroxymethamphetamine and amphetamine. Analysis of d-methamphetamine in urine is
cOmplicated as it can be a metabolite of other drugs such as benzphetamine and
famprofazone [Baselt 2008:947-949]. Pseudoephedrine is metabolised to
norpseud

h .
.
oep ednne but only in a minor way. In fact up to 88% of the dose IS excreted

unchang d'
.
e m 36 hour urine with less than 1% present as norpseudoephednne [Bye et al.,
1975]. Blood concentration when given a dose of 180 mg gave plasma half-lives of 5.28.0 hOurs under normal conditions however if urine was kept acidic the half-lives ranged

~m3-64

.
. hours and when urine was basIc was 9.2-16 hours (Kuntzman et al., 1971].

The half r~
-he of pseudoephedrine is 3-16 hours [Kuntzman et al., 1971].
MDMA'
.
IS metabolised by N-demethylation to MDA and by fissIOn of the methylene
bridge t ~
. .
o tOrm hydroxylated mono- and di- hydroxy denvatIves. A study by Zhao et al.,

[2001] showed that 43 MDMA users had approximately 19 mg L- 1 MDMA and lA mg LI

MDA in th

.
.,
.
e unne within 8 hours of drug admInIstratIOn.

Most of the dose of MDMA excreted in the urine is unchanged. The half-life is 5-9 hours
[Barnes

~am

et al., 2009]. Other metabolites include MDA and O-demethylated compounds.

.
Ount of MDA in blood or urine obtained from a person that has only mgested

MDMA

tends to be le s than 10%. [Kolbrich et al., 2008, Barnes et al., 2009, Baselt
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2008: 997-999J. Human metabolism data of MDA in urine/blood is limited. Cimbura et
aI., [1 072J

.
states that m fatal cases up to 160 mg/L MDA were recorded as unchanged

drug. Animal studies on MDA show metabolism is by O-dealkylation, deamination and
coni u .
~ gatIon [Midha et aI., 1978J.

2.3.3 2 U
.

ses of amphetamine type drugs

Amphetamine can be used in the treatment of attention deficit hyperactivity disorder
(ADI-ID)

.
or narcolepsy. Methamphetamine can be used accordmg to the USFDA for the

treatment f
.
.
o exogeneous obesity, ADHD, and off-label for treatment-resIstant depreSSIOn
·and narcolepsy [Mitler et aI., 1993]. There are reports that amphetamines have been used
~~fur
.
mance enhancers also. Since January 1st 2010, Pseudoephednne has been

banned due to its illegal use by athletes in order to enhance performance by World AntiDOPing A '
.
gency [WADA 2010J. Pseudoephedrine can be used as an oral or topICal
·decongest

. ,

.

ant. It may also be useful as an anti-tussIve drug [MmamIzawa et aI., 2006].

Some st d'
..
u les have Shown that MDMA-assisted psychotherapy can be admmIstered to
POsHraum .
. ,.
atIc stress disorder patients to reduce the seventy of the condItIOn
[htt ://
~.ma s.or re earch/mdma/J. (Accessed May 2012)

2.3.3 3 R.'
.

asks to individual Inge ting Amphetamines

In the Cent I
. '
d
ra nervou sy tern amphetamine acts as a stImulant and causes mcrease
alertness
, euphoria, wakefulne ,lack of fatigue, decrease in appetite and increased motor
and s
Peech activity. A a re ult, amphetamine users can experience tremor, insomnia,
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a .
gItation, restlessness sleep deprivation, fatigue and mental depression. [Fenton 2002].
Amphetamine i dangerous for people with a history of heart disease or hypertension or
people sUffering with narrow-angle glaucoma and can induce mydriasis. In addition
amphetamine type drugs have been shown to transfer into breast milk [Skeiner et aI.,

1984' LI
,

ett et al. 2007' Bartu et aI., 2009]. Drug users can rapidly develop tolerance to

amphetamine drug and require increasing amounts of the drug in order to obtain the
same effect [Merck Manual 2007]. Withdrawal can lead to depression, fatigue and
. suc h as paranoIa,
. ha11 ucmatIOns,
. .
.Increased ap pe t'Ite, temporary stimulant pSYChOSIS

~.
d.
delusions M th
h
d
.
. e amp tamine withdrawal can lead to epreSSIOn, latIgue an mcreased
ap .
petite. It pas es into brea t milk in addition. Methamphetamine drug users may lose
their teeth

.
. . .
qUIckly and this is called "meth mouth". Methamphetamme IS hIghly

addictive . Th e m ntal depres ion a sociated wIth
' met hamp hetamme
. WIt
. hd rawa I 1asts
longer ad'
n I mor
PseUd

. '
evere than that of cocaine wIthdrawal effects [Wmslow et aI., 2007].

h
oep edrine can b a ociated with the occurrence of stroke [Cantu et aI., 2003]. It

lllay also c
fixed d

.
J d
.
.
ause palpitation, in omnia [http://home.mtecom.com an non-plgmentmg

rug eruption [Vidal tal., 1998J. It can also cause myocardial infarction [Biyik et

aI., 2006]. MDMA eft! ct
lllouth c

uch a grinding of teeth during sleep, lack of appetite, drug

"
oncentratIOn dlfficultie w re common but occurred in vary amounts depending

On the gend er [Liechti et aI., 2001]. MDA causes tremor, agltatIOn,
..
tac h ycard'la, rapl'd
breathin

. '
h
g, yp rth rmia, mu cuJar rigidity convulSIOns and coma [RIchards et aI., 1971].
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(i)
(ii)

(iii)

(iv)
(v)

o

H

< ~N"
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°
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2

Figure 2-4'
Pseudo h' Molecular structures of (i) Amphetamine, (ii) Methamphetamine, (iii)
ep edrine, (iv) MDMA, (v) MDA
2.3.4 Piper

.
aZIDe Type Drugs

Although th
e amphetamine drugs are extremely popular drug users searched for
altern .
ahves

h' h
w IC produced similar effects that could be easily obtainable commercially

and were not

h'b'
pro I Ited. Piperazine drugs became popular as a result. N-

BenzYlpiperazine IS
. a pIperaZine
.
. denvatlve
. . filrst synth
' d'In th e 1940' san d"InltIa
. 11 y
eSlse
Underwe
nt testing as an anthelminthic agent in livestock. Piperazines are synthetic
sUbstan
Ces and do not OCcur naturally. BZP has no stereoisomers. BZP has similar effects
to amPhetamines and it was reported that it should be controlled similiarly [Campbell et
aI., 19 73]. A .
.
mphetamIne and Piperazine based stImulants are a cause for concern

througho

.
,
e World today as both have been widely abused Since the 1990 s. It has a
PotencYa.
.
pproXlmately one-tenth that of d-amphetamine as a stimulant drug. NBenzYPiper
I
.
aZIne is generally purchased as hydrochloride salt capsules and tablets for
Oral ad ..
ministration.
utth
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The Specific action of N-Benzylpiperazine is on the serotonin re-uptake transporter

wh'

Ich increases the serotonin levels in extracellular fluids around the cell increasing

activatio

f h
not e serotonin receptors [Tekes et aI., 1987; Lyon et aI., 1986]. It has a lower

Potency e f f i ,
,
ect on noradrenalme reuptake transporter and the dopamme reuptake
transp

orter [Baumann et aI., 2004].

2.3.4.1 Ph

"

.

armacokinetIcs and MetabolIsm

N-BenzYlpip

.
,.
dh
"
erazme undergoes substantial biotransformatIOn m rats an umans via rIng

hYdrox I '
.
.
,.
YatlOn, N-dealkylatlOn, O-methylatlOn and conjugatIOn [Baselt 2008: 155-156]
and met b I'
,
.
a 0 Ites are found together with large amounts of unchanged drug m the UrIne.

T~re~

.
e very few studies performed on this substance. One study was carned out by

.,
d ,.
d
Antia et al [200
9] in which a 20 mg dose of N-BenzylpIperazme was a mmlstere
"
orally and blood and urine samples were collected. The elimination half life was found to
be 5,5 hOurs, Plasma major metabolites were BZP, 4-OH BZP and 3-0H BZP [Antia et

aI., 2009],

2.3.42 U
.

ses of piperazine type drugs

N-B enzYI '
,
. . , .
Plperazme during the 1990's was assessed for Its antI-depressant propertIes m

h

.

UInans b t
d' I
u never authorised for marketing and therefore has no real me Ica use.
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2.3.4.3 Risks to m
. d"d
I'
.
.
.
IVI ua s mgestmg plperazme type drugs
After an average of 4.5 dosage units of the drug expected to contain 70-100 mg each
ind' 'd
IVI uals showed symptoms of anxiety, agitation, sweating, hyperventilation, vomiting,
dizzines h
s, eadache, confusion and collapse [Gee et aI., 2005; Alansari et aI., 2006]. The

drug w ~
as lound at levels of 1.7 mg L- 1 in blood simultaneously with
ruethYlenedioxymethamphetamine and methylenedioxyamphetamine and was implicated
In

the death ofa young man in post-mortem blood [Wikstrom et aI., 2004], A single 100

rug oral do

f
"
se 0 N-benzylplperazme caused increased heart rate and systolic blood

presSur .
e rIse [Bye et aI., 1973],

(i)

Figure 2-5' M I I '
.,
.
0 ecu ar structure of (i) Benzylplperazme

2.35)(
.
etamine
I(eta .
tnIne has been utilised in the United States as an anesthetic induction agent since
19
72, It is structurally and pharmacologically related to phencyc I'd'
~ '1 ed
I me w h'IC h lal
.cl'Inical t .
rIals due to it unpleasant side effects but subsequently became a popular street
drug. I(eta .
dh
. d b
mIne has Some of the ame hallucinogenic side effects an as game a use
POPularity
haUucin

~ . fI .
as a result. The drug ha been abused by the medical prolesslOn or ItS

'
.,
°gelllc effects [Ahrned et aI., 1980]. Ketamine is a non competItIve N-methyl-D-

aSPartate n.. T
\l'lMDA) antagoni t [ urran et aI., 2001], It binds to the NMDA receptor
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complex in the calcium channel. It inhibits a global number of excitatory amino acid
neUro tran

.
smIttors [Cotman et aI., 1987; Hampton et aI., 1982] but in its action as a

NMDA agonist causes an increase in dopamine in the brain possibly causing schizotypal
and diss

. .
OClatIve symptoms [Frances et aI., 2011].

2.3.5.1 Ph

"

.

armacokinetlcs and Metabolism

ketamin .
e IS metabolised firstly by N-demethylation to norketamine which subsequently
undergoes d h
'.
.
e ydrogenatIOn to dlhydronorketamme and these two substances are
available at con cen t
'
"1 ar to ketamme
. .m serum. I
'
ketamme
. IS
. eI'Imma
. ted
rations
SImI
n unne
primar'l
I y as unchanged drug (2.3%), norketamine (1.6%), dehydronorketamine (16.2%)
and Co .
.
nJugates of hydroxylated derivatives of ketamine (80%). [Wieber et aI., 1975]
Stenber
g et aI., [1981] has suggested that dehydronorketamine is an artefact of the
analYtic I
. .
a procedure rather than a metabolite. In blood, men gIven an oral dose achIeved
Peak plasm

I

'

a Concentrations averaging 0.08 mg C at 0.5 hours for ketamme and 0.36 mg

L-'
at 0.8 hours for norketamine', the oral bioavailability ofthe drug averaged 20%
[Yanagiha

..,
-) 5
.
ra et aI., 2003]. Upon intravenous admmlstratIOn of2.5 mg kg to patIents an

average seru

.
ft...
m concentration of I mg/L was observed at 12 mmutes a er mJectIOn

declinin

g to 0.5 mg L-' by 30 minutes [Wieber et aI., 1975]. The serum half-life of the
drug was .
estimated at 3-4 hours [Baselt:2008: 806].

2.3.5.2 tJ
.
es of Ketamine
keta .
mine'
.
.
h'
h
I U ed In human and animal medicine as an anaesthetic. T ere IS researc
bein
g undertak en acr
the world evaluating the effectiveness of ketamine in the
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treatme nt 0 f pain,
. depression
. alcoholism [Krystal et aI., 2006] and heroin addiction
[Jovaisa et al. 2006].

2.3.5.3 Ri ks t o ID
. d·IVI·d ual inge ting Ketamine

Ketam'me can cau

hallucination d lirium, irrational behaviour, nausea, vomiting,

re .
Splratory timulation and d pre ion tachycardia, bradycardia, hypertension, seizures
and cardiac arrhythmia [Ba elt:2008:806] Ketamine may exhibit post-mortem
redistribution a it wa found that heart/femoral blood concentrations ratios averaged 1.6
.(range 08
. -2.3) [Dalp _ cott tal. 1995] and in another two cases averaged 3.3 (range
2.7-3 .8) [LaIond

tal., 2004].

(i)

o
Figure 2 6
- : Molecular tructure of (i) Ketamine

2.36 Ad
.
ulterant Dru

It. is a com m n p r pti n th t illicit drug contain ub tance other than the active
Ingredient

d
an th t adult r ti n I

benign ub tan

id pr ad. Illicit drug adult ration involves adding

t bulk and dilut (ugar), ub tanc
it dru

pr am

uh

and th Impr

I

n

that might nhance or mimic the

r lid cain in c caine which give

imilar and

f high qu lity c cain) or drug that will help the

f th ill i it cl ru ) ( u h

af[l in in her in which facilitat

moking or
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quinine in heroin which mimics the rush of heroin). Other agents in the production may
be added accidentally such as a result of manufacturing, storage or production techniques.
A review carried out by Berridge [1978] showed that foreign substances were often
added to opium pre and post importation [Berridge 1978]. A report on case studies by

h

.

erom users has stated that heroin has been cut "six or seven times" when it reaches the

Pusher [Richter et al. 1968]. More recently in 2010 a study entitled" A guide to
adUlterants and bulking agents and other contaminants found in illegal drugs" was
Published by public health bodies in the United Kingdom (UK) giving comprehensive
details 0 th
.
.
n e type of adult rants found [Cole et aI., 2010]. Adulterants such as lidocaIne
and levami so Ie were .mclud d in the analysis of drugs in
. th'IS theSls.
. The stu d'
y m the UK
in 2010 state that lidocaine and levami ole were usually foun d as aduIterants m
. cocaIne.
.
Lidoca ' .
Ine IS an anesthetic which ha

. '
tronger anaesthetic effects compared to cocaIne and

gives th .
.
. . , .
e Impre Ion of a high r quality cocaine. Levamlsole IS an anthelmIntic
Inedicatio (
., dd d h
. .
n u ed for xp lling worm) and it is unknown why It IS a e owever It IS
hYpothe' d
.
Slse that It may giv a mor inten e high.

(i)
(ii)

olecular tructur of (i) Lidocaine and (ii) Levami ole
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'2.4 Extraction and Purification Procedures

2.4.1 Introduction to Sample Preparation
In an analyt' I
Ica method the sample preparation stage is followed by a separation and
detection t
s ages, Generally the sample preparation stage can take the most time in an
anal '
ytlcal method, In the field of residue analysis sample preparation is an extremely
Important stage, Selected compounds must be recovered in low concentrations from
COmplicated matrices with a large number of potential interfering substances which can
be present
Integrit

h'
at Igh levels, The desired sample preparation procedure must ensure that the

d
Yan recovery of the selected analyte is not adversely affected prior to the

separation and d t '
,
, , , d h
e ectlOn steps and that matnx components are mInImIse t at may
adversely f~
a lect the latter stages, In order to develop robust analytical procedures a
Proper s a m
p l ' procedure is important. The pnnclpa
, , I 0 b"~ectIves 0 f samp Ie
e preparatIon
'"
preparatio'
,
n 10 reSIdue analysis are preconcentration of analytes, dIssolutIOn of analytes In
a PartiCUlar solvent and eparation of analytes from the largest number of interfering
SUbstances pOSSI'bl e,

' 'd!"d
'
xtraction techniques include hqUl
hqUl extractIOn,
so I'd
I p hase

extraction (SPE) , olid pha e microextraction (SPME), matnx
, so I'd
,
I phase d'IsperSIOn
(MSPE)
affinity technique column witching, supercritical fluid extraction/accelerated
SolVe
nt extraction (
/ A ) only tho utilis d will be discussed,

2.4.1. 1 Li . . .
qUU/lhqUld extraction (LLE)
LLEi
a trad'ItIonal
.
t 'Ive
t chniqu , Th b n fit of thi technique is that t hroug hseIec
ch '
OICes of
h' d ' h
olv nt and pH manipulati n, xtrem Iy clean extracts can be ac leve WIt
gOOd re
COy ry for th targ t analyte , Di po al of olvent can be a problem as solvent
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volumes used can be large. A further drawback of the sample preparation technique is the
difficulty in automation of this step. In a regulatory laboratory there is a need to develop
a method for the analysis of a large number of samples in a single day and poor
utilisation ofth'IS techn'lque can lImIt
. . sample throughput slgm
"fi
Icant Iy.

s:0 I'd
I phase extraction (SPE)

2.4.12
•

SPE is a technique that has been used extensively in laboratories as a sample preparation
teChni

~
,
.
que tor a number of analytical samples. The number of commerCIally avaIlable

sorbent phases has expanded in the last number of years. Early problems relating to
sorbent manUfacture variability have been, in most cases, successfully eliminated. One of
these d'
Isadvantages relates to the reverse phase silica sorbents and the occurrence of
residual '1
.
"
SI anol groups which can lead to more than one retentIOn mechamsm bemg
emplOyed and this can cau e variations in results between batches, Polymer based
Sorbents h

b
.
'd 1 ' l I b .
ave een manufactijI'ed to overcome issues WIth resl ua SI ano groups ut m

addition th
COPOly

. .
S VB)
e polymer based sorbents Le polystyrene-dlvmylbenzene (P -D

mer allow a broader range of pH and stability for method development.

Advanta

.
.
.
.
ges Includmg reduction of the presence of sIlanols mean one retentIOn

lllechanism

11
tIt
.
eXIsts r suiting in impler protocols and P -DVB a ows a grea er ana y e

retentio
n compared with bonded ilicas. Disadvantages of the polymer type sorbents
Include

'
. '
unde Irable hrinkl well charact ri tics, hydrophobIc PS-DVB samples reqUIre a

Condition

.
st P WIth a wat r w ttabl

Prepar .
ahon of a numb r
autolllat d
.
e . Di advantag
In addition clog In

olv nt. Th overall advantages of SPE include
in parallel, low volume of solvents and can be

of P

include problems with maintaining a constant flow and

f artridge .
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2,5

Specific Biological Matrices Availablefor Testing

2.5.1 Vet .
ermary Drug Residue Monitoring
The rules regarding the sampling of matrices in veterinary drug residue monitoring are
different d

d'
epen mg on whether the substances analysed are non-authorised or authorised.

Regulatory agencies involved in the detection of veterinary drug residues must take this
IOto acc

Ount when sampling. In the case of authorised veterinary drug substances, the EU

legisl .
atlOn outlines the list of edible matrices which have MRLs established that require
Sampling to identify if MRL levels are being adhered to. Edible matrices sampled include
Skin, kidney

'Ik I'
h . d
.
d
,mI , Iver, eggs, honey and muscle. For non-aut onse vetermary rug

sUbstances'
.
.,.
matrIces such as unne, plasma, haIr, retma, lIver and faeces can be taken. In
the case of i
d
I' . " f i
I
mporte foods the availability of matrices for samp mg IS SIgn! lCant y
reduced I
. n order to have retail import/export control and enhance consumer safety
.salllPIin
. '
g can be restricted to edible matrices such as mIlk, muscle, honey, skm, fat and
eggS to b

. ,
e tested. Milk is an important matrix therefore as It allows the detectIon of drugs

In r
lYe anim I
.
. .
'Ik .
a s pnor to slaughter. Development of analytical strategIes m mI IS
adYanta

geous for residue control.

2.5.} 1 E
. xtraction Method and Purification Strategies for NSAIDs

NS A1Ds a
re a cIa

d '
.
of anti-inflammatory drugs that are commonly use m vetennary

llled' .
ICIne D
.
Id 'd ~
. Ue to the potential for adverse effects to occur there IS a need wor WI e J.or
regUlatory
.
agencl to id ntify re idues in a variety of food animal and food animal
prOdUcts

AID hav div r

tructure and are not structurally related thus developing
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analytical t t ' .
s ra egles In regulatory laboratories for these substances is complicated.
Residues of these substances can be detected in slaughtered animals in kidney or liver
matrices. The detection of these substances in live animals can be achieved in biological

fl'

UIds such as plasma and in milk matrices. In 2009 the Community Reference

Laboratory (CRL) for NSAIDs recommended that in order to achieve sufficient control of
NSAIDs that the broadest number of residues should be monitored in analytical
strategies. In general NSAIDs are extracted using an organic solvent with subsequent
clean_up us'Ing I'IqUl'd/'lIquid partitioning and/or SPE. In early days 0 f NSAID method
,develop

ment there were a number of methods developed that monitored only single or a

few NSAIDs, NSAIDs have been extracted with acetonitrile [Hardee et aI., 1982; Neto et
aI., 1996' P' .
, Ion et aI., 2004; Miksa et aI., 2005, Jedziniak et aI., 2007] from plasma and

'Ik

from

mI

.

[Daeseleire et aI., 2003; Thompson et aI., 2010]. NSAIDs have been extracted

.from I ,
.
,
p asma with ethyl acetate [Grippa et aI., 2000] or by straight forward ultra
centrifu

.
gatlOn [De Veau et al. 1999]. NSAIDs have been extracted from urine with

rnethan I [S
'
o tanley et al. 2007] or a mixture of dichloromethane:ethanol solutIOn [Neto et
aI., 1996]

, NSAIDs have been extracted from muscle using ethyl acetate:methanol and

-DL-dith'
.
. '
.
lo-threltol [ larke et al 2002] and from kidney uSing water:ammonlUm hydroxIde
[Clarke et I
a.,2002].

'
. k . h'
f
AID have been extracted from bovine mIl Wit a mixture 0

ethanol' am
"1
d
' monium hydJOxidt? [Martin et aI., 1983] or in presence of acetomtn e an
sOdiu

.
.
m chlonde [Jedziniak et aI., 2009]. Dubreil et aI., 2011 extracted NSAIDs from mIlk

USing m
ethanol alone. After a hydrolysi

tep has been performed NSAIDs have been

extracted fI
rom pIa ma u ing dichloromethane [ ingh et aI., 1991] or dichloromethane:nhexan

'
e:dIethyl th r [Hine et,al. 2004]. Urine wa extracted with chloroform [Igualada
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et aI., 2005], dichloromethane [Singh et aI., 1991] and diethyl ether [Gonzalez et aI.,
1996]. After hydrolysis or solvent extraction, solid phase extraction [SPE] is often used
in the pur' fi .
I IcatlOn of extracts containing NSAIDs. Bovine plasma has been shown to be
Purified

.
USIng C I8 SPE for the determination of PBZ and DCF [Gowik et aI., 1998], IBP,

KPF, DCF and PBZ [Vinci et aI., 2006] and IBP, KPF and DCF [De long et aI., 1989]
and NSAIDs from milk [Gallo et aI., 2008;Gallo et aI., 2010]. Plasma from pigs and
rabbits W
.
ere punfied using this approach to determine IBP, KPF, DCF and PBZ [Vinci et
aI., 2006] E .
. qUIne plasma was purified using C 18 for the determination of IBP, KPF, DCF
and PBZ .
sImultaneously [Vinci et aI., 2006] or PBZ alone [Taylor et aI., 1995] or the C I8
was sub f
s Ituted for an Oasis HLB ™ cartridge [Quintana et aI., 2004] for the
determination of PBZ. Bovine, equine and porcine muscle was purified using a Florisil
SPE Cart 'd
n ge. Bovine muscle extracts were applied to an Oasis HLB

TM

cartridge for the

remOval f .
o Interferences in the determination ofPBZ and KPF [Van Hoof et aI., 2004].
MUscle s .
.
amples were Incubated with acetate buffer and B-glucuromdase followed by
eXtractio'
.
.
.
n WIth acetomtrile and extracts passed through Sep Pak Alumma N cartndges
and the I
e uates were further purifified using C18 SPE. [Jedziniak et aI., 2010]. Chrusch et
al [2008]

.
..
developed a method for NSAIDs in bovine muscle and kIdney. Bovme kIdney

eXtracts

.
.
Were applIed to silica cartridges [Clarke et aI., 2002] and bovme plasma extracts
were P .
Untied Using affinity columns [Fiori et aI., 2004] for the determination ofPBZ.

Gall o et I

a ., [2010] extracted 18 NSAIDs from milk using C18 SPE. Plasma of dogs and

.horses ha

.
.'
TM
ve been dIluted with water and samples were pUrIfied usmg Waters
HLB for

the extract'
IOn offirocoxib u ing PE [Kvatemick et aI., 2007]. Urine and plasma from
dogS
and horses wa diluted with an aqueous solution of 5 % acetic acid for extraction of
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firocoxib using a Waters Oasis HLB ™ 96 -well solid phase extraction plate [Letendre et
aI., 2007].
Methods have been reported for the analysis ofNSAIDs in plasma by LC-UV [De Veau
et aI., 1999; Kvatemick et aI., 2007; Luo et aI., 2004; Hardee et aI., 1982; Neto et aI.,
1996; Grippa et aI., 2000; Jedziniak et aI., 2007; Singh et aI., 1996; Gowik et aI., 1998;
QUintana et al. 2004; Fiori et aI., 2004; Jedziniak et aI., 2009], LC-fluorescence [Gallo et
aI., 2010], GC-MS [Neto et aI., 1996; Singh et aI., 1991; Hines et aI., 2004;Gonzalez et
aI., 1996; Jaussaud et aI., 1992], LC-MS [Luo et aI., 2004; Miksa et aI., 2005; Vinci et aI.,

.
2006' Q .
, UIntana et aI., 2004; You et aI., 2008, Stolker et aI., 2008, Chrusch et aI., 2008;
Thompson et aI., 2010] and capillary electrophoresis [Gu et aI., 1997]. The majority of
methods that have been cited to date have been developed in equine plasma alone or in
1

combination with other matrice

with limits of detection ranging from 0.1 ng mL- to 5

rug mL-) [Miksa et aI., 2005' Luo et aI., 2004; Hardee et al. 1982; Neto et aI., 1996;
Grip pa et al. 2000'

ingh tal. 1991; Hines et aI., 2004; Gonzalez et aI., 1996; Gowik et

aI., 1998; Vinci et aI., 2006' Gu et aI., 1997; You et aI., 2008]. Other methods for the
determ'
Ination of

AID in bovine plasma are available but with limits of detection

ranging from 20 ng to 3.4 ug mL-) [De Veau et aI., 1999, Miksa et aI., 2005; Jedziniak et
al. 2007; Gowik tal., 1998' Vinci tal. 2006; Quintana et aI., 2004; Fiori et aI., 2004].
Only tw

Om thod ar availabl in quine pIa ma to date capable of meeting 5ng mL-

leVel A
. meth d by Lu

tal [Lu

detect'
Ion of 0.1 ng mL-) for L.
al. 199

6] had a limit f d t

detect'
IOn of nly 10-25 ng m

I

tal., 2004] for a ingle re idue had a limit of
multi-re idue method by Gonzalez et al [Gonzalez et
f 5 ng mL-) for IBP, LU, DCF and TLF, but limits of

-I

c uld b achieved for KPF, M Nand PBZ. Therefore
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there are

h
.
.
no met ods avaIlable to date for KPF, MFN and PBZ m plasma that can meet

the target level of 5 ng mL- I . A disadvantage of the method developed by Gonzalez et al
[Gonzalez et aI., 1996] is that the method monitors 3 ions and this is not a confirmatory
rnethod according to Commission Decision 2002/657/EC [European Commission

De ..

CISlon. 2002] and a second analytical technique is required. There are few analytical

rnethods for the determination of authorised and non-authorised NSAIDs in milk and
these us

11

ua y analyse for only a few residues. Those that have been described use LC-

VV [Martin et aI., 1983; Gallo et aI., 2008; Feely et aI., 2002; Rubb et aI., 1995; De Veau
et aI., 1996], LC-MS [Gallo et aI., 2008; Boner et aI., 2003; Daeseleire et aI., 2003;
Malone et aI., 2009, Dubreil et aI. 2011] and GC-MS [ Rubb et aI., 1995]. A method by
Gallo et al [Gallo et aI., 2008] is capable of analysing 16 NSAIDs in milk using two
separate analytical techniques and involves using a screening LC-DAD method with
lirn'
Its of detection (LaD) of between 2- 15 ng mL

-I

and a runtime of 35 min with an

' an LC ESI eqUilibrati on time
.
. IS
. ac h'Ieved
of 15 min per injection. ConfirmatIOn
usmg
Iontrap Ms
I '
.
- /MS method with an LaD of 5 ng mL- except for flurbIprofen WIth a
runtirne f
.
.
o 40 mm per injection. The LC-MS method does not meet the reqUIrements for a
Confirm

.,
. .
.
atory method according to CommIssIOn DeCISIOn 2002/657/EC and a thud

analYt'
Ical technique i required. A method by Stolker et aI., [ 2008] is capable of
analYsing 20

~~LOD

AIDs in milk using a quantitative screening method (UPLC-TOF-MS)

s for specific

AID such a NAP, PBZ and DCF at 12.5, 25 and 6.3 ng mL

-

I

1

and a runtime of 8.5 min. The method cannot meet the 5 ng mL- level set for NAP and
PBZoro

..

.

.1 ng mL- 1 level recently et for DCF; addItionally, analysIs by T

OF MS
,

ll1ed'
IUrn to high r olution of approximately 10,000 FWHM is not included in
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Commission Decision 2002/657/EC. Other methods for the determination ofNSAIDs in
milk have limits of detection of20 ng mL- 1 for PBZ [Martin et al. 1983],0.2 ng mL- 1 for
FLU and FL -OH [Bon r et aI., 2003], 0.5 ug kg-I for FLU FLU-OH and 1 ug kg- 1 for
KPF [Dae eleire tal. 2003], 53.05 15.82,61.39,45.04 ng mL- 1 for TLF, MLX, 4-

MM and FLU-OH [Malon

1

tal., 2009] 0.46-2.86 ng mC', 1 ng mL- for FLU [Feely

et aI., 2002] 1.7 ng mL- 1 for FLU [Rubb et aI., 1995] and the lowest fortification in
mat'nx wa 25 ng mL- 1 for PBZ [De Veau et aI., 1996]. Dubreil et aI., 2011 analysed 12
NSAID in milk and obtain d limit of detection of between 0.69 and 27.54 for non-

MRL ub tanc

hich includ d PBZ, OBZ, LU NAP, MFN, KPF VDP and decision

Ii mitsforMRL

r 0.1 forD F 15.37 forMLX,45.08 for FLU-OH, and

62.96 Ilg kg-I for TL [Dubr il tal., 2011]. Th r ar limited method available for the

detenn'matl. n of

ID in

In

.
pIa ma and milk matric s that meet EU Iegl. IatIve

requirem nt
. . It was th e purpose 0 f th e
and ·
t nnar drug r idu c nfirmatory cntena.
work earn. d out in thi th

d I p analytical trat gi

were P .
revl u Iy n t a ailabl

m t th

for N AIDs resl'd ues that

guid line.

ic

w rk d

rvl

alu

t n

th
impr

eXpand th cl

lab ratory and
amination ample of

hI oOd and u .

nn

t

nd

nt t th lab rat r f r t ic I gical analy i . The
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legislation that covers this work is based on the Coroner's Act 1962 and The Coroner's
(Amendment) Act 2005, Drugs such as amphetamines, cocaines, opioids and adulterants
Were studied as they are commonly requested by the Coroners,

2.5.2.1 Extraction Methods and Purification Strategies for amphetamines, cocaines,

o ..
PIOlds and adulterants

Therefore the availability of a rapid sample preparation procedure for urine was
Investigated. To date the simplest sample preparation procedures in urine in the literature
for the determination of drugs included in this study such as AMP MDA and MDMA
[Andersson et aI., 2008], MOR, M-3-G, M-6-G, COD, COD-6-glucuronide, ethyl

.morph'me, M-6-G and 6-MAM [Gustavsson et aI., 2007] and MOR, BENZOYL, 6-

MAM, COC, COCA METH and EDDP [Dams et aI., 2003] were accomplished using
direct in'~ectlOn,
,
, to d'lrect InjectIOn
"
, [Chen et a I"
Alternatively KET has been filtered pnor
2007] W'th
b
'
b I'
.
. h
1 su sequent LC-MS detection or KET and Its meta 0 Ites In urIne ave
.underwent micro dialy i

ampling coupled with online SPE [Chen et aI., 2010]. Other

Simples
I
'
. spot
ne d unne
amp e preparation methodologies
have utilised
analyzIng d'
specime ns on filter paper. The filter paper was soaked In
. water an d t he reconstitute
'
d
Urine anaI
ysed directly '
[Meany et aI., 2009]. There is a scarcity 0 f meth 0 d s t hat proVl'd e
.rapid sa
differe

mple preparation procedur

in urine that cover a wide range

0

fd

f
rugs rom

h
nt cia e, Ther ha b n a move in recent years from Gas Chromatograp y Mass

SPectro

metry to Liquid

hromatography Ma

pectrometry, This thesis focuses on the

apPlication of L -M t chnology for the determination of drugs in this study. To date
lllet
' hod that ha

b n it d in th lit ratur for amphetamines, cocaines, opioids and
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adulterants covered in this study have been analysed in urine by LC-Ion TRAP MS [Chen
et al. 2007; Tsutsumi et al. 2005; Wu et aI., 2005; Cheng et aI., 2006; Katagi et aI.,
1996; Suni et aI., 2011], LC Tandem MS [Andersson et aI., 2008; Gustavsson et aI.,
2007; Dams et aI., 2003; Cheze et aI., 2007; Concheiro et aI., 2007; Kuwayama et aI.,
2008; Gergov et aI., 2009; Musshoff et al. 2004; Mueller et aI., 2011; Nema et aI., 2011;
De lager et aI., 2011' Sasaki et al. 2009; French et aI., 2009; Lamshoft et aI., 2011;
Menchijkanti et aI., 2011; Noriaki et aI., 2009; Mueller et aI., 2005] and hybrid LC-MS
[Mueller et aI., 2005]. The LC-M chromatography methods to date cover only a few
analYtes in the urine matrix u ually with long chromatographic run-times.
BlOOd was the second matrix targeted in the Thesis. To date sample preparation
procedures in whole blood for amphetamines cocaines, opioids and adulterants in the
literature for the determination of drugs included in this study was achieved by solvent
extraction using methanol liquid/liquid extraction [Juhascik et aI., 2009;Gergov et aI.,
2009· M
, ueIJer et aI., 2005' G rgov et aI., 2003; Logan et aI., 1987] or SPE [Juhascik et
al. 2009' MueH r tal. 2005;Johan en et al. 2007; Bogusz et aI., 1997; Dams et aI.,
2002- D
, ecaesteck r tal., 2003;
/liqUid
sOdiu
baCk

.
extraction proc dur for the determination of 122 drugs involved addition of
b

111 Orat (pH 9.3) t bl

extraction w

centrifu

Was

. .
h n et aI., 1993; Gerostamoulos et aI., 1995]. A hqUld

d and toluene:hexane:i oamyl alcohol (78:20:2, v/v/v). A

p rform d upon addition of ulphuric acid. Samples were mixed and

. '
ged and th top layer a pirat d to wa te. odium hydroXIde and n-butyl chlonde

evaporat d and

procedur

tra t r

n titut d in ethyl acetate [Juha cik et aI., 2009]. The

wa

procedure wa

rg

tal., [2009] for 25 opioid drugs in blood and urine.
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Urine w

'"

as lOltIally hydrolysed using p-glucuronidase enzyme and sodium hydrogen

phosphate bUffer pH 9 was added to both blood and urine matrices. The samples were
adjusted to pH 7 and extracted with butyl acetate. The method only covered a single class
of drugs in either matrix. Mueller et aI., [2005] extracted 301 forensically important
drugs by performing a basic extraction by adding pH 11 buffer and extracting with butyl
acetate. An acidic neutral extraction was performed by adding sodium chloride and
phosphate bUffer and phosphoric acid. Extraction was performed by addition of
dichIoromethane:2_propanol (95:5, v/v). Although a wide variety of drug classes were
,covered the method did not detect cocaethylene which is a forensically important
sUbstance. Gergov et aI., [2003] added Tris (hydroxymethyl)-aminomethane buffer pH 11
and extracted with butyl acetate. Sodium chloride and phosphate buffer and phosphoric
acid Were extracted with dichloromethane:isopropanol (95:5 v/v). Logan et aI., [1987]
,added pH 9 borate buffer to blood and subsequently added ethyl acetate. Drugs were reextracted with sulphuric acid and samples centrifuged. The organic layer was discarded
and aqueous layer saturated with ammonium carbonate and re-extracted with ethyl
acetate.
SPE sorbent chemistries utilized were reverse phase [Decaestecker et aI., 2003; Bogusz et
aI., 1997; Gerostamoulos et aI., 1995], cation exchange [Johansen et aI., 2007; Dams et
aI., 2002; Decaestecker et aI., 2003,] strong/weak mixed mode cation exchange sorbents
[Dams et aI., 2002; Decaestecker et aI., 2003; Chen et aI., 1993] and polymeric sorbents
,utiIiz' 0 .
lng aSIS HLB [Decaestecker et aI., 2003]. Chen et al [Chen et aI., 1993] evaluated
a number of sample pre-treatment methods for the extraction of morphine from blood
prior to SPE. The pretreatments involved protein precipitation. The first involved

80

addi'
.
hon of ZinC suIfate-methanol (70:30, v/v) and the supernatant was transferred into 0.1

Msodium acetate buffer. The second involved addition of acetonitrile and transfer of
sUpernatant to tube with O. 1 M phosphate buffer. The third involved addition of
methanol instead of acetonitrile. In the fourth method blood was vortexed upon addition
of 0.1 M phosphate buffer at pH 6.0 or pH 3.3 and subsequently centrifuged. The fourth
sample pre-treatment was found to be the most suitable and extracts were purified on
BOndElut Certify columns. Johansen et al., [Johansen 2007] pretreated blood by adding
Water and hydrochloric acid prior to loading onto SPEC MPI columns from Kingo Diag.
Inc for the extraction of cocaine, ecgonine methyl ester, benzoylecgonine, norcocaine and
ethYlene cocaine. Bogusz et al., [ 1997] extracted morphine, M-3-G, M-6-G, codeine,
cOdeine glucuronide, 6-monoacetylmorphine drugs using C18 SPE whereas Dams et al.,
[2002] extracte d 17 opium alkaloids including drugs und
' " In t h'IS t heSls
.
er'investigatIOn
SUch as buprenorphine, codeine, morphine, methadone, 6-MAM using Bond Elut CBA
SPE col

.
Umns [Dams et al., 2002]. Automated SPE was performed USing the Zymark

R.apid T

.
race SPE Workstation by Decaestecker et al., [2003]. The following sorbents

were studied C2, C4, C18, C18 MF, PH, CN, Isolute HCX, HCX3, HCX5, Oasis HLB,

MCX. Authors found that C8 was the best. Gerostamoulos et al., [1995] purified
mO~h'

.
.
lOe and ItS metabolites from blood usmg C 18 SPE.

10 date drugs in our study have been analysed using LC coupled to different detectors
Includ'
109 LC-diode array and' fluorescence detectors [Dams et al., 2002], LCelectr h
Oc emical detector [ Logan et al., 1987; Chen et al., 1993; Gerostamoulos et al.,
199
5], LC-MS [Gergov et al., 2009;, Bogusz et al., 1997;, Noriaki et al., 2009], LC-

MS/MS

.

[Shlma et al., 2008;, Gergov et al., 2003;, Johansen et al., 2007, Decaestecker et
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aI., 2003; Jagerdeo et aI., 2008; Sergi et aI., 2010; Kjaerguard et aI., 2010; Kriger et aI.,
.
.
2010' O·
, Iestad et aI., 2011; ScuratI et aI., 2009; Kannen et aI., 2009; Gergov et aI., 2009;
Fernandez et aI., 2009; Dress et aI., 2009; Sadig et aI., 2011] and hybrid LC-MS [Mueller
et aI., 2005]. There was a paucity of studies that used hybrid LC-MS technology in the
literatur
h
"
.
e as t e m~onty of studIes use LC- tandem MS. A method by Mueller et al
[2005] analyses 301 drugs qualitatively in blood and urine by 3200 QTRAP hybrid LC-

Ms with a chromatographic runtime of 30 min. Blood was mentioned in the study but no
validation results were evident and results were qualitative only. A disadvantage of the
Published methodology was that only one MRM transition is monitored and if a situation
a'
nses Were the EPI scan does not trigger produce a satisfactory spectrum re-injection of

the samples would be

necess~ry. Three EPI scans in addition were utilised at three

..
separat
.
e collISIOn energies (CE) which increases the duty cycle of the study and
~~

ances such as COCA, BNZY, LEV and PHEN were not analysed

,

In

blood,

The aim of this work was to develop single, fast, simple and reliable sample preparation
procedures In
' blood. and urine with detection by hybn'd L C -MS as ana lytIca
' 1 strategIes
" In
a fore

'
.
.
nSIC laboratory for the determination of drugs of abuse whIch were prevIOusly not

availabl e.

Overview of Mass Spectrometry

2.6.1 I

ntroduction to Ma

Mass S

pectrometry

.
. '
h
.
pectrometry IS an analytIcal techmque that measures the mass-to-c arge ratIo of

Charged particles or ions [Sparkman 2000]. Ions are generated by causing either loss or
gain of a ch arge from a species that is neutral. The technIque
.
. utI'}'Ise d to es ta bl'IS h th e
IS
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mass of particles, to identify elemental composition of a sample or molecule, for
identification of the chemical structure of a compound, In 1958, the combination of gas
chromatography and mass spectrometry as the detector was achieved [Gohlke 1959],
John B, Fenn the 2002 Nobel Laureate in Chemistry for development of electrospray
ionisation gave to date the most apt definition of mass spectrometry as

"h

teart ofmeasuring atoms and molecules to determine their molecular weight. Such

mass or weight information is sometimes sufficient, frequently necessary, and always
usefUl in determining the identity ofa species. To practice this art one puts charge on the
moleCUles ofinterest, i.e., the analyte, then measures how the trajectories ofthe resulting
ions respond in vacuum to various combinations ofelectric and magnetic fields. Clearly,
the s'
.
'
zne qua non ofsuch a method is the conversIOn ofneutral analyte molecules mto
,ions F:
. or small and simple pecies the ionization is readily carried by gas-phase
enCOUnters between the neutral molecules and electrons, photons, or other ions" [Fenn et

al. 1990; Fenn 2002]

2.6.2 LC-MS versus GC-MS

'The methodology used in the IX chapters of this thesis focused on the use of gas
chro m
'
atography and liquid chromatography ma s spectrometry technIques as a means for
the detecrIon of trace re idues in complicated matnces
.
'
such as
anlmaI ml'lk ,p Iasma an d
'human
and ch

.
UrIne and blood.
apter four to

detectio n of drug,

hapter three utilised gas chromatography mass spectrometry

ight focu ed on liquid chromatography mass spectrometry for
'
a chromatography ma s spectrometry was utI'I'Ise d as the detectIon

techniqu '
"dI
,. fl
e 10 the third chapt r of this the is fOCUSIng on non-sterol a antI-In ammatory
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drugs (NSAIDs). NSAIDs have been derivatised for GC-MS USIng the following
derivatisation

reagents;

methelut

(Neto

et

aI.,

2003),

bis(tri-methylsilyl)

trifluoroacetamide (Singh et aI., 1991), n-trimethylsulfonium hydroxide (Hines et aI.,

2004) and N-methyl-N-(trimethylsilyl) fluoroacetamide and trimethylanilium hydroxide
(TaYlor et aI., 1995), methyl iodide/anhydrous potassium carbonate (Gonzalez et aI.,
1996) and Trimethylsilyldiazomethane (Migowska et aI., 2010). Derivatisation can be
,.
quite time consumIng
" In ord
er to'Improve peak s hape, .
IOmsatIon
an d/or vo IatI'1'Ity and
rnay introduce a larger variability and decrease the precision of the methodology. The
-advantages of GC-MS include its low cost, superior resolution and low limits of detection
and GC-MS detection is still a widely used analytical tool in laboratories. The availability
of sUch meth 0 d s IS
. Important
.
'
L"d
to regulatory l
a b
oratones.
IqUl chromatograph y mass
spectrometry was utilised as the detection technique for NSAIDs, opioids, cocaines,
amPhetamines and adulterant drugs in the remaining five chapters of the thesis.

The

prirnary advantage of LC-MS is that it does not require derivatisation and that sample
preparaf
.
Ion can be more simplified. Sample preparatIon procedures such as SPE or
liqUid/I' .
"
IqUId extraction can be performed but more SImple procedures such as direct

i .

llJection, d'lI utIon
.
.
, the
or protein precipitation can also be Uti'I'Ise d , Th e re d uctIOn
In

sarnple preparation stages saves both time and money and in addition the reduced number
.c:
of steps can reduce the possibilities of errors and Improve
'
"
Th erelore
met h0 d preCISIOn.

Le-Ms was the most widely used technique
rn'
aIn aims
lab

In

' as more sUlta
'bl e to ach'leve the
in the theSIS

the thesis to develop rapid multi-residue strategies for regulatory

oratories, It hould be noted that GC-MS is an established technique for the analysis
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of complicated mixture of compound because of it combination of sensitivity and wide
range of applicabilit and v r atility and i wid ly u d.
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2.6.2.1

vverv

h mati

f

f

hniqu ari ing

tr m tr

hr m t gr ph
I til and

ml-

tr m t r id nti fi . ca h

ti I

mp und with

mp und by

. m I n i tur is intr du cl int a m bile pha

which is an inert gas such as helium. The mobile phase carries the sample mixture
through the stationary phase. The stationary phase is contained in a column. The column
IS Coated with a stationary pha e that can selectively attract the constituents of the sample
mixture. Columns are available with a wide variety of stationary phases and dimensions
and can be manufactured with fused synthetic silica, glass or stainless steel. As the
Constituents of the mobile phase are attracted to the stationary phase at different rates,
those that interact the lea t will elute from the column the most quickly. If the
stationary pha

is alter d then differ nt mixture of compounds can be separated due to

different interactions. The separation in GC can also be affected if the pressure of the
.mobile phase or the temp rature of the tationary phase is adjusted. The column in a GC
is held'In an ov n that i programmed to increa e the temperature. As the temperature IS
.
Increased compound that hav low boiling points elute from column sooner compared to
sUbstan ce that have high r boiling point . As the constituents
.
'
0f
a mIxture
eIute ""trom a
colum n, they nter th ma
electro

p ctrom t r wh re they are bombarded WIt. h a stream 0 f
d.

.h

.

n cau ing th m to br ak apart. Th fragment are charge Ions WIt a certam

tnass . Th e mas of th fragm nt divid d by the charge IS
. called the mass to charge ratio
.
(MJZ)

.

. !nce mo t fr gm nt ha

a charg of + I, th M/Z u ually represents the

tnol ec 1
u ar w ight ofth fragm nt.
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ch mati
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Both techniques are highly compatible as in both techniques the sample is in the vapour
phase and both techniques deal with approximately the same sample size and can be
applied to a variety of analytical chemistry problems. Gas chromatographs operate at
atmospheric pressure but the ion sources of mass spectrometers operate at low pressure
and this can cause a considerable problem. Due to the incompatibility with pressure
SUitable interfaces were designed in order to combine the two techniques. The interface
allows the tran ference of all the column eluent at reduced pressure from GC into the
mass spectrom ter. Th analyte mu t not decompose or condense in the interface before
entering the ma

p ctrometer ion source. Also the gas load entering the ion source must

be with'In the pumping capacity of the mass spectrometer. In the case of capillary
columns the mas

p ctrom ter can handle the entire column effluent however in the case

ofmacro bore and pack d column th column effluent must be reduced. To reduce the
column emu nt fl

plitting wa u din th early days but is generally not as utilised a

~~ uces the en itivity. The
carrier ga

eparator and th y

interfaces were no longer carrier gas splitters but
. target mo Iecu Ies
parated the carrier ga from organic

and'
Increased th c n entration of the organic targ t molecules in the gas stream. The
Illost valuable arri r ga
seParat
diffe

Or. Th principl

eparat r that i comm rcially available is called the jet
f th t chn I gy i that i that it tak

rence in diffu bilit b t

the Ca .
rn r ga i a tin
coeffici nt wh r
the devic "
gas) i p

th

fun ti nin th

f h
advantage 0 t e

n th carri r ga and the organic compound. Generally
u h a hydr g n or h lium with a larg diffu ion
ni m I cui

hav I wer diffu ion coefficient. While

nu nt ( ntain th targ t molecule and th carrier

ra d thr u h
tin n zzl int a p rtially vacuat d chamber (about 10 -2 torr).
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Due to helium's diffusion coefficient, the helium is sprayed over a wide solid angle,
whereas the heavier target molecules are sprayed over a much narrower angle and tend to
go straight across the vacuum region. Upon collecting the middle section of the solid
angle with a skimmer and passing it to the mass spectrometer, the higher molecular
weight target organic molecules are separated from the carrier gas which is removed from
the vacuum pump. Generally jet eparators are made from glass by drawing down a glass
capillary sealing into the vacuum envelope and cutting out the middle spacing but it is
Imperative that the skimmer and the spray orifice are perfectly aligned. The higher flow
rates Used for packed columns work the best for these jet separators but there are certain
disadvantage for consideration. Packed GC columns can be a source of small particles

who
Ich can enter the j t

parator and become tuck in the spray orifice. Subsequently this

can block or dra tically reduc' the flow from the GC column into the mass spectrometer.
The mOst Common approach when utili ing capillary GC columns is to pass all the
carrier gas flow into th ma
spectromet r pumpin
Mass

p di

p ctrometer if the flow is suitably small and the mass
uffici nt to handle the ga flow. [Gas Chromatography

'
pectrom try Ronald A Hit ]

l-Io
"
. wev er It I cu t m n w that

' I'
.
h
-M interfacing i performed by slmp
y msertmg t e

capillary c lumn dir tly int th i n ourc,
10 .

n1 atio n nt r th i n

line into th .
IOn

ur

thr ugh a

uch a methane for chemical

j int around the capl'11 ary co I umn. A separate

u d fI r a th rm coupl vacuum gauge tube to monitor source

Pressure , Th ma
throu h
g an th r
JUn .
Ctlo n ofth

ther ga e

n tandard i deliv r d .mto th'
e Ion source
lin int th i n

ur . h

nly r mo able fitting i at th

lumn nd th f: r nd fth inl t tube and utli e Ve pel ferrule,
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Once GC columns are fitted with the ferrules it is recommended to cut off a few
centimetres of the column to eliminate fine particles blocking the end of the column. The
interface is held at temperatures between 250 to 280°C.
The types of ioni ation techniques used in GC-MS are electron ionisation and chemical
Ionisation. Electron ionisation is the most widely used technique when coupled to GC-

MS. A heated filament emits electrons which are accelerated by a potential difference of
generally 70 eV into the ample chamber. Ionisation of the ample is achieved by
rernoval of an electron from the molecule thus generating a positively charged ion with
one unpaired electron. The technique produces abundant fragment ions and library
searchable pectra.
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h mic I J ni ati n which wa d veloped from 1and
intr du dint th chamb r in exce
tr n

ptur m d and P itiv
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molecules leaving a neutral reagent gas species. This is a softer ionisation technique than
El and is used to produce more abundant molecular ions. The spectra generated under Cl
conditions are not reproducible and therefore no Cl libraries are commercially available.
Electron ionisation was chosen as the ionisation technique for the work carried out in the
follOwing chapter of this thesis. Other authors have used electron ionisation in the
literature for the determination ofNSAIDs [Stanley et aI., 1995].
In the technique of GC-MS virtually all compounds capable of passing through a GC
Column can be ionized. In LC-MS when a mass spectrometer is coupled to an LC system,
compounds cannot be directly ionised and an interface must be utilised for the removal of
the mobile phase.

2.6.2.2 Overview of Le-MS
LiqUid chromatography- mass spectrometry (LC-MS) is a hyphenated analytical
technique arising from the combination of two separate analytical techniques. The liquid
Chromatograph combine the physical separation capabilities of liquid chromatography
and the mass spectrometer identifies each compound by providing structural information.

A major difference between established high performance liquid chromatography
(lIPLC) and LC-M is the scale. The size of the analytical columns used in LC-MS is
generally much maller and h nce flow rates are reduced. If standard HPLC columns are
Used th e fl ow I. g nerally plit. There are a number of different types 0 f anaI ysers that
canbeud'
e In L /M
flight (T
timew

uch a

.
. 0f
ingle quadrupoles, tnple
quadrupoI
es,'IOn trap, time

.
OF) and quadrupole time of flight (QTOF) analysers. A dIfficulty for a long

as combining th liquid pha e technique and the gas phase technique operated in a
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vacuum. Interfaces were developed in order to deal with this difficulty. The use of
atmospheric pressure ionisation (API) interfaces for coupling Le with quadrupole mass
spectrometers overcame these difficulties and gave rise to analytical strategies with good
selectivity, sensitivity and robustness [Niessen et aI., 1992]. For API techniques the
sample composition e.g the mobile pha e, additives utilised, matrix constituents affect the
ionisation and the sub equent analytical result.
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A wide range of API source designs are available from the instrument vendors. These
Sources include electrospray ionization (ESI), atmospheric pressure chemical ionization
(APCI), atmospheric pressure photoionisation, (APPI), desorption electrospray ionisation
(DESI) and direct analysis in real time (DART) when coupling to LC-MS. These sources
ionise the sample at atmospheric pressure and the atmospheric pressure interface transfers
lons into the high vacuum region of the mass analyser.
An API source according to Niessen [2003] consists of 5 separate components:

(i)

The liquid introduction device.

(ii)

The actual atmospheric-pressure ion-source region, where the ions are generated
by ESI , APCI, or other means.

(iii)
(iv)
(v)

The ion-sampling aperture.
The atmospheric-pressure to high-vacuum interface: the transition region.
The ion-optical system, where the ions generated in the source are analyte enriched

and tran

Sported towards the hIgh-vacuum mass analyser.
0

In this th eSlS
. the 5 papers illustrated in chapters four to eIg
. ht utI'1'Ise d e Iectrospray
IOnisation as the technique for ionisation. The use of electrospray has gained widespread
acceptance in analytical chemistry due to its mild ionisation, high ion transmission,
lmproved senSItIvltyat
'"
lower flow rates and"ItS lmprove d mass accuracy. The polar
nature of N
b
for the ESI source to'
e partICU Iar Iy
AID tudi d in this research allows
SUitabl ~
.
.
e lor theIr M detection although some work has been reported us10g APCI
SOUrce .
s In the literature [Abel-Hamid et aI., 2001; Loffer et aI., 2003]. NSAIDs are
generall
functio

.
h
b
1
Od
Yanaly ed in negative ion mode after deprotonatlOn oft e car oxy lC aCl
0

I
II . d
. .
na group. In addition protonation of the same Slte can occur a ow1Og etectIon m
°
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positive mode [Ferrer et aI., 2005]. LC-MS and LC-MS/MS have largely replaced GCMS in the analysis of drugs of abuse. In the forensic toxicology part of this thesis the
toxicologically relevant compounds studied have basic properties and positive mode was
applied in their analysis by LC-MS.
The main advantage of LC-MS over GC-MS is that the LC-MS allows for the
simultaneous analysis of both free and conjugated drugs of abuse in a single analysis
Without the need to carry out an intermediate hydrolysis step (e.g GC analysis of
cannabinoids). It also allows for the analysis of polar, low volatility and/or thermolabile
drugs (e.g cocaine" heroin) without the need to perform a derivatisation step (GC
reqUirement). A number of papers have been published in the literature for the
determination of drugs of abuse analysed in this work utilising electrospray ionisation in
the Positive mode [Clauwaert et aI., 2000; Shima et aI., 2006; Jeanville et aI., 2000;
Needham et aI., 2000; Dams et aI., 2003; Mueller et aI., 2005; Maralikova et aI., 2004] or
APCI in the positive mode [Apollonio et aI., 2006; Dams et aI., 2003; Bogusz et aI.,
2000] . Oth er forensic toxicology studies utilised an atmosp henc
' pressure p hotoIOnISatIon
. , ,
i\PPI source [Marchi et aI., 2009] for the analysis of alprazolam and flunitrazepam
' I
llletabol't
' blood, Ambient mass spectrometry IS
, a rapl'dl y growmg
' area m
. anaIytIca
I es In
chemist

'I
. , .
ry and ambient ionisation methods such as desorptIOn e ectrospray IOnISatIOn

(DESI -M

) and de orption atmospheric pressure photoIOnISatIOn
. . . mass spec t rome try

(Di\PPI_M ) have al

0

been utili ed in the analy is of morphine and codeine [Suni et aI.,

2011 ].
F'enn t
, . '
,
e aI., [1989] how d that multiply charged Ions were obtamed from protems

aliO win

.
I
g their mol cular weight to be determined [Fenn et aI., 1989; Mann et a " 1989].
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The electrospray interface is recommended for use with highly polar and ionized
materials. It is a soft ionisation technique that results in little fragmentation.
As electrospray ionisation was utilised in all Le-MS studies in this research and the
principle of this technique is outlined in this thesis.
In the literatur numerou applications are reported ranging from the analysis of
carbohydrates and nucl otide to mall polar molecules utilizing ESI. The technique of
ESI involves a number of steps including the formation of charged droplets, desolvation,
IOn generation, declu t ring and ion sampling [Mansalli et aI., 2006]. A strong electric
field'I applied
. to cr at an exc

of charge at the tip of the capillary which contains the

analYte solution. The proce s of volatili ing the samples is achieved due to setting a
Potential differenc of 2-6 kV b tween the tip of the E capillary and the counter
electrode [Ro

200 I; mith et at. 1990]. harged droplets emerge from the capillary as

.
a Spray an d migrate
at atmo ph ric pre ur in an electricaI grad'lent to t11e gas
Conductanc limitIng
' . . oritic or tub . The charged droplet emergIng
. contaIn
. so Ivent,
electrol Yt cation
. , and analyt mol cui . olvent evaporation from the charge d d rop Iets
gives ri

t
o vOlum

of repul ion (kn
srnall radiu
daugh

hrinkag thu increa ing oulombic repul ion. When a critical limit
a th Ra I igh tability limit) i

f dr pi t ,a mm tric fi i n known a droplet-jet fi ion, generates

ter dropl

and th

proc dur

20 00' T
, ang

xce ded a a r suit of a

dr pi twill b

ubmitted to the am

hrinkage and fission

f fi i n i a number of ~ to m [ mith
t

I., 1
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Subsequently gas phase ions travel through various vacuum stages to the mass analyzer
and finally the detector. E I has been utilised with a variety of mass analysers each with
their own advantages/disadvantages. A review of various mass analysers is given by Cole
[1997]. The theory of electrospray has been outlined in a review by Manisali et al.,

[2006]. In E I, a potential difference of a large magnitude is applied between an
electrode shaped a a wire and a counter electrode and a strong electric field is produced
at the tip. In practice in

I the capillary containing the analyte solution has a high

vOltage applied. In the ca

of a positive potential being applied due to electric field

gradient at the tip, charge

paration in the solution occurs a anions migrate towards the

meniscus of the droplet produced at the tip [Cole 2000]. Charged species are focused into
the ma

pectrom t ruing a

Potential diffi r nc

rie of counter electrodes with decreasing potential. The

t d P nd on xperimental parameters such as flow rate of solution,

charge state of analyt , 01

nt compo ition, di tance between tip and counter electrode.

The TaYlor cone wa d crib daft r work completed by Taylor [1964] which detailed
mathematically th fI rmula b hind th formation of the lectro pray cone and hence this
Was referr d to a a" a
the el

[ ayl r 1964]. Thi is illu trated in Figure 2-13. As
harged mol cule at urface of the Taylor cone

ectr tatic r pul i

reache h
t e urfac t n i n
charged dr I
p

luti n thi i call d meeting the Rayleigh Limit and
mitt d fr m th tip. h principl

ar

hi k t al., I 98].
n,

pray m de can be affected by

pillar diam t r nd liquid fl w rat

I., [2

fproducing the Taylor

if gradient elution i

th pr blem with gradi nt lution by

4]

tr

nJ

t m ith th ability t id ntifya larg van ty
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of spray modes under different conditions. A small droplet released from the Taylor cone
has less solvent therefore desolvation and ionization is more efficient. The size of the
droplet ultimately depends on the flow rate and the capillary diameter. Smaller droplets
undergo less evaporation-fission cycles to produce ions, the salt concentration in final
offspring droplets can be less. Also this may lower the background noise in the mass
Spectrum. [Karas et aI., 2000] but also smaller droplets that are not surface active will
have a greater opportunity of transfer to gas phase instead of loss in larger parent
droplets. Generally solvents used in ESI are acidified water and organic modifier.
Organic solvents help lower the surface tension of liquid helping formation of gas phase
IOns. During evaporation of the solvent, the droplet shrinks and the electrostatic repulsion
between the charges within the droplet becomes larger. As the Rayleigh limit is
'approached droplets begin to break away by 'coulombic fission' [Cole 2000]. Further
evaporation of the droplets leads to a new fission series which is repeatable. Actual
creation o f gas phase ions from droplets is expected to be a com b"matlOn 0 f two
l1l.

echanisms known a 'ion evaporation mechanism [IEM] proposed by Iribarne et aI.,

[1 97 6] and the , charg d re idue model' [ChRM] put forward by Dole et aI., [Dole et aI.,
1968' M
, ack et aI., 1969] and upported by Schmelzeisen-Redeker et aI., [1989]. T he

d'
Ifferences betw n both mechani m are in how the gas phase ions are generated. rEM
ivate
d
propos es that If
. an electri field on a charged droplet is at a high level, smg
. l
e, so
analYt

e rnolecul

as the en
to tak
IOns

tran porting ome of the droplet charge are emitted with the gas pha e

rgYofth in clo

toth

urfac becomes high enough to allow evaporation

e place [Th omp on t a.,
I 1979] . Th

hRM mechanism proposes that gas phase

are formed wh n ucce iv fis ion lead to a charged droplet with a single analyte.
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Some studies show that ChRM is the mechanism of choice in the case of producing
charged globular protein in gas phase [Kebarle et aI., 1999; Felitsyn et aI., 2002; GameroCastano et aI., 2000] even though it is not known which is the more exact. The
mechanism of producing small analyte ions is not clear and can be achieved by more than
one process [Cech et al. 2001]. The E I source utilised in this work was supplied by
Applied Biosystem (MD

ciex). Thi

I source technology involves a strategy for

desolvation whereby heated auxiliary nitrogen is focused at an angle from the direction of
the Spray (Turbolon pray TM) [Li et aI., 1996; Allanson et aI., 1995]. In addition a
COunter current nitrogen ga flow (Curtain gas

TM)

is emitted from the front of the gas

Conductance limiting orifice which further aids desolvation [Bruins 1997]. The curtain
gas carne
. neutral mol cuI

away from the sampling orifice by the nitrogen fl ow but

charged molecule ar fI cu ed through the gas flow under the effects of an electric field.

ure : Appl ra

Figure 2-12:

rporalion and MD

n urb V

IM

ur

(ne

perator Training Manual

fr rn Applied Bio y tern

97

,.

'",'

: h. 1'.1 :1'11, .'

........

/

...

...

+

.. +1+
... ...... \

".,

/

..

hTili

...
~,I',·
r~~:h

l2

\\

,. it;

,11111,'
"

... \

~

chematic of an E I interface

2.6.2.3 Ma

pectrometry and

Tandem ma

onfirmatory Criteria

p ctrom try i a divi ion of ma

pectrometry which involves selection

of a parr
.
Icular Ion pr duc d from a molecule by applying collision nergies to form
characten. tic
condary fra m nt in. (Futr 11 2000). In a review by Le Bizec et al it
was t
ated that' m n th diffi r nt ma analy er app I'le d.rJor th
'I e
targetI
ana y'I , tnp
qUadrupOI ( q ) i
Veter'
Inary drug [
qUad

m t id Iy u d fI r mea uring and quantifying re idue of
17

rupole anal

qUadrup I

th

With a h
ea
Produc d .
In th

tal.,2009]" h tripl quadrup 1 (Qq ) consi t of a Q 1
par ti n fth

t

ng

m I ul

nning

2 unit. h r ar fI ur p

ri inal pr cur or ion( ), an un cann d Q2

11 t fragm nt th ion

nt to it by colli ion

quadrup I that can eparat th fragm nt
ibl m de

f p rati n f th two

98

analysers; Ql scanlQ3 SIM, known as daughter mode or precursor scanning; Ql SIM/Q3
Scan, called parent mode or product scan; Q 1 scan/Q3 scan, referred to as neutral loss
SCanning mode; and Q I IM/Q3 IM, referred to as selected reaction monitoring (SRM)
mode [McMaster 2005]. SIM refers to the operation of a mass spectrometer in which the
lntensities of several sp cific ion beams are recorded rather than the entire mass
Spectrum. RM refer to data acquired from specific ions corresponding to m/z selected
precursor ion recorded via two or more stages of mass spectrometry. In this research,
triple quadrupole (QqQ) in RM mode of operation was used in chapters three-six for the
analysis of

AIDs in the veterinary drug residue section of the thesis.
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forces each fragment ion into an unstable orbit, causing it to escape through one of the
seven holes in the exit electrode and into the dynode electron multiplier detector which
distributes signal to the data system. An ionised molecular ion trapped between the ring
electrodes and application of collision gas can lead to fragmentation to aid identification
of target ion's molecular structure [McMaster 2005]. A limited amount of sample can
enter the ion trap without overloading and affecting performance. A newer technology
iOn trap called the linear ion trap was developed, This technology combines the
separation capability of the quadrupole analyser with MS/MS capability of an ion trap.
This type of analyser can be operated in normal scanning mode for separation and
detection of mass ions, or the ends of electrodes can be turned on to retain a specific ion
10 the trap for collision with a damping gas and further fragmentation can be achieved by

apPlYing a resonance excitation voltage, The daughter ion fragments can be released to
the ion detector sequentially by scanning the dc/RF voltage on the quadrupole rods while
Utilising a resonance ejection voltage on the trapping electrodes. The advantage of this
tYpe of analyser is the capacity is increased thus much greater sensitivity for analysing
trace

components in column effluent [McMaster 2005].

In th'

is work hybrid LC-MS was used for the analysis of drugs of abuse (chapters 7 and

8). The mass analysers used in the hybrid LC-MS system were t he com b"matlOn 0 f a tnp
. 1e
qUadrupole (QqQ) and linear ion trap (LIT) where Q3 in this technology can be utilised
as a quadrupole or a linear ion trap with axial ion injection [Hager 2002]. The
cornbinahon
' of both analysers in the ame instrument allow runnmg
. as a true Q q Q tnp
. 1e
qUadru po1e (very sensitive RM) as well as the abIlIty
. , to proVi' d
"
e sensitive

i::

IU

11 scan mass

SPectra wh'lch has the ability to perform MS" experiments thus a11 owmg
. c haractensatIon
..
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of structures and ability to identify metabolites. This has been utilised in the analysis of
drugs of abuse in the forensic toxicology section of this thesis utilising the 4000 hybrid
linear ion trap-triple quadrupole mass spectrometer from Applied Biosystems. Triple
quadrupole (QqQ) in SRM mode of operation was used for the forensic toxicology
research and was previously described above. Enhanced product ion (EPI) mode was
also utilised in the hybrid LC-MS for the forensic toxicology research where Q 1 was used
to filter the precursor ions. Q2 acted as a collision cell to generate fragments while Q3
.was working in ion trap mode to scan product ions. This results in a triple quadrupole MS
like fragmentation pattern but with higher sensitivity. In general operation as a triple
quadrupole mass spectrometer is useful when high sensitivity and selectivity of SRM
transitions is needed for example in quantitative analysis or targeted screening. In
general, operation as a linear ion trap mass spectrometer is necessary when higher
sensitivity in full scan experiments is required thus giving triple quadrupole MS like
fragmentation patterns but with higher sensitivity. The QTRAP hybrid LC-MS system
from Applied Biosystems instrument used in this research has a built in collision energy
spread ( E ) feature which allows for collection of data at different collision energies in
one EPI pectrum.

ommi ion Decision 2002/657/EC [Commission Decision 2002]

Outline the u e of identification points (IPs) in the veterinary drug residue field and the
validation protocol ha b en utili ed in the post-mortem forensic toxicology section of the
the i al

0

a an alt rnative validation procedure. Commission Decision 2002/657/EC

lay down p rformance crit ria for analytical m thods In
. the vetennary
.
d rug res)'d ue area.
This d ci ion in addition to gen ral performance requirements delivered requirements for
Confirmation utili ing id ntification points (IPs) and defined criteria for ion intensities.
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The EU notion of IPs and tolerated ion intensities ratio for the confirmation of the
identity of a compound is based on agreement obtained by members of the so called EU
working group of experts [Andre et aI., 2001].
When SRM mode is utilised for samples and two precursor-product ion transitions are
analysed an ion ratio can be obtained from the relative ratio of their response.
This ion ratio value obtained can be compared with that of the ion ratio for the known test
compound (usually obtained by analysing material fortified with the test compound). This
approach gives rise to four identification points (lPs) if a precursor ion and two transition
product ions are monitored (Table below). A review by Stolker et aI., [2005] gives a good
Overview of legislation and regulations in the veterinary drug residue field. Van Eenoo et
aI., [2004] summarises that there is no fundamental chemometric basis for the criteria
utililised in the EU as regards the number of IPs and applied tolerances but it was
intere ting to note that they do not differ much from the criteria established by the
Association of Official Racing Chemists (AORC), United States Food and Drug
Admini tration (FDA) the International Olympic Committee (lOC) and the World AntiDOping Agency (WADA) [Van Eenoo et aI., 2004]. Stolker et aI., [2005] states that the
difference noted i the EU allows the use of a combination of different independent
technique to confirm the identity of a substance whereas the other bodies only allow the
U

e of eith r G -M or L -M . The tables below outline the information contained in

COmmi ion Decision 2002/657/ C in relation to jp's and tolerances for ion intensities.
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Table 2-3: Relationship between a range of classes of mass fragments and
identification points earned

b

MS technique 8

lP's gained per ion

Low-resolution MS (LR MS)

1.0

LRMS" precursor ion

1.0

LRMS" transition product ions

1.5

High-resolution MS (HR MS)

2.0

HRMS" precursor ion

2.0

HRMS" transition product ions

2.5

a

n~

o Source

Table 5 2 00 2/65 7/EC

Table 2-4: Examples of the number of IPs earned for a range of techniques and
their combinations

-MS technique

C

Number of ions

lP's

N

n

2 (El) + 2 (Cl)

4.0

2 (derivative A) + 2 (derivative B)

4.0

N

n

GC-MS/MS or LC-MS/MS

One precursor and two daughter products

4.0

~
iC-MS/MS or LC-MS/MS

Two precursors each with one daughter

5.0

8

GC-MS (El or Cl)

-GC-MS (El and Cl)

-

GC-MS (El or Cl); 2 derivatives

t--

LC-MS
r--

product
~

LC-MS J

5.5

One precursor one daughter product and
two daughter

~S

2n

N
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[GC-MS and LC-MS

2+2

GC-MS and HRMS

2+1

C

I

Source Table 6 2002/657/EC

Table 2-5: Maximum permitted tolerances for relative ion intensities

8

Relative Intensity

Relative Maximum Tolerance (%)

(% of base peak)

EI-GC-MS

CI-GC-MS , GC-MS" ,

(relative)

LC-MS LC-MS Il

>50%

±10%

±20%

20-50 %

±15 %

±25 %

10-20 %

±20%

±30%

±50%

±50%

10-

S10%

-a Source Table 4 2002/657/EC
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Chapter 3: Determination ofibuprofen,
ketoprofen, diclofenac and phenylbutazone in
bovine milk by gas chromatography tandem mass
spectrometry
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3.1

Abstract

A method has been developed to analyse for ibuprofen (lBP), ketoprofen (KPF),
diclofenac (DCF) and phenylbutazone (PBZ) residues in bovine milk. Milk samples were
extracted with acetonitrile and sample extracts were purified on Isolute ™ C I8 solid phase
extraction cartridges. Aliquots were analysed by gas chromatography tandem mass
spectrometry (GC-MS/MS). The method was validated in bovine milk, according to the
criteria defined in Commission Decision 2002/657/EC. The decision limit (CCa) was
0.59,2.69,0.90 and 0.70 ng mr l , respectively, for IBP, KPF, DCF and PBZ and for the
detection capability (CC~) values of 1.01,4.58, 1.54 and 1.19 ng mr respectively, were
l

obtained. The measurement uncertainty of the method was 17.8, 80.9, 28.2 and 20.2 %
for IBP KPF, DCF and PBZ. Fortifying bovine milk samples (n = 18) in three separate
assays show the accuracy of the method to be between 104 and 112 %. The precision of
the method expressed as RSD values for the within-lab reproducibility at the three levels
of fortification (5, 7.5 and lOng mr') was less than 8 % for IBP, DCF and PBZ
respectively. Poor precision was obtained for KPF with an RSD value of28 %.

Key.words: Ibuprofen; Ketoprofen; Diclofenac; Phenylbutazone; Bovine Milk; Method
ValIdation
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3.2

Introduction

Phenylbutazone (PBZ), ibuprofen (lBP), ketoprofen (KPF) and diclofenac (DCF) are
non-steroidal anti-inflammatory drugs (NSAIDs). The molecular structure of these
compounds is shown in Fig. 3.1. NSAIDs are used widely in veterinary medicine in the
treatment of food producing animals. Depending on their heterogeneous molecular
structures the NSAIDs can be classified into four main sub-classes: (a) salicyclic acid
derivatives; (b) propionic acid derivatives; (c) pyrazole derivatives and (d) aniline
derivatives including both anthranilic acid derivatives and nicotinic acid derivatives. PBZ
IS

a pyrazole derivative IBP and KPF are propionic acid derivatives and DCF is an

aniline derivative. In the USA a survey was carried out involving 2000 veterinarians
whose practices dealt 50% of the time with food producing animals [US Code of Federal
Regulations 1988]. The survey showed that 93 % of veterinarians use NSAIDs on a
regular basi . Dairy practitioners reported more frequent use ofNSAIDs than did beef
practitioners. Overall veterinarians indicated that NSAIDs were an important group of
compounds which were routinely used for the treatment of food producing animals
I<.opcha et a1. 1992. According to EU law, all substances for veterinary use need to be
inclUded in Annexe ]-3 of Regulation 2377/90 [European Commission 1990], This
regUlation

tablishe li t of compounds that have a fixed MRL (Annex I), that need no

MRL (Annex 11) or that have a provisional MRL (Annex Ill).

PBZ and IBP are

Co mpound that have not been included in Annexes 1-3 and have no maXImum
'
resI'd ue

limit (MRl)

tabli h d.

ub tance that have no MRL established are prohibited for use

in fOod pr ducing animal. 0 F i li ted in Annex I and a provisional MRL has been set
for different animal p cie aDd target matrices. DCF is however prohibited for use in
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milk producing animals. KPF is listed in Annex II and is allowed for the application to
species that produce milk but are not intended for human consumption. NSAIDs can
cause adverse health effects in humans such as aplastic anaemia, gastrointestinal
disorders and agranulocytosis [Insel 1990] and changes in renal function [Goodman et aI.,
1992]. Longtenn exposure to PBZ has caused kidney tumors in mice and liver tumors in
rats [Kari et aI., 1995]. The widespread use ofNSAIDs presents a potential risk to the
consumer if food containing residues enter the food chain so there is a need for the
development of methods to monitor compliance with legislation in the European Union in
a variety of animal tissues and products. In the determination ofNSAIDs in animal
tissues PBZ has been shown to be extracted from equine plasma using acetonitrile
[Hardee et aI., 1982;

eto et aI., 1996] or ethyl acetate [Grippa et aI., 2000], from equine

urine with methanol [Stanley et aI., 2007] or a mixture of dichloromethane:ethanol
solution [Neto et al. 1996]. PBZ has been shown to be extracted from bovine plasma
Using acetonitrile [Fiori et al. 2004; Miksa et aI., 2005] or a straight forward ultracentrifugation procedure [De Veau 1999]. IBP, KPF and DCF has been shown to be
extracted from bovine plasma: using acetontrile [Miksa et aI., 2005]. PBZ have been
shOWn to be extracted from ovine, equine, and porcIne
. muscI
' a mIxture
.
f h I
e USIng
0 et y
acetate:methanol and DL-dithio-threitol [Clarke et aI., 2002]. PBZ has been shown to be
extract d from bovine kidney u ing a mixture of water: ammonium hydroxide [Clarke et
al. 2002]. PBZ has been hown to be extracted from bovine milk with a mixture of
ethanol:ammonium hydroxide [Martin et al. 1983]. KPF has been shown to be extracted
fro

b
.
.
f
rn ovine milk u ing ac tonitrile [Daesel eire et aI., 2003]. The IncorporatIOn 0 a

hYdrOly i

tep at the beginning of the extraction procedure for the detennination of
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NSAIDs is also reported in the literature. This hydrolysis step allows the deactivation of
plasma bound proteins and the release of the protein bound NSAID residues. After
hydrolysis PBZ has been shown to be extracted from bovine plasma using
dichloromethane [Singh et aI., 1991] or a mixture of dichloromethane:n-hexane:diethyl
ether solution [Hines et aI., 2004], porcine, ovine, bovine and caprine urine were
extracted with chloroform [Igualada and Moragues 2005] and equine urine was extracted
with dichloromethane [Singh et aI., 1991] or diethyl ether [Gonzalez et aI., 1996] for the
determination of PBZ. After hydrolysis or solvent extraction, solid phase extraction
[SPE] is often used in the purification of extracts containing NSAIDs. Bovine plasma has
been shown to be purified using C 18 SPE for the determination ofPBZ and DCF [Gowik
et ai., 1998] IBP, KPF, DCF and PBZ [Vinci et aI., 2006] and IBP, KPF and DCF [De

long et al. 1989]. PIa ma from pigs and rabbits were purified using this approach to
determine IBP, KPF, DCF and PBZ [Vinci et aI., 2006]. Equine plasma was purified
Using C I8 for the determination of IBP, KPF, DCF and PBZ simultaneously [Vinci et aI.,
2006] or PBZ alone [Taylor and Westwood 1995] or the C I 8 was substituted for an Oasis

BLB ™ cartridge [Quintana et aI., 2004] for the determination ofPBZ. Bovine, equine
and porcine muscle wa purified using a Florisil SPE cartridge. Bovine muscle extracts
were applied to an Oasis HLB ™ cartridge for the removal of interferences in the
determination ofPBZ and KPF [Van Hoof et aI., 2004]. Bovine kidney extracts were
applied to ilica cartridge [ larke et aI. 2002] and bovine plasma extracts were purified
uSing affinity column [Fiori tal., 2004] for the determination ofPBZ. A few methods
have been reported for the analy i of

AIDs in animal tissues using LC-DV [Hardee et

al. 1982' ingh t ai. 1991' Taylor and We twood 1995; Gowik et aI., 1998; De Veau et
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aI., 1999, Grippa et aI., 2000; Quintana et aI., 2004; Van Hoof et aI., 2004; Vinci et aI.,
2006] and GC-MS [Singh et aI., 1991; Taylor and Westwood 1995, Gonzalez et aI., 1996;
Neto et aI., 1996; Hines et aI., 2004]. There are a few methods that analyse for IBP, KPF,
DCF and PBZ in animal products such as milk and those are based on LC-UV [Martin et
aI., 1983] for the determination ofPBZ or LC-MS detection [Daeseleire et aI., 2003] for
the determination ofKPF and FLU. NSAIDs have been derivatised for GC-MS using the
following derivatisation reagents; Methelut [Neto et aI., 1996], Bis(trimethylsilyl)
trifluoroacetamide [Singh et aI., 1991], n-trimethylsulfonium hydroxide [Hines et aI.,
2004] and N-methyl-N-(trimethylsilyl) fluoroacetaminde and Trimethylanilium
hYdroxide [Taylor and Westwood 1995]. Gonzalez et al. [1996] monitored for IBP, KPF,
DCF and PBZ simultaneously in equine plasma and urine by GC-MS in SIM mode used
methyl iodide/anhydrous potassium carbonate as derivatisation agents. The method
developed in this study was ba ed on a method developed by Vinci et al. [2006] but
adapted to include deuterated analogues ofIBP, DCF and PBZ and the LC-MS detection
Was replaced with GC-MS/MS coupled with a derivatisation step for detection ofIBP,
.J<.PF and D F. The advantage of the additional derivatisation step is the ability to
produce two daughter ions for the determination of !BP whereas by LC-MS only
precur Or (parent) and one daughter ion for these compounds could be obtained [Vinci et
aI., 2006]. This method involve the addition of acetonitrile to bovine milk followed by
Clean_up u ing I olut ™

18

olid phase extraction (SPE) cartridges and analysis by GC-

M IM . To th b t of our knowledge there are no methods published for the
determination of IBP KPF D F and PBZ in bovine milk using GC-MS/MS in multiple
reactio

'.
n monltonng mode.
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Figure 3.1 Structures of ibuprofen (IBU), diclofenac (DCF), ketoprofen (KPF) and
phenylbutazone (PBZ)

3.3 Experimental

3.3.1 Materials and reagents
Water, ethanol, ethyl acetate, methanol, acetonitrile, acetic acid, hydrochloric acid (37
%), n-hexane and iso-octane (HiPerSolv grade) were obtained from BDH (Merck, UK).
I-Ieptafluorobutyric Acid Anhydride was obtained from Pierce, (Pierce, USA). 1,1,13,3,3- Hexafluoro-2-propanol was obtained from Sigma (Sigma Aldrich, Ireland). PBZ
was purcha ed from igma ( igma Aldrich, Ireland). dwPBZ was obtained from
Cambridge I otope Labs ( arilbridge Isotope Labs, USA). KPF was purchased from
FIUka R'ledel-de-Haen ( igma Aldrich, Ireland). IBP and DCF were purchased from
Igrna Aldrich ( igma Aldrich, Ir land). d3-IBP and d4 -DCF were obtained from CD
l~op

D

.
fP BZ, KPF,IBP,
0
I otop , anada). Primary stock standard solutIOns

DCF d- 10 PBZ d3-IBP and d4-D F (stable for 12 months) were prepared in ethanol at a
concentration of 1 mg mL- I . Intermediate inglc standards solutions of all analytes (stable
III

for 6 months) were prepared in methanol at a conceptration of 10 Ilg mL -I. PBZ, KPF,
IBp and DCF standard fortification solution (stable for 6 months) was prepared in
methanol at a concentration of 500 ng mL- 1 from the 10 Ilg mL- 1 intermediate stock
solution. A fortification solution of dlO-PBZ, d3 -IBP and d4-DCF (stable for 6 months)
Was prepared in methanol at a concentration of 500 ng mL- 1 from the 10 Ilg mL- 1
intermediate stock solution. All standards were stored at 4 QC in the dark. Isolute ™
endcapped C l8 solid phase extraction cartridges (6 mL, 1 g) were obtained from Biotage
(Biotage, UK). Methanol:water (10:90, v/v) and 10 mM ascorbic acid were used as solid
phase extraction wash solvents. N-hexane:diethyl ether (50:50,v/v) was used as the solid
phase extraction elution solvent. Injection solvent was iso-octane.

3.3.2 GC conditions
The GC sy tern con isted ofa Varian CP-3800 Gas Chromatograph coupled to a Varian
1200 L Quadrupole M and a Varian 8400 Autosampler (Varian, CA, USA). The carrier
gas Was helium at flow of 1.5 mL min- I . IBP, KPF, DCF and PBZ were chromatographed
On a column with film thickne

of 0.25 /lm, diameter 0.25 mm, length 30 m packed with

E-54/ P il 8 type material (Restek, Buchs, UK). The injector temperature was
maintained at 275

0

and it wa a constant temperature splitless programmable

temperature vaporising (PTV) injection. The injection volume was 2 Ill. The oven
temp ratur wa

t at 100

for 1 min and ramped to 300 QC in increments of 10 QC per

minut . Th t mp ratur i held at 300 QC i held for] min. The runtime is 22 minutes.
Data acqui iti nand integrati n were performed using Varian MS Workstation (version
1] 2

6.5) chromatographic management software (Varian, CA, USA). The described GC
system was shown to be suitable for the analysis ofIBP, KPF, DCF and PBZ (Figures 3-2
to 3-9).

3.3.3 MSIMS parameters
The analysis was performed using El positive MS/MS with multiple reaction monitoring
(MRM) mode. Two transitions per compound were used and the collision voltages were
Optimised as shown (Table 1). The MS/MS detector conditions were as follows: electron
energy, -70 eV; detector voltl:\ge, 1950 volts; detector setting, fixed voltage; collision cell
pressure 1.5 mTorr; ion source temperature, 250°C; transfer line temperature, 290°C;
and the collision gas was argon.

3.3.4 Milk ample
Milk obtained for use as negative controls was separated into 50 mL aliquots and stored
at -20

0

•

The milk was obtained from local supermarkets and was analysed in previous

batches. Th milk was found to contain no detectable residues ofIBP, KPF, DCF and

paz and wa

used as negative controls.

3.3.5 a rnp Ie e traction and clean-up
Milk arnpl

(5 ml) wer aliquoted into 50 ml polypropylene tubes. Samples were

fOrtified with int mal

tandar~ at 1 vel

POrtion fa 500 n m

-I

fOrtified at 1

1

corresponding to 15 ng mL- by adding a 150 ilL

mix olution of d3- IBP d4-DCF and d1o-PBZ. Samples were
1

rr p nding t 5, 7.5 and lOng mL- by adding 50, 75 and 100 ilL
113

1

portions of a 500 ng mL- solution ofIBP, KPF, DCF and PBZ. After fortification ,
samples were held for 15 min prior to extraction. Acetonitrile (5 mL) was added and the
samples were vortexed (30 sec), centrifuged (3500 rpm, 10 min, 4 QC) and the
supematant was transferred to a clean polypropylene tube. The sample pellet is reextracted with 5 mL of acetonitrile and the supematants were combined. A total of 10
mM ascorbic acid (20 mL) and 1 M hydrochloric acid (0.2 mL) were added to the
extracts and the pH of the samples were checked to ensure they were at pH 3 before
proceeding to the solid phase extraction (SPE) stage. The sample extracts were purified
by SPE using C l8 SPE cartridges. Sample extracts were loaded onto the cartridges
(preconditioned with n-hexane:diethyl ether (50:50, v/v) (3 mL), methanol (3 mL) and
Water (5 mL). The samples were loaded onto cartridges under gravity. The cartridges
Were washed with 10 mM ascorbic acid (3 mL) and methanol:water (10:90, v/v) (3 mL).
The cartridges were dried under vacuum (30 min). The cartridges were eluted with nhexane:diethyl ether (50:50, v/v) (3 mL). The eluates were reduced to dryness under
nitrogen without heat before re-dissolving in 50 ilL of heptafluorobutyric acid anhydride
(BF AA) and 25 ilL 1,1,] -3,3,3-Hexafluoro-2-propanol (HFPOH) and vortexed (1 min).

Sample are capped and placed in an oven at (60 QC, 45 min). Samples were allowed to
cOme to room temperature and the derivatisation reagent is evaporated under a gentle
stream of nitrog n with no h at. amples were reconstituted in 50 ilL of iso-octane. An
aliquot (2 ilL) i inj cted onto th GC column.
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Table 3.1 MS/MS parameters for determination of IBP, KPF, DCF and PBZ
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3.3.6 Matrix-Matched Calibration
Matrix matched calibration curves were prepared and used for quantification. Control
milk previously tested and shown to contain no residues was prepared as above (3.3.4).
One control milk sample was used for each calibration standard level. Milk samples (5
ml) were aliquoted into 50 ml polypropylene tubes. Samples were fortified with internal
standard at levels corresponding to 15 ng mr' by adding alSO j.LL portion ofa 500 ng
1

mL- mix solution of d3-IBP, d 4-DCF and d,o-PBZ. Samples were fortified at levels
corresponding to 0, 2, 5, 7.5, 10 and 20 ng mr' by adding 0, 20, 50, 75, 100 and 200 j.LL
portions of a 500 ng mL-' standard solution ofIBP, KPF, DCF and PBZ. After
fortification samples were held for 15 min prior to the extraction procedure as described
abOve (3.3.5). Calibration curves were prepared by plotting the response factor (peak area
analyte/peak area internal standard) as a function of analyte concentration (0 to 20 ng mr
I

) to quantify amples.

3.3.7 Method validation
For e timation of accuracy, blank milk samples were fortified with IBP, KPF, DCF and
PBZ at 5 7.5 and 10 ng mr'.

ix replicate test portions, at each of the three fortification

levels Were analysed. Analysis of the 18 test portions was carried out on three separate
occa ion.

or th e timation of the precision of the method, repeatability and within-

laboratory reproducibility wa calculated. The decision limit (CCa) of the method was
calculated according t th calibration curve procedure using the intercept (value of the
.'
signal, Y whe re th concentratIOn
x I eq ual to zero) and 2 .33 times the standard error of
the .
h d'
b'I'
Int rc pt fI r a t of data with ix replicate at 3 levels. T e etectlOn capa I Ity
(C a) wa calculat d by adding 1.64 time the tandard error to the

CC~.
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3.4. Results and Discussion

3.4.1 Preliminary experiments

The GC-MS/MS method was developed to provide confirmatory data for the analysis of
bovine milk for IBP, KPF, DCF and PBZ. The MS/MS fragmentation conditions were
Investigated and collision energies were optimised. For a method to be deemed
confirmatory four identification points are required. These identification points can be
obtained by monitoring one precursor ion (parent mass) and two daughters
(corresponding to strong and weak ion).

IBP, KPF and DCF are derivatised with a mixture ofHFAA and HFPOH. The reagents
form a derivative with the hydroxyl group of the carboxylic acid on IBP, KPF and DCF.
PBZ does not have any functional groups that are easily derivatised. The ions monitored
for each analyte generally result from cleavage of the aliphatic chains containing the
hexafluoropropyl moiety.

IBP, KPF D F and PBZ are chromatographed on a Restex-l MS column with retention
times of 6. I, 11.9 14.4 and 16.4 min respectively. d3-IBP is used as I.S for IBP and KPF.
cLt-DCF

and d1o-PBZ were used as I.S for DCF and PBZ.

3.4.2 V I'
a Idation tudy

Valid t'
. C
. , D ..
a IOn of the method wa according to procedures described In ommlSSlOn eClSlon
20

02/657/ C [ uropean orrimission 2002J covering specificity, calibration curve
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linearity, recovery (accuracy), precision, decision limit (CCu) and detection capability
(CCP).

3.4.2.1 Specificity
The technique of GC-MS/MS itself offers a high degree of selectivity and specificity. To
establish the selectivity/specificity of the method, a variety of milk samples were fortified
with the IBP, KPF, DCF and PBZ and d3-IBP, d4-DCF and d 10 -PBZ and non-fortified
samples were also analysed. Additionally samples were fortified with 2.0 ng ml- I of other
NSAIDs which included vedaprofen (VDF), tolfenamic acid (TOLF), mefenamic acid
(MEF), flunixin (FLU), oxyphenylbutazone (OXYPHEN) and suxibutazone (SUXI). No

Interferences were observed in the retention window of IBP, KPF, DCF and PBZ in
chromatograms when fortified with these substances.

3.4.22
. of the re pOD e
. L·meanty
The linearity of the chromatographic response was tested with matrix matched curves
Using'
.
.
.
20 ng m L- 1. The regressIOn
.
SiX calIbratIOn points in the concentratIOn range of 0 to
coefficient (r 2) for all the calibration curves used in this study were

~ 0.99.

3.42
3A CCuracy
••
The accuracy of th method wa determined using bovine milk samples fortified at 5.0,
7.5 and 10.0 ng ml

I.

Mean corrected recovery (n

= 18)

of the analyte, determined in

three eparat a ay (Tabl 3.2) wa between 104 and 112 % for IBP, KPF, DCF and

Paz.
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3.4.2.4 Precision
The usefulness of suitable deuterated standards is demonstrated in the excellent
repeatability and within-laboratory reproducibility obtained for IBP, DCF and PBZ
(Table 3.2). No deuterated analogue is available for KPF so poorer precision was
obtained for this analyte. The precision of the method, expressed as RSD values for the
Within-lab reproducibility at the three levels of fortification (5, 7.5 and 10 ng mr J), for
IBP, DCF and PBZ was less than 8 %. The RSD values were less than 28 % for KPF.
Even by applying correction by means of the 1.S of the other analytes to KPF a much
higher RSD was achieved and this indicates the necessity for the incorporation of a
structurally identical isotopically-labelled IS ofKPF in the method. Due to the low
precision obtained for KPF without a suitable 1.S, the method developed was suitable for
qualitative confirmation only.

'fable 3.2 Intra- and inter-assay variation for accuracy of IBP, KPF, DCF and PBZ
fro III bovine milk'
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3.4.2.5 CCaand CCp
The deci ion limit (

a) i d fined a the limit above which it can be concluded with an

errOr prObability of a, that a ample contain the analyte. In general, for non-MRL
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substances an a equal to 1 % is applied. The detection capability (CC[3) is the smallest
Content of the substance that may be detected, identified and quantified in a sample, with
a statistical certainty of 1-[3, were [3

= 5 %. CCa and CC[3 were calculated using the

intercept (value of the signal, y, were the concentration, x is equal to zero) and the
standard error of the intercept for a set of data with 6 replicates at 3 levels (5.0, 7.5 and
10.0 ng mr'). Blank milk was fortified at 1, 1.5 and 2 times the minimum required
l

performance level of 5 ng mr set for IBP, KPF, DCF and PBZ. CCa is the concentration
corresponding to the intercept + 2.33 times the standard error of the intercept. CCa
values of 0.59, 2.69, 0.90 and 0.70 ng mr' were achieved for IBP, KPF, DCF and PBZ.

cep is the concentration corresponding to the signal at CCa + 1.64 times the standard
error of the intercept (i.e the intercept + 3.97 times that standard error of the intercept).

cep values of 1.01,4.58,1.54 and
Paz.
Table 3.3 Calculated CCa

A

1.19 ng mr' were achieved for IBP, KPF, DCF and

a~d CC[3 values based on data from Assay 1, 2 and 3
-I.~

CL:fl(

-I.)

L ]

".Sg
LS4
LI9
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3.4.2.6 Measurement Uncertainty
According to SANCO/2004/2726 rev 1 the within laboratory reproducibility can be
regarded as a good estimate of the combined measurement uncertainty of individual
methods [SANCO 2004]. For the calculation of the extended uncertainty a safety factor is
required. The within laboratory reproducibility should be multiplied by a value of2.33
and this should be used when determining the CCa, corresponding to a confidence level
of 99 %. As the only source of variation during the validation was the different days and
different milk sourced from different animals it was decided to use a safety factor of 3.0
Instead of2.33. The measurement uncertainty of the method was estimated at 17.8,80.9,
28.2 and 20.2 %. This was determined by calculating the within laboratory
reproducibility of the method, followed by multiplication of the within laboratory
reprOducibility by the safety factor of 3.0.

3.4.2.7 Evaluation
The confirmatory method developed in this study has been used to confirm the presence
OfIBP, KPF, D F and PBZ in bovine milk in the National Monitoring Plan in Ireland in
2006 2007 and 2008. In routin monitoring for these substances at our laboratory, it was
POs 'b
1- I ·
I. I
SI le to d tect the pr cur or ion and two daughter ions (at 2 ng m ) In mu tip e

react'
.'
. t
I
IOn rn nitoring mod . Furth rmore the relative retentIOn tIme versus In erna
standard r quir m nt and th product ion ratio requirement was also met. The method has
been Carri d out by diff! rent analy t ov r a period of three years under varying
enVironmental condition and th method was shown to be robust. The method was
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accredited by the Irish National Accreditation Board in 2006 according to IS017025
standard used by testing and calibration laboratories.

3.5 Conclusions
A relatively fast, simple and selective GC-MS/MS method for the detection of IBP, KPF,
DCF and PBZ in bovine milk has been developed. There is no published confirmatory
method for the simultaneous determination ofIBP, KPF, DCF and PBZ in bovine milk by
GC-M /MS that is validated according to Commission Decision 2002/657/EC
[Commission Decision 2002]. Recently it was proposed by Community Reference
Laboratories (CRLs) in Europe that laboratories should be capable of monitoring for
l

KPF, D F and PBZ in bovine milk at a level of 5 ng mr and IBP at a level of lOng mr

l

in EU member states [ ANCO 2007]. This study shows that the required sensitivity was
achieved for all compounds that easily meet the proposed levels. The method performs
Very Well in terms of accuracy and within-laboratory reproducibility. For KPF
Improvement can b made if a suitable deuterated analogue becomes available.
The objective of the work to develop, validate and accreditate a method for these residues
in bOVine milk at low ng mr l levels and validate according to the requirements in
C° rntni ion Deci ion 2002/657/

therefore has been achieved successfully.
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Chapter 4: Confirmatory analysis of firocoxib in
bovine milk by rapid resolution liquid
chromatography tandem mass spectrometry

PUbli h d .
e 10 Journal of hromatography B, 877,2009, Pages 541-546
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4.1 Abstract
A rapid method has been developed to analyse for firocoxib (FIRO) residue in bovine
milk. Milk samples were extracted with acetonitrile and sample extracts were purified on
Evolute ™ ABN solid phase extraction cartridges. Aliquots were analysed by rapid
resolution liquid chromatography tandem mass spectrometry (RRLC-MS/MS). The
method was validated in bovine milk, according to the criteria defined in Commission
Decision 2002/657/EC. The decision limit (CCa) was 1.18 ng/mL and for the detection
capability a (CCP) value of 2.02 ng/mL was obtained. The measurement uncertainty of
the method was 27 %. Fortifying bovine milk samples (n = 18) in three separate assays,
show the accuracy of the method to be between 96 and 105 %. The precision of the
method, expressed as R D values for the within-lab reproducibility at the three levels of
fortification (5 7.5 and 10 ng/mL) was less than 11 % respectively.
KeYWord: Firocoxib; Bovine Milk; Method Validation; Decision Limit; Detection
Capability; Mas

pectrometry
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4.2 Introduction
Fir
'b (3
OCOXl
- cyclopropymethoxy-5,5-dimethyl-4-[4-(methyl sulfonyl) phenyl]-2-(5H)furanone), (FIRO) is a non-steroidal anti-inflammatory drug (NSAID). The molecular
structure of this compound is shown in Fig. 4.1.

p'

Igure 4.1 Structure of Firocoxib

NSAIDs are u ed widely in veterinary medicine in the treatment of food producing
animals. FIRO gives therapeutic efficacy due to inhibition of prostaglandin synthesis via

.
selectiv b' .
e tndtng to the type II cycloxygenase (COX-2) Isoenzyme [McCann et aI., 2004,
MCCann t al. 2005]. A survey involving 2000 veterinarians reported that 93 % of
Veterinar'
lan u eN AID in food producing animals and dairy practitioners reported the
mOst frequent u

[U

ode 1988]. Overall NSAIDs are an important group of

comPOund which are routinely u ed for the treatment of food producing animals
[I<oPcha et aI., 1992]. A urvey in 1995 reported that NSAIDs were the second most
Prescrib d
e cia

of drug after microbial for dairy practitioners [Sundlof et aI., 1995]. In

2008 a
tUdy r port d th increa ed incid nce of re idue violations for NSAIDs in cattle
[Smith et I
11 b
~
a " 2008] in th pa t 10 year. According to ED law, a su stances lor
veterinary u

n d t b in lud d in Ann x

1-3 of Regulation 23

77/90 [E

uropean
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Commission 1990]. This regulation establishes lists of compounds that have a fixed MRL
(Annex I), that need no MRL (Annex 11) or that have a provisional MRL (Annex Ill).
FIRO is a compound that has been included in Annex 1 and has a maximum residue limit
(MRL) established only in equine tissues. Substances that have no MRL established are

prohibited for use in food producing animals. FIRO has no MRL established in bovine
Species. It is anticipated that due to the large increase in NSAID use in recent years that
this sub tance may be used to treat food producing animals other than equines. Off label
application of veterinary drug compounds to cows that produce milk for human
consumption in the Republic of Ireland and the European Union is illegal. In Ireland in
2007, Ivermectin, a veterinary drug which is licensed in liver, kidney and fat of all
mammalian food producing p cies but not authorised in animals that produce milk for
human Consumption wa found in milk by the ational Reference Laboratory for
Avermectin in Ir land. Th finding of this substance in milk is illegal within the EU.
FIRQ i an wly lic n d

AID in hor es [EMEA 38346206] and has become available

On the mark t und r the trade name Previcox since 2007 [EMEA 082 ] an dE'
.
qUloxx SInce
2008 [ M A V-142]. IRa cannot be u ed in mares in which milk is intended for human
consUmption. IR

ha b n hown to be comparable in efficacy to meloxicam and

carprofen [ M A 082] and al

0

be n hown to be comparable in efficacy to

PhenYlbutazon [D uc t tal., 2008]. In the ca e of carprofen and meloxicam these
SUbstances ar I'IC n d ~ ruin hor

Id
and cattle, therefore .It canno t b
e exc
u ed that

FIR.Q would n t bud in attl . A in th ca e of iv rmectin, there is a need to

anrIcipat th

.
r qUlr m nt

adn:' .
•Inl trati n f FIR

f th futur wh re ri k could occur due to the

t milk pr du ing p cie. h refor the development of an
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analytical method at the National Reference Laboratory for NSAIDs in Ireland was
undertaken to provide an analytical tool to monitor for this substance. Longterm exposure
to NSAIDs has caused kidney tumors in mice and liver tumors in rats [Kari et al., 1995].

It has been reported in recent years that the COX -II inhibitor class ofNSAIDs of which
FIRo is a member has been implicated in cardiovascular harm in humans [Van Staa et al.
2008, Debabrata et al., 2008J. FIRO shows the the same undesirable side effects [EMEA
082J as other NSAIDs (diarrhoea, mouth lesions and lethargy) therefore monitoring of its
illegal use in milk producing animals is important for consumer protection. There are
very limited methods for the determination of FIRO in food producing animals and no
lllethods for the determination of this substance in animal products.
Plasma of dogs and horses have been diluted with water and samples were purified using
Water ™ HLB olid phase extraction cartridges and analysed by LC-DV [Kvaternick et
al., 2007J. Urine and plasma from dogs and horses was diluted with an aqueous solution
of 5 % acetic acid and passed through a Waters Oasis HLB ™ 96 -well solid phase
extraction plate and analysed by liquid chromatography tandem mass spectrometry ( LC-

'Ms

/M ) [Letendre et al. 2007J.

This method involve the addition of acetonitrile to bovine milk followed by clean-up
Using Evolut

TM

AB

olid pn a e extraction (SPE) cartridges and analysis by RRLC-

MS/M . To the best of our knowledge there are no methods published for the
dete1"l'h'l
.
.
.
d
t dId
<lI lOatIon of FIRO in bovine milk. The objectIve of thIS stu y was
0 eve op an
validate a rugg d,

n ItIv,

I ctive and efficient method for the analysis of FIRO in

bOVine milk for implementation into the National Programme in the Republic of Ireland.
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4.3 Experimental

4.3.1. Materials and methods
Water, ethanol, ethyl acetate, methanol, acetonitrile, acetic acid, hydrochloric acid (37

%), n-hexane and iso-octane (HiPerSolv grade) were obtained from BDH (Merck, UK).
FIRO was given as a gift from Merial (Saint-Vulbas, France). Primary stock standard
solution of FIRO (stable for 12 months was prepared in ethanol at a concentration of 1
mg/mL. Intermediate single standard solution of FIRO (stable for 6 months as standard
.injected throughout 6 months period gave similar results) was prepared in methanol at a
Concentration of 10 J-lg/mL. FIRO standard fortification solution (stable for 6 months as
standard injected throughout 6 month period gave similar results) was prepared in
methanol at a concentration of 500 ng/mL from the 10 J-lg/mL intermediate stock solution.

A.B standards were stored at 4 °c in the dark. Isolute ™ Evolute ABN 50 J-lm solid phase
ex.traction cartridges (l0 mL, 100 mg) were obtained from Biotage (Biotage, UK).
Methanol:water (l0:90, v/v) and 10 mM ascorbic acid were used as solid phase extraction
wash solvents.

-hexane:diethyl ether (50:50,v/v) was used as the solid phase extraction

elution olvent. Inj ction olvent wa water:acetonitrile (90: 10, v/v).
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4.3.2 Le conditions
The LC consisted of an Agilent 1200 Rapid Resolution LC equipped with a G 13128
Binary pump, G 1316B-HiPALS SL autosampler and a G 1316B-TCCSL column oven
(Agilent Ireland). FIRO was chromatographed on a 1.8 Ilm Agilent Eclipse Plus C I8
column (2.1 x 50 mm) (Agilent, Ireland) and the column temperature was maintained at
0

55 C. A gradient was applied with water and acetonitrile (90: 10, v/v + 0.001 M acetic
acid) (A) and acetonitrile (B). The flow rate throughout the chromatographic analysis was
0.75 mLlmin and the following gradient was applied: 0 min, 90% A; 0.4 min, 90% A;
1.0 min, 85% A; 3.1 min, 80% B; and 4.7 min, 90% A. The column was regenerated for
1.8 min before injection (Table 4.1). The total run time was 6.5 minutes. The injection
VOlume was 15 ilL. The mass spectrometer used was a QTRAP 4000 with a
TUrboIo n pray source from Applied Biosystems (Applied BiosystemsIMDS-Sciex,
Canada). The M was controlled by version 1.4.2 of Analyst software. The described
LC-M /M

y tern wa

hown to be suitable for the analysis of FIRO (Figure 4.2-4.3).
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4.3.3 MS/MS parameters
The analysis was performed using positive ion electrospray MS/MS in multiple reaction
monitoring (MRM) mode. Two transitions were used and the collision voltages were
Optimised as shown (Table 4.2). Each transition was perfonned with a 13 ms dwell time
and a pause time of 3 ms. The MS/MS detector conditions were as follows: Ion mode
electrospray positive; curtain gas 45 psi; ion spray voltage 4400 V; temperature 6500C;
IOn source gas I 70 psi; ions source gas 2 70 psi; Interface heater on; entrance potential

10 V; Resolution QI unit; Resolution Q3 unit; CAD gas =high
.Table 4.1 Le gradient profiJe for determination of FIRO.
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4.3.4 Milk samples

Untreated milk from 8 individual cows was obtained by veterinary inspectors and milk (5
different brands of whole milk) obtained from a local supermarket were used as negative
Controls. The milk was analysed separately and no detectable residues of FIRO were
found. Milk samples previously analysed were pooled together and separated into 50 mL
aliquots and stored at -20 QC and used as negative controls in the experiments.

.4.3.5 Sample extraction and clean-up

Milk samples (5 m!) were aliquoted into 50 ml polypropylene tubes. Samples were
fOrffi
.
1 led at levels corresponding to 5, 7.5 and 10 ng/mL by addmg 50, 75 and 100 ilL
POrtions of a 500 ng/mL solution of FIRO. After fortification, samples were held for 15
tnin prior to extraction. Acetonitrile (5 mL) was added and the samples were vortexed (30
sec), centrifuged (3500 rpm, 10 min, 4 DC) and the supematant was transferred to a clean
Polypropylene tube. The sample pellet is re-extracted with 5 mL of acetonitrile and the
supe1llatants are combined. 10 mM ascorbic acid (20 mL) and 1 M hydrochloric acid (0.2
tnL) Were added to the extracts and the pH of the samples were checked to ensure they
Were at pH 3 before proceeding to the solid phase extraction (SPE) stage. The sample
extracts Were purified by SPE' using Evolute ABN ™ SPE cartridges. Sample extracts
were loaded onto the cartridges (preconditioned with methanol (3 mL) and ascorbic acid
(3 rnL). The samples were loaded onto cartridges under gravity. The cartridges were
Washed with methanol:water (10:90, v/v) (2 mL). The cartridges were dried under
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vacuum (15 min). The cartridges were eluted with n-hexane:diethyl ether (50:50, v/v) (2
x

2 mL). The eluates were reduced to dryness under nitrogen without heat before re-

dissolving in 150 ilL water:acetonitrile (90: 10, v/v) and vortexed (1 min). An aliquot (15
ilL) is injected on the LC column.

4.3.6 Matrix matched calibration
Matrix matched calibration curves were prepared and used for quantification. Control
milk previously tested and shown to contain no residues was prepared as above (4.3.4).
One Control milk sample was used for each calibration standard level. Milk samples (5
ml) Were aliquoted into 50 ml polypropylene tubes. Samples were fortified at levels
corresponding to 0, 2, 5, 7.5, 10 and 20 ng/mL by adding 0, 20, 50, 75, 100 and 200 ilL
POrtions of a 500 ng/mL standard solution of FIRO. After fortification, samples were held
for 15 min prior to the extraction procedure as described above (4.3.5). Calibration curves
were prepared by plotting the peak area as a function of analyte concentration (0 to 20
nglmL) to quantify samples.

4.3.7 Method validation
For estimation of accuracy, blank milk samples were fortified with FIRO at 5, 7.5 and 10
nglmL.

ix replicate test portions at each of the three fortification levels, were analysed.

A.nal Y IS
. of the 18 t t portions wa carried out on three separate occasIOns.
.
For the
estimation of th

preci ion of the method, repeatability and within-laboratory

reprOducibility wa calculated. The decision limit (CCa) of the method was calculated
aCCording to the calibration curve procedure using the intercept (value of the signal, y,
Where the c ncentration, x i equal to zero) and 2.33 times the standard error of the
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intercept for a set of data with 6 replicates at 3 levels. The detection capability (CCP) was
calculated by adding 1.64 times the standard error to the CCa.
4.4 Results and Discussion
4.4.1 Preliminary experiments

The LC-MS/MS method was developed to provide confirmatory data for the analysis of
bovine milk for FIRO. The MS/MS fragmentation conditions were investigated and
Collision energies were optimised. For a method to be deemed confirmatory four
identification points are

requi~ed. These identification points can be obtained by

.monitoring one precursor ion (parent mass) and two daughters (corresponding to strong
and Weak ion).

FIRO Was Chroma~ographed on a 1.8 Ilm Agilent Eclipse Plus C I 8 column with retention
time of2 .57 mm.
.

4.4.2 Validation tudy
. . D ..
Valid .
. d' C
ahon of the method was according to procedures descnbe In ommlSSlOn eClSlOn

0
'2 02/657/

[ommi ion Deci ion 2002] covering specificity, calibration curve

linearity recovery (accuracy), precision, decision limit (CCa) and detection capability

(CC~).

143

'4.4.2.1 Specificity
The technique of LC-MS/MS itself offers a high degree of selectivity and specificity. To
establish the selectivity/specificity of the method, a variety of milk samples were fortified
with the FIRO and non-fortified samples were also analysed. No interfering peaks were
observed at the retention time for FIRO (Figure 4.2-4.3). Additionally samples were
fortified with 2.0 ng/mL of other NSAIDs which included flunixin (FLU), carprofen
(CPF), meloxicam (MLX), oxyphenylbutazone (OXYPHEN) and diclofenac (DCF). No
interferences were observed in the retention window of FIRO in chromatograms when
fort'fi
I led with these substances.

4.4.2.2 Linearity ofthe response
The linearity of the chromatographic response was tested with matrix matched curves
USing 6 calibration points in the concentration range of 0 to 20 ng/mL. The regression
Coefficients (/) for all the calibration curves used in this study were ~ 0.99.

4.4.2.3 Accuracy
The aCCuracy of th method wa determined using bovine milk samples fortified at 5.0,
7.5 and 10.0 ng/mL. Mean corrected recovery (n = 18) of the analyte, determined in three
separat

e a ay (Table 3) wa 'between 96 and 105

01
10.

4.4.2.4 Preci ion
The pr ci ion fth
.,
b
d 'b'l'
e met h0 d ,expre ed as R 0 values for the wlthm-la repro UCI Ilty
at the thr

lev I of tI rtification (5, 7.5 and 10 ng/mL) was less than 11 % (Table 4.3).
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Table 4.3 Intra- and inter-assay variation for recovery of FIRO from milk

Ibrtt1lcZlon level

r. mL-l ,

IMtbJalllJo

5

11lU

75
l:J

gS3

11152

29
1.1
19

CV(~

2.5
7.1

5.2

J.g
11.3
lOA

5, 75,10

~I

4.4.2.5 CCa and CCp
The decision limit (CCa) is defined as the limit above which it can be concluded with an
error probability of a, that a sample contains the analyte. In general, for non-MRL
Substances an a equal to 1 % is applied. The detection capability (CCP) is the smallest
Content of the substance that ~ay be detected, identified and quantified in a sample, with
a st . .
. atlstlcal certainty of 1-P, were p = 5 %. CCa and CCp were calculated using the
Intercept (value of the signal, y, were the concentration, x is equal to zero) and the
s t a nerror
d aof
rthe
d 'Intercept for a set of data WIth
.
'
6 replIcates
at 3 IeveI s (5. 0 ,7.5 and

10.0 nglmL) . Blank milk was fortified at ], ].5 and 2 tImes
.
.,
. d
the minImUm
requIre
. correspond'Ing to
.Perform ance lev I of 5 ng/mL et for FIRO. CCa is the concentratIOn
the'
Intercept + 2.33 time the tandard error of the intercept. CCa value of 1.18 ng/mL
\Vas ach'leved for IRO.

pi

. to th
'
I at CC a +
the concentration corresponding
e SIgna

1.64 tim es the standard error of the intercept (l.e
.
.
'
the Intercept
+ 3.97
tImes that stan dard
error f
o the interc pt).

p value of2.02 ng/ mL was achieved for FIRO.
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4.4.2.6 Measurement Uncertainty
According to SANCO/2004/2726 rev 1 the within laboratory reproducibility can be
regarded as a good estimate of the combined measurement uncertainty of individual
methods [SANCO 2004]. For the calculation ofthe extended uncertainty a safety factor is
required. The within laboratory reproducibility should be multiplied by a value of 2.33
and this should be used when determining the CCa, corresponding to a confidence level
of 99 %. As the only source of variation during the validation was the different days and
different milk sourced from different animals it was decided to use a safety factor of3.0
Instead of2.33. The measurement uncertainty of the method was estimated at 27 %. This
was determined by calculating the within laboratory reproducibility of the method,
follOwed by multiplication of the within laboratory reproducibility by the safety factor of

3.0.

4.5 Conclusions
A relatively fast, simple, sensitive and selective RRLC-MS/MS method for the detection
of FIRo in bovine 'milk has

b~en developed. There is no published confirmatory method

for the determination of FIRO in bovine milk that is validated according to Commission
Decision 2002/657/EC [Commission Decision 2002]. This is the first time that milk
extracts have been purified using Evolute ™ ABN solid phase extraction cartridges for
the determination of FIRO and the first time that FIRO has been analysed using RRLC.MS/MS. The method performs very well in terms of accuracy and within-laboratory
reproducibility. In routine monitoring for this substance at our laboratory in 2008 it was
POssible to detect the precursor ion and two daughter ions (at 2 ng/mL) in multiple
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reaction monitoring mode in the lowest standard in the matrix matched curve.
Furthermore the product ion ratio requirement was also met. The method meets the
requirements for a confirmatory method according to 2002/657/EC. The method has been
carried out by different analysts under varying environmental conditions and the method
Was Shown to be robust.
The objective of the work to develop and validate a method for this residue in bovine
milk and incorporate into the National Monitoring Programme in Ireland at low nglmL
levels and validate according to the requirements in Commission Decision 2002/657/EC
'therefore has been achieved successfully.
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Chapter 5: Rapid confirmatory analysis of nonsteroidal anti-inflammatory drugs in bovine milk
by rapid resolution liquid chromatography
tandem mass spectrometry
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5.1 Abstract

A rapid method has been developed to analyse carprofen (CPF), diclofenac (DCF),
mefenamic acid (MFN), nitlumic acid (NIFLU), naproxen (NAP), oxyphenylbutazone
(OXYPHEN), phenylbutazone (PBZ) and suxibuzone (SUXI) residues in bovine milk.
Milk samples are extracted with acetonitrile and sample extracts were purified on Evolute
TM

ABN solid phase extraction cartridges. Aliquots were analysed by rapid resolution
liquid chromatography tandem mass spectrometry (RRLC-MS/MS) with a runtime of 6.5
min. The method was validated in bovine milk, according to the criteria defined in
Commission Decision 2002/657/EC. CCa values of 0.46, 1.08,0.92,1.26,1.29,2.12,
.0.55 and 2.86 ng mL- 1 were determined for CPF, DCF, MFN, NIFLU, NAP, OXYPHEN,
PBZ and SUXI respectively. CCp values of 0.79, 1.85, 1.56,2.15,2.19,3.62,0.94 and
4.87 ng mL- 1 were determined for CPF, DCF, MFN, NIFLU, NAP, OXYPHEN, PBZ and
SDXI respectively. The measurement uncertainty ofthe method was estimated at 9, 28,
'28,45,46,45, 10 and 39 % for CPF, DCF, MFN, NIFLU, NAP, OXYPHEN, PBZ and
SDXI. Fortifying bovine milk samples (n

= 18) in three separate assays, show the

accUracy of the method to be between 82 and 108 %. The precision of the method,
expressed as RSD values for the within-lab reproducibility at the three levels of
'fOrtification (5, 7.5 and 10 ng mL-') was less than 16 % respectively. The advantage of
the method is that low ng mL- 1 levels can be detected and quantitatively confirmed
rapidly in milk and that 3 batches of samples can be analysed within a single day using

RRLC-MS/MS with a runtime of 6.5 minutes.
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Keywords: Non-steroidal Anti-Inflammatory Drugs; Bovine Milk; Rapid Resolution
Liquid Chromatography Mass Spectrometry; Method Validation

5.2 Introduction

Carprofen (CPF), diclofenac (DCF), mefenamic acid (MFN), niflumic acid (NIFLU),
naproxen (NAP), oxyphenylbutazone (OXYPHEN), phenylbutazone (PBZ) and
suxibuzone (SUXI) are non-steroidal anti-inflammatory drugs (NSAIDs). The molecular
structure of these compounds is shown in Fig.5-1.
Structure a: Carprofen
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Structure b: Diclofenac
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Structure c: Mefenamic Acid
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Structure d: Naproxen
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Structure e: Niflumic Acid
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Structure f: Oxyphenylbutazone
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Structure g: Phenylbutazone
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Structure h: Suxibuzo ne

o

F·Ig. 5-1 Structures of the NSAIDs
Depending on the their heterogeneous molecular structures, NSAIDs can be classified
Into six main subclasses, sharing common pharmacological activity: (a) salicylic acid
derivatives; (b) propionic acid derivatives; (c) pyrazole derivatives; (d) aniline
derivatives, (e) oxicam derivatives and (t) COX 11 inhibitors. According to EU law, all
SUbstances for veterinary use need to be included in Annexes 1-3 of Regulation 2377/90
[European Commission 1990]. This regulation establishes lists of compounds that have a
fixed maximum residue limit, MRL (Annex I), that need no MRL (Annex 11) or that have
a provisional MRL (Ill). In mIlk CPF has been included in Annex 11 of the regulation
.only for bovine milk [European Commission 2005] and there is no MRL level for this but
it was still included in this study. DCF is not authorised for use in animals that produce
l11ilk for human consumption [Eur9pean Commission 2004]. No MRL is established for
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MFN, NIFLU, NAP, OXYPHEN, PBZ and SUXI and are considered as prohibited
sUbstances. The European Council recomend a stringent control of NSAIDs in food
producing animals [SANCO 2000] because of the potential teratogenic and carcinogenic
effects due to the considerable use of these drugs. NSAIDs can cause other adverse health
effects in humans such as aplastic anaemia, gastrointestinal disorders and agranulocytosis
[lnsel 1990] and changes in renal function [Goodman and Gilman 1992]. Longterm
expOSure to PBZ has caused kidney tumors in mice and liver turnors in rats [Kari et aI.,
1995]. NSAIDs are widely used in veterinary medicine in the treatment of food
prOducing animals. In 2008,

astudy reported the increased incidence of residue violations

.for NSAIDs in cattle [Smith et aI., 2008] in the past 10 years. A survey in 1995 reported
that NSAIDs were the second most prescribed class of drugs after microbials for dairy
practitioners [Sundlof et aI., 1995]. A survey involving 2000 veterinarians reported that
93 % of veterinarians use NSAIDs in food producing animals and dairy practitioners
reported the most frequent use [US Code 1988]. NSAIDs are an important group of
compounds which are routinely used for the treatment of food producing animals
[I<opcha et aI., 1992]. The widespread use ofNSAIDs presents a potential risk to the
consumer if food containing r~sidues enter the food chain so there is a need for the
development of methods to monitor compliance with legislation in the EU in a variety of
animal tissues and products. Milk is an important matrix for residue control. In Ireland
milk is one of the target matrices chosen to identify the misuse ofNSAIDs in animal
prOduction. There are few analytical methods for the determination ofNSAIDs in milk
.and those that have been described use high-performance liquid chromatography (HPLC)
[De Graves et aI., 1993, De Graves et aI., 1996, De Veau et aI., 1998, Musser et aI., 1998,
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De Veau 1996, Martin et aI., 1983, Gallo et aI., 2008], Liquid chromatography/mass
spectrometry [Gallo et aI., 2008, Feely et aI., 2002., Boner et aI., 2003, Daeseleire et aI.,
2003, Stolker et aI., 2008, Malone et aI., 2009] and gas chromatography/mass
spectrometry [Rubb et aI., 1995, Dowling et aI., 2008]. Most of the detection methods
focused onjust one or a few NSAID substances. However some multi-residue methods
eXist. A method developed by Gallo et al [18] is capable of analysing for 16 NSAIDs in
milk Using two separate analytical techniques and involves a screening LC-DAD method
.with limits of detection between 2 and 15 ng mL- 1 and a runtime of 35 min with an
eqUilibration time of 15 min per injection followed by confirmation using a LC ESIIontrap_ MS/MS method with an LOD of 5 ng mL- 1 except for flurbiprofen and a runtime
of 40 min per injection. The LC-MS method does not meet the requirements for a
confirmatory method according to Commission Decision 2002/657/EC [Commission
Decision 2002/657/EC] and a third analytical technique is required. A method by Stolker
et al. [Stolker et aI., 2008] is capable of analysing 20 NSAIDs in milk using a quantitative
screening method (UPLC-TOF-MS) with LOD's for specific NSAIDs such as NAP, PBZ
and DCF at 12.5,25 and 6.3 ng mL-) with a runtime of8.5 min. The method cannot meet
the minimum level for analysis ofNSAIDs in milk set at 5 ng mL-) for these substances
and furthermore the analysis by TOF-MS, medium to high resolution of approximately
10,000 FWHM is not included in Commission Decision 2002/657/EC [Commission
.Decision 2002]. Therefore a second analytical technique is required. Other LC-MS/MS
methOds available analyse between 1 and 4 NSAIDs residues in milk [Feely et aI., 2002,
Boner et aI., 2003, Daeseleire et aI., 2003, Malone et aI., 2009] with runtimes of 17, 20
and 20 and 33 min with detection limits ranging from 0 to 5 ng mL-l [Feely et aI., 2002,
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Boner et aI., 2003, Daeseleire et aI., 2003] or at their associated maximum residue limits
[Malone et aI., 2009].
Although some NSAIDs are licensed for use in milk, this study in milk concentrated on
the detection of those NSAIDs that are prohibited for use (except carprofen) as there is a
lack of available analytical methods. In Ireland in 2007, ivermectin, a veterinary drug
which is licensed in liver, kidney and fat of all mammalian food producing species but
not authorised in animals that produce milk for human consumption was found in milk by
the National Reference Laboratory for Avermectins in Ireland. The presence of this
sUbstance in milk is illegal. The development of a rapid analytical method at the National
Reference Laboratory for NSAIDs in Ireland was undertaken to provide an analytical tool
to monitor for non-authorised substances in bovine milk. The NSAIDs selected in this
stUdy Were chosen to allow a method to be developed for the analysis of a wide variety of
non authorised drugs from different NSAID sub-classes (b-d). The newly developed
Water wettable polymer based Evolute™ ABN (acidic basic neutral) solid phase
extraction (SPE) sorbent from Biotage was selected due to its drying properties and the
,Potential for monitoring structurally diverse substances with a single cartridge chemistry.
The new technology of Rapid Resolution Liquid Chromatography (RRLC, trade name
given by Agilent Technologies) was selected as can obtain rapid analytical results, speed
up method development times and utilise less solvent. This is the first time that milk
,extracts have been purified for the determination of the tested NSAIDs residues using
Evolute™ ABN solid phase extraction (SPE) cartridges and the first time that the
NSAIDs chosen have been analysed using RRLC-MS/MS to the best of our knowledge
at levels below 5 ng mL- 1 for all substances tested. The advantages of the developed
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method are that it is a rapid quantitative confirmatory method that meets the requirements
according to Commission Decision 2002/657/EC [Commission Decision 2002] for a
broad number ofNSAIDs using a single analytical technique. Also the developed method
is the most sensitive available to the best of our knowledge and the theoretical values
calculated for the CCa according to 11843 calibration curve procedure were shown
experimentally to be valid by spiking milk at levels below the CCa values calculated to
illustrate the sensitivity [CRL 2007]. Furthermore the method represents savings in time
and consumables (solvents) over existing methodologies. The objective of this work was
to develop a method that is capable of the determination ofNSAIDs residues in bovine
milk below 5 ng mL

-I ,

a level set in accordance to requirements of the Community

Reference Laboratories in the'EU [SANCO 2004] and to validate the method according
to the guidelines of 2002/657/EC [Commission Decision 2002, CRL 2007]. In this paper
a fast, simple and reliable RRLC-MS/MS method is described for a wide range of
NSAIDS in milk. The proposed method does not cover the glucuronides.

5.3 Experimental
5.3.1 Materials and reagents
Water, ethanol, ethyl acetate, methanol, acetonitrile, acetic acid, hydrochloric acid (37
%), n-hexane and iso-octane '(HiPerSolv grade) were obtained from BDH (Merck, UK).

CPF, DCF, MFN, NIFLU, NAP and PBZ were purchased from Sigma (Sigma -Aldrich,
Ireland). OXYPHEN and SUXI were obtained as a gift from Istituto Zooprofilatico
Sperimentale del Mezzogiomo (Naples, Italy). dw- PBZ was obtained from Cambridge
Isotope Labs (Cambridge Isotope Labs, USA). d3-CPF and d4 -DCF were obtained from
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CON Isotopes (CDN Isotopes, Canada). d3-TLF was obtained as a gift from Agri-Food &
Biosciences Institute (Belfast, UK).

Primary stock standard solutions (stable for 12

months) were prepared in ethanol at a concentration of 1 mg mL-

1
•

Intermediate single

standard solutions (stable for 6 months) were prepared in methanol at a concentration of
10 Jlg mL- 1• CPF, DCF, MFN, NIFLU, NAP, OXYPHEN PBZ and SUXI standard
fortification solution (stable for 6 months) was prepared in methanol at a concentration of
500 ng mL-) from the 10 Jlg mL- 1 intermediate stock solution. Internal standard
.fortification solution of d3- CPF , <4-DCF, d3-TLF and dlO-PBZ was prepared at a
concentration of 500 ng mL- 1• All standards were stored at 4 °c in the dark. Evolute ™
ABN 50 Jlm solid phase extraction cartridges (10 mL, 100 mg) were obtained from
Biotage (Biotage, UK). Methanol:water (10:90, v/v) and 10 mM ascorbic acid (used as a
·stabiliser) were used as solid phase extraction wash solvents. N-hexane:diethyl ether
(50:50, v/v) was used as the solid phase extraction elution solvent. Injection solvent was
Water:acetonitrile (90: 10, v/v).

5.3.2 Le conditions
The LC consisted of an Agilent 1200 Rapid Resolution LC equipped with a G 1312B
Binary pump, G1316B-HiPALS SL autosampler and a G1316B-TCCSL column oven
.(Agilent Ireland). The NSAIDs were chromatographed on a 1.8 Jlm Agilent Eclipse Plus
C I8 column (2.1

x

50 mm) (Agilent, Ireland) and the column temperature was maintained

at 55 ° C. A gradient was applied with water and acetonitrile (90:10, v/v + 0.001 M
acetic acid) (A) and acetonitrile (B) (Table 5.1). The total run time was 6.5 minutes. The

·i I1jection
.
volume was 15 JlL. The mass spectrometer used was a QTRAP 4000 with a
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TurboIonSpray source from Applied Biosystems (Applied Biosystems/MDS-Sciex,
Canada). The MS was controlled by version 1.4.2 of Analyst software. The described
LC-MS/MS system was shown to be suitable for the analysis ofNSAIDs (Figure 5.25.11 ).

5.3.3 MS/MS parameters
The analysis was performed using negative ion electrospray MS/MS in multiple reaction
monitoring (MRM) mode. Two transitions were used and the collision energy was
Optimised as shown (Table 2), Each transition was performed with a 13 mSec dwell time
and a pause time of 3 mSec. The MS/MS detector conditions were as follows: ion mode
°electrospray negative; curtain gas 45 psi; ion spray voltage 4400 V; temperature 650°C;
Ion source gas 1 70 psi; ion source gas 2 70 psi; interface heater on; entrance potential 10

V; resolution Ql unit; resolution Q2 unit; collision -activated dissociation CAD gas
::::high

Table 5.1 LC gradient profile for determination ofCPF, DCF, MFN, PBZ, NAP, NIFLU,
OXYPHEN and SUXI

15

Component A:
Component B:

Component A: water containing 0.001 M acetic acid +
acetonitrile (90 + 10, v/v)
Acetonitrile
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Table 5.2: MS/MS parameters for determination of CPF, DCF, MFN, PBZ, NAP,
NIFLU, OXYPHEN, and SUXI
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Note: Matrix matched curves were used for quantification of all compounds
d3·CPF was used as internal standard (I.S) for CPF, c4-DCF was used as internal standard

I.S for DCF, d,o-PBZ was used as I.S for PBZ, d]- TLF was used as I.S for MFN. No I.S
Was used for remaining analytes.
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5.3.4 Milk samples
Milk obtained for use as negative controls were separated into 50 mL aliquots and stored
at -200C. The milk was analysed in previous batches and milk found to contain no
detectable residues ofNSAIDs were used as negative controls.

5.3.5 Sample extraction and clean-up
Milk samples (5 ml) were aliquoted into 50 ml polypropylene tubes. The milk aliquots (5

roL) were fortified with internal standard at levels corresponding to 15 ng mL-\ by adding
a 150

~L portion ofa 500 ng mL- 1 mix solution ofd3- CPF , c4-DCF, d3-TLF and dlO-

PBZ. Samples were fortified

~t levels corresponding to 5, 7.5 and lOng mL-

1

by adding

50,75 and 100 ~L portions ofa 500 ng mL- 1 solution ofCPF, DCF, MFN, NIFLU, NAP,
OXYPHEN, PBZ and SUXI. After fortification, samples were held for 15 min prior to
extraction. Acetonitrile (5 mL) was added and the samples were vortexed (30 sec),
centrifuged (3568 x g, 10 min, 4°C) and the supernatant was transferred to a clean
.Polypropylene tube. The sample pellet is re-extracted with 5 mL of acetonitrile and the
SUPematants are combined. 10 mM ascorbic acid (20 mL) and 1 M hydrochloric acid (0.2

roL) Were added to the extracts and the pH of the samples were checked to ensure they
were at pH 3 before proceeding to the solid phase extraction (SPE) stage. The sample
extracts were purified by SPE using Evolute ™ ABN SPE cartridges. Sample extracts
were loaded onto the cartridges (preconditioned with methanol (3 mL) and ascorbic acid
(3 roL). The samples were loaded onto cartridges under gravity. The cartridges were
Washed with methanol:water (10:90, v/v) (2 mL). The cartridges were dried under
'vacuum (15 min). The cartridges were eluted with n-hexane:diethyl ether (50:50, v/v) (2
161

x

2 roL). The eluates were reduced to dryness under nitrogen without heat before re-

dissolving in 150 ilL water:acetonitrile (90: 10, v/v) and vortexed (1 min). An aliquot (15
ilL) is injected on the LC column.

5.3.6 Matrix matched calibration
Matrix matched calibration curves were prepared and used for quantification. Control
milk previously tested and shown to contain no residues was prepared as above (5.3.4).
.One control milk sample was used for each calibration standard level. Milk samples (5
ml) were aliquoted into 50 ml polypropylene tubes. Samples were fortified with internal
standard at levels corresponding to 15 ng mL'1 by adding a 150 ilL portion ofa 500 ng
mL· 1 mix solution of d3- CPF , <4-DCF, d3-TLF and dw- PBZ . Samples were fortified at
levels corresponding to 0, 2, 5, 7.5, 10 and 20 ng mL'1 by adding 0, 20, 50, 75, 100 and
200 ilL portions ofa 500 ng mL'1 standard solution ofCPF, DCF, MFN, NIFLU, NAP,
OXYPHEN, PBZ, and SUXI.. After fortifica~ion, samples were held for 15 min prior to
the extraction procedure as described above (5.3.5). The concentration of the NSAIDs
(ng mL 'I) was determined from the matrix matched calibration curves. The calibration
CUrves were calculated by linear regression, plotting the response factor (peak area
analyte/internal standard peak area ofCPF, DCF, MFN, PBZ) or peak areas (NIFLU,
NAP, OXYPHEN and SUXI) of the strong transition as a function ofanalyte
Concentration. The equation of the line y=mx+c is used to obtain the concentration of the
sample response factor or peak area (y).
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5.3.7 Method validation

For estimation of accuracy, blank milk samples were fortified with CPF, DCF, MFN,
NIFLU, NAP, OXYPHEN, PBZ and SUXI at 5, 7.5 and 10 ng mL-

I
.

Six replicate test

portions, at each of the three fortification levels, were analysed. Analysis of the 18 test
POrtions was carried out on three separate occasions. For the estimation of the precision
of the method, repeatability and within-laboratory reproducibility was calculated. The
decision limit (CCa) of the method was calculated according to the ISO 11843
calibration curve procedure using the intercept (value of the signal, y, where the
concentration, x is' equal to zero) and 2.33 times the standard error of the intercept for a
,set of data with 6 replicates at 3 levels. The detection capability (CCP) was calculated by
adding 1.64 times the standard error to the CCa. Milk samples were fortified at
theoretical CCa values calculated according to ISO 11843 calibration curve procedure to
ensure the calculated levels were realistic using the developed methodology.

5.4 Results and Discussion
5.4.1 Preliminary

experime~ts

The RRLC-MS/MS method was developed to provide confirmatory data for the analysis
ofCPF, DCF, MFN, NIFLU, NAP, OXYPHEN, PBZ and SUXI. The ionisation of all
NSAIDs were studied in neg~tive and positive mode. Most NSAIDs can be detected by
ESI-MS both in the negative mode and the positive mode, showing different ionisation
'efficiencies. The optimum conditions (declustering potential, collision energy, collision
cell exit potential) were determined for each drug and the best diagnostic ions for MS/MS
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analysis were obtained and can be seen in Table 5.2. Negative ion mode was chosen as
the required sensitivity was satisfactory for all compounds and less baseline noise was
obtained. For a method to be deemed confirmatory 4 identification points must be
obtained. This is achieved by monitoring one precursor ion (parent mass) and two
daughters (corresponding to strong and weak ion) which is a suitable confirmatory
method in accordance with 2002/657/EC [Commission Decision 2002]. Chromatographic
x

tests were carried out using a 1.8 Il m Agilent Eclipse Plus CI8 column (3.0 50 mm). All
I
analytes were eluted with a flow rate of 750 ilL min- and a run time of 6.5 min per
injection with good peak shape when using amobile phase of water and acetonitrile
(90:10, v/v + 0.001 M acetic acid) (A) and acetonitrile (B). As a result a batch of30
samples can be analysed using the developed RRLC-MS/MS method in less than 4 hours
allowing the running of up to 3 batches of extracted samples within a single day.
The primary advantage ofthi$ developed RRLC-MS/MS method is the speed of analysis
and to the best of our knowledge this is the most rapid multi-residue detection technique
for the determination ofNSAIDs published in the literature. The second advantage of the
developed RRLC-MS/MS method in this study is that the quantitation and confirmation
can be carried out using a single technique as opposed to other multi-residue methods
Which require longer runtimes and two separate analytical techniques [Gallo et aI., 2008,
Malone et aI., 2009] and this method meets the requirements of2002/657/EC as a
Confirmatory method. The developed methodology has been applied for the analysis of
other NSAIDs not analysed in this study and satisfactory results were obtained [Dowling
et aI., 2009, Dowling et aI., 2008].
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5.4.2 Validation study
Validation of the method was according to procedures described in Commission Decision
2002/657/EC [Commission Decision 2002] covering specificity, calibration curve
linearity, accuracy, precision, decision limit (CCa) and detection capability (CC~).
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5.4.2.1 Specificity
The technique of RRLC-MS/MS itself offers a high degree of selectivity and specificity.
To establish the selectivity/specificity of the method, milk samples were fortified with
CPF, DCF, MFN, NIFLU, NAP, OXYPHEN, PBZ, and SUXI and non-fortified samples
were also analysed. No interfering peaks were observed at the retention time for CPF,
DCF, MFN, NIFLU, NAP, OXYPHEN, PBZ and SUXI. Additionally samples were
fortified with licensed NSAIDs for use in milk producing animals which included
flunixin (FLU), meloxicam (MLX), tolfenamic acid (TLF) and vedaprofen (VDP). No
interferences were observed in the retention window of CPF, DCF, MFN, NIFLU, NAP,
OXYPHEN, PBZ, and SUXI in chromatograms when fortified with these substances.

5.4.2.2 Linearity of the response
The linearity of the chromatographic response was tested with matrix matched curves
1

Using 6 calibration points in the concentration range of 0 to 20 ng mL- • The regression
coefficients (r 2) for all the calibration curves used in this study were ~ 0.99.

.5.4.2.3 Accuracy
The accuracy (n= 18) of the method was determined using bovine milk samples fortified
at 5.0, 7.5 and 10.0 ng mL-1for CPF, DCF, MFN and PBZ in three separate assays was

82-108% .
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5.4.2.4 Precision
The precision of the method, expressed as RSD values for the within-lab reproducibility
at the three levels of fortification (5.0, 7.5 and 10.0 ng mL'I) was less than 16 % (Table
5.3). Commission Decision 20021 657/EC states that the precision for quantitative
methods for mass fractions lower than 100 ng mL'1 the application of the Horwitz
Equation gives unacceptable high values. Therefore, the RSD values for concentrations
lower than 100 ng mL· 1 shall be as low as possible.

Table 5.3 Intra- and inter-assay variation for accuracy of CPF, DCF, MFN, PBZ,
NAP, NIFLU, OXYPHEN and SUXI
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5.4.2.5 CCaand CCp
The decision limit (CCa) is defined as the limit above which it can be concluded with an
error probability of a, that a sample contains the analyte. In general, for non-MRL
substances an a equal to 1 % is applied. The detection capability (CC~) is the smallest
Content of the substance that may be detected, identified and quantified in a sample, with
a statistical certainty of 1-~, were ~

=5 %. CCa and CC~ were calculated using the

Intercept (value of the signal, y, were the concentration, x is equal to zero) and the
standard error of the intercept for a set of data with 6 replicates at 3 levels (5.0, 7.5 and
10.0 ng mr l ). Blank milk was fortified at 1, 1.5 and 2 times the minimum required
perfonnance level of 5 ng mL- 1 set for CPF, DCF, MFN, NIFLU, NAP, OXYPHEN, PBZ
and SUXI. CCa is the concentration corresponding to the intercept + 2.33 times the
standard error of the intercept. CCu values of 0.46, 1.08,0.92, 1.26, 1.29,2.12,0.55 and
2.86 ng mr1were determined for CPF, DCF, MFN, NIFLU, NAP, OXYPHEN, PBZ and
SUXI respectively. According to SANCO/2004/2726 rev 1 [SANCO 2004] it is
recognised in som~ instances where ISO 11843 has been used the extrapolated theoretical
.values for the decision limit (CCa)' may be too low to be confirmed experimentally. Milk
1
samples were subsequently fortified at a level of 0.4 ng mL- for CPF, DCF, MFN,
1

NIFLU, NAP and PBZ and at a level of 2 ng mL- for OXYPHEN and 8UXI to establish
that the theoretical decision limits (CCa's) calculated according to 18011843 calibration
cUrve procedure were valid.

CC~ is the concentration corresponding to the signal at CCa + 1.64 times the standard
error of the intercept (i.e the intercept + 3.97 times that standard error of the intercept).
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CCf3 values of 0.79, 1.85, 1.56,2.15,2.19,3.62,0.94 and 4.87 ng mL- 1 were determined
for CPF, DCF, MFN, NIFLU, NAP, OXYPHEN, PBZ and SUXI respectively.

Table 5.4 Calculated CCa and CCf3 values based on data from Assay 1,2 and 3
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5.4.2.6 Measurement Uncertainty
According to SANC0/2004/2726 rev 1 the within laboratory reproducibility can be
regarded as a good estimate of the combined measurement uncertainty of individual
lllethods [SANCO 2004]. For the calculation of the extended uncertainty a safety factor is
.required. The within laboratory reproducibility should be multiplied by a value of2.33
and this should be used when detennining the CCa, corresponding to a confidence level
of99 %. As the only source of variation during the validation was the different days and
different milk sourced from different animals it was decided to use a safety factor of 3.0
Instead of2.33. The measurement uncertainty of the method was estimated at 9, 28, 28,
45,46, 45, 10, and 39 % for CPF, DCF, MFN, NIFLU, NAP, OXYPHEN, PBZ and

SOXI. This was detennined by calculating the within laboratory reproducibility of the
lllethod, followed by multiplication of the within laboratory reproducibility by the safety
'factor of 3.0.
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5.4.2.7 Evaluation
The method developed in this study has been used to evaluate the presence ofCPF, DCF,
MFN, NIFLU, NAP OXYPHEN, PBZ and SUXI in bovine milk. In monitoring for these
substances at our laboratory it was possible to detect the precursor ion and two daughter
Ions (at 2 ng mL-), reporting level) in multiple reaction monitoring mode for CPF, DCF,
MFN, NIFLU, OXYPHEN, PBZ and SUXI. Furthermore the product ion ratio
requirement was also met. The method has been carried out by different analysts under
varying environmental conditions and the method was shown to be robust. To
demonstrate the applicability of the method milk samples taken from animals treated with
CPF, DCF and PBZ from the Community Reference Laboratory in Berlin were tested.
I

These samples had values ranging from about 4- 13 ng mL- . The samples were analysed
by the method developed in this study and all samples were found to be non-compliant as
they contained levels above the calculated CCa and also met the confirmatory criteria for
both ion ratio and relative retention time. This study shows that suitable sensitivity was
obtained and that the method performs very well in terms of accuracy and withinlaboratory reproducibility. The developed method was evaluated by comparison of results
When the method was performed by different analysts under different environmental
Conditions, using different batches of reagents and solid phase extraction cartridges. The
results (unpublished) were highly acceptable providing evidence of the development of a
rugged analytical method in this study.
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5.5 Conclusions
A fast, simple, sensitive and selective RRLC-MS/MS method for the determination of
CPF, DCF, MFN, NIFLU, NAP, OXYPHEN, PBZ and SUXI in bovine milk has been
developed. There is no published method available to the best of our knowledge for the
simultaneous determination of CPF, DCF, KPF, MFN, NIFLU, NAP, OXYPHEN, PBZ
and SUXI in bovine milk that purifies sample extracts using Evolute TM ABN solid
phase extraction cartridges and analyses extracts by RRLC-MS/MS with a runtime of 6.5
min. This is the first time that a rapid multi-residue methodology for the above NSAIDs
has been validated according to Commission Decision 2002/657/EC [Commission
Decision 2002] and the measurement uncertainty of the methodology has been described.
The RRLC-MS/MS provides quantitative confirmatory data for the analysis of bovine
milk for CPF, DCF, MFN, NIFLU, NAP, OXYPHEN, PBZ and SUXI using a single
technique and as a result a batch of 30 samples can be analysed using the developed
RRLC-MS/MS method in less than 4 h allowing the running of up to 3 batches of
ex.tracted samples in a single day.' The rapid sample procedure and the reduced run-time
per analyses of the RRLC method make it very amenable for high throughput regulatory
monitoring. The primary advantage of the developed RRLC-MS/MS is the speed of the
analysis and to the best of our knowledge this is the most rapid multi-residue technique
available for the determination of NSAIDs available to date in which quantitation and
Confirmation can be carried out using a single technique that meets the requirements
according to Commission Decision 2002/657/EC. Other multi-methods require longer
runtimes and do not meet the requirements according to Commission Decision
2002/657/EC for a quantitative confinnatory method. The method developed allows for
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the analysis of a wide variety of non authorised drugs from different NSAID sub-classes
such as CPF, NAP (arylpropionic acid derivatives), SUXI, PBZ and OXYPHEN
(pyrazolidinedione derivatives),
(nicotinic acid derivatives).

DCF, MFN (anthranilic derivatives) and NIFLU

Recently it was proposed by Community Reference

Laboratories (CRLs) in Europe that laboratories should be capable of monitoring for
NSAIDs at a level of 5 ng mL') in EU member states where no MRL exists in milk and
this study shows that these limits can be reached using the developed methodology
[Commission 2002]. The second advantage of the developed RRLC-MS/MS method in
this study is that the values determined for the decision limit (CC a.) in milk by RRLCMS/MS are lower than those recorded for these substances recorded in the literature to
date to the best of our knowledge and furthermore the calculated values according to the
IS011843 calibration curve procedure were verified by spiking milk samples at levels
between 0.4- 2 ng mL'\ to illustrate the sensitivity in the method. A third advantage is
that the NSAID RRLC-MSIMS detection method can be used with other sample
preparation procedures as it is an efficient detection technique for the determination of
NSAIDs providing the sample extraction and clean-up is sufficient.
The objective of the work to validate a method for these residues in bovine milk at low
ng mL'\ levels and validate according to the requirements in Commission Decision

2002/657/EC ther~fore has also been achieved successfully. The present study provides

.an analytical tool to anticipate the requirements of the future where risks could occur due
to the administration of these NSAIDs in milk.
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for the determination of authorised and nonauthorised non-steroidal anti-inflammatory drugs
in milk by liquid chromatography tandem mass
spectrometry
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6.1 Abstract
A sensitive and selective method for the determination of six non-steroidal antiinflammatory drugs (NSAIDs) in bovine plasma was developed. An improved method for
the determination of authorised and non-authorised residues often non-steroidal antiinflammatory drugs in milk was developed. Analytes were separated and acquired by

high performance liquid chromatography coupled with an electrospray ionisation tandem
mass spectrometer (ESI-MS/MS). Target compounds were acidified in plasma and
plasma and milk samples were extracted with acetonitrile and both extracts were purified
On an improved solid phase extraction procedure utilising Evolute ™ ABN solid phase
extraction cartridges. The accuracy of the methods for milk and plasma was between 73
and 109 %. The precision of the method for authorised and non-authorised NSAIDs in
milk and plasma expressed as % RSD, for the within -laboratory reproducibility was less
than 16 %. The % RSD for authorised NSAIDs at their associated MRL(s) was less than
10 % for meloxicam, flunixin and tolfenamic acid and was less than 25% for hydroxy
flunixin. The methods were validated according to Commission Decision 2002/657/EC.

KeYWords: Non-steroidal Anti-Inflammatory Drugs; Plasma; Milk; Liquid
Chromatography Tandem Mass Spectrometry; Method Validation
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6.2 Introduction
Carprofen (CPF), diclofenac (DCF), ibuprofen (IBP), ketoprofen (KPF), mefenamic
acid (MFN), phenylbutazone (PBZ), flunixin (FLU), hydroxy-flunixin (FLU-OH),
tolfenamic acid (TLF) and meloxicam (MLX) are non-steroidal anti-inflammatory drugs
(NSAIDs) and their structures are illustrated in Figure.6.1.

Structure a: Carprofen
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Structure b: Diclofenac
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Structure c: Mefenamic Acid
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Structure f: Phenylbutazone
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Structure g: Flunixin
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Fig. 6-1 Structures of the NSAlDs
Over the past number of years, residues ofNSAIDs in food are a cause for concern.
Studies have shown that the second most prescribed class of drugs after microbials is
NSAIDs [Sundlof et aI., 1995]. Dairy farmers and veterinarians are using NSAIDs in
dairy animals more frequently [US Code, 1988] and studies have shown that their
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Increased use [Kopcha et aI., 1992] poses a threat to human health as permitted residue
levels are being violated [Smith et aI., 2008). In 2007 the EC Rapid Alert System for
Food and Feed reported alert notifi~ations in relation to horse meat for these substances.
The European Council recommend rigorous control ofNSAIDs in food producing
animals [SANCO 2000] because of the health effects in humans such as aplastic
anaemia, gastrointestinal disorders, agranulocytosis [Insel 1990] and changes in renal
function [Goodman et al. 1992). Long term exposure to PBZ has caused kidney tumors in
mice and liver tumors in rats [Kari et aI., 1995]. In recent years the COX-II inhibitor class
ofNSAIDs has been implicated in cardiovascular harm in humans [Debabrata et aI.,
2008. Van Staa et aI., 2008). According to EU law, all drugs for veterinary use need to be
inclUded in Annexes 1-3 of Regulation 2377/90 [Commission Decision 1990]. This
regulation establishes lists of compounds that have a fixed maximum residue limit, MRL
(Annex I), that need no MRL (Annex 11) or that have a provisional MRL (Ill). There are
no MRL's set in plasma as is not an edible matrix. The recommended minimum
concentration for NSAIDs in plasma is set at 5 ng mL

-I

[SANCO 2007]. In milk FLU,

FLU-OH, TLF and MLX are included in Annex I. CPF has been included in Annex 11 of
the regulation only for bovine milk [European Commission 2005]. DCF was not
authorised for use in animals that produce milk for human consumption [European
COmmission 2004] until recently [EMEA). KPF is listed in Annex 11 of the regulation.
PBZ, MFN and IBP are considered as prohibited substances and are not included in
Annexes 1-3 and have no maximum residue limit (MRL) established however the
minimum recommended concentration for analysis ofNSAIDs with no MRL set in milk
IS

5 ng mL- I . The widespread use ofNSAIDs presents a prospectIve
.
. k to the consumer
ns
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if food containing residues enter the food chain. In Ireland plasma and milk are some of
the target matrices chosen to identify the misuse ofNSAIDs in animal production. The
advantages of using plasma as a target matrix in regulatory control are that it is an easy
matrix to handle for analysis and PBZ residues can be found in this matrix for a long time
(personal communication with the CRL). Therefore the analytical method developed in
this study in plasma concentrated on the analysis of six NSAIDs in bovine species.
Methods have been reported for the analysis ofNSAIDs in plasma by LC-UV [De Veau,
,19 99; Kvaternick et aI., 2007; Luo et aI., 2004; Hardee et aI., 1982; Neto et aI., 1996;
Grippa et aI., 2000; Jedziniak et aI., 2007; Siilgh et aI. 1991; Gowik et aI. 1998; Quintana
et aI., 2004; Fiori et aI., 2004], GC-MS [Neto et aI., 1996; Singh et aI., 1991; Hines et aI.,
2004; Gonzalez et aI., 1996; Jaussaud et aI., 1992], LC-MS [Luo et aI., 2004; Miksa et
,aI., 2005; Vinci et aI., 2006; Quintana et aI., 2004; You et al,. 2008] and capillary
electrophoresis [Gu et aI., 1997]. The majority of methods that have been cited to date
have been developed in equine plasma alone or in combination with other matrices with
limits of detection ranging from 0.1 ng mr l to 5 mg mrl[Miksa et aI., 2005; Luo et aI.,
2004; Hardee et aI., 1982; Neto et aI., 1996; Grippa et aI., 2000; Singh et aI., 1991; Hines
et aI., 2004; Gonzalez et aI., 1996; Gowik et aI., 1998; Vinci et aI., 2006; Gu et aI., 1997;
You et aI., 2008]. Other methods exist for the determination ofNSAIDs in bovine plasma
are available but with limits of detection ranging from 20 ng to 3.4 Ilg mr I [De Veau et
,al.,. 1999, Miksa et aI., 2005; Jedziniak et aI., 2007; Gowik et aI., 1998; Vinci et aI.,
2006; Quintana et aI., 2004; Fiori et aI., 2004]. Only two methods are available in equine
Plasma to date capable of meeting this requirement. A method by Luo et al [2004] for a
1

single residue had a limit of detection of 0.1 ng mL- for FLU. A multi-residue method
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by Gonzalez et al [1996J had a limit of detection of5 ng mL- 1 for IBP, FLU, DCF and
rLF, but limits of detection of only 10-25 ng mL- J could be achieved for KPF, MFN and
PBZ. Therefore no methods available to date for KPF, MFN and PBZ in plasma that can
meet the target level of 5 ng mL- I . A disadvantage of the method developed by Gonzalez
et al [1996J is that the method monitors 3 ions and this is not a confirmatory method
according to Commission Decision 2002/657/EC [Commission Decision. 2002J and a
second analytical technique is required. Overall there is a paucity of methods in the
,literature that are available for the analysis ofNSAIDs in bovine plasma and of those
available, the methods are not sensitive enough to meet the minimum required
concentration of analysis set at 5 ng mL- I . Milk is the second target matrix analysed in
this stUdy and is important in food safety because sampling can often be restricted to
Sampling of meat, milk, eggs and honey, as in the case of retail import/exports. Milk also
allows the detection of drugs in live animals prior to slaughter. There are few analytical
methOds for the determination of authorised and non-authorised NSAIDs in milk and
Usually analyse for only a few residues. ,Those that have been described use LC-UV
,[Martin et aI., 1983; Gallo et aI., 2008; Feely et aI., 2002; Rubb et aI., 1995; De Veau et
al. 1996J, Le-MS [GaIIo et al. 2008; Boner et aI. 2003; Daeseleire et al. 2003; Malone et
aI. 2009; Dowling et aI. 2009J and GC-MS [Dowling et aI. 2008; Rubb et aI., 1995]. A
method by GaIIo et al [GaIIo et aI., 2008J is capable of analysing 16 NSAIDs in milk
,Using two separate analytical techniques and involves using a screening LC-DAD method
With limits of detection (LaD) of between 2- 15 ng mL

-I

and a runtime of 35 min with

an eqUilibration time of 15 min per injection. Confirmation is achieved using an LC ESI1

Iontrap -MS/MS method with an LaD of 5 ng mL- except for flurbiprofen with a
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runtime of 40 min per injection. The LC-MS method does not meet the requirements for a
confirmatory method according to Commission Decision 2002/657/EC and a third
analytical technique is required. A method by Stolker et al [Stolker et aI., 2008] is
capable of analysing 20 NSAIDs in milk using a quantitative screening method (UPLCrOF-MS) with LOD's for specific NSAIDs such as NAP, PBZ and DCF at 12.5,25 and
1

6.3 ng mL- 1 and a runtime of 8.5 min. The method cannot meet the 5 ng mL- level set for
NAP and PBZ or 0.1 ng mL- 1 level recently set for DCF; additionally, analysis by TOFMS, medium to high resolution of approximately 10,000 FWHM is not included in
.Commission Decision 2002/657/EC.
Other methods for the determination ofNSAIDs in milk have limits of detection of20
1

nglmL for PBZ [Martin et aI., 1983], 0.2 ng mL- for FLU and FLU-OH [Boner et aI.,
2003], 0.5 ug kg-I for FLU, FLU-OH and 1 ug kg-I for KPF [Daeseleire et aI., 2003],
-53.05, 15.82,61.39,45.04 ng mL- 1 for TLF, MLX, 4-MAA and FLU-OH [Malone et aI.,
2009],0.46-2.86 ng mL- 1 for CPF, DCF, MFN, niflumic acid (NIFLU), naproxen (NAP),
OXyphenylbutazone (OXYPHEN), PBZ and suxibuzone (SUXI) [Dowling et aI., 2009]
0.59,2.09, 0.90 and 0.70 ng mL- 1 for IBP, KPF, DCF and PBZ [Dowling et aI., 2008],
1

'1 ng mL- 1 for FLU [Feely et aI., 2002], 1.7 ng mL- for FLU [Rubb et aI., 1995] the
1

lowest fortification in matrix was 25 ng mL- for PBZ [De Veau et aI., 1996]. The
objective of this study was to develop an analytical strategy for the determination of
NSAIDs in bovine plasma and for authorised and non-authorised simultaneously in milk
that meet the EU target levels set and validate according to Commission Decision

2002/657/EC.
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In this study an improved purification procedure was developed using Evolute ABNTM
solid phase extraction cartridges for the analysis of a wider range ofNSAIDs including
authorised and non-authorised NSAIDs in bovine milk. The developed procedure was
SUitable for the purification of six NSAIDs in bovine plasma. An improved liquid
chromatography tandem mass spectrometry detection technique was developed to analyse
ten NSAIDs simultaneously with a run-time of 15 min. The methods in each matrix were
comprehensively validated according to Commission Decision 2002/657/EC. The
methods were implemented into the National Monitoring Programme in Ireland for
veterinary drugs residues and "accreditated according to ISO 17025 Standard. The
proposed method in milk does not cover the glucuronides. This is the first time that
SUitably sensitive methods for the analysis ofNSAIDs in plasma and for the analysis of
the selected range of authorised and non-authorised NSAIDs using Evolute ABN ™ solid
phase extraction cartridges

si~ultaneously in bovine milk are available

6.3 Experimental

6.3.1 Materials and reagents
Water, ethanol, ethyl acetate, methanol, acetonitrile, acetic acid, hydrochloric acid (37
%), n-hexane and iso-octane (HiPerSolv grade) were obtained from BDH (Merck, UK).

CPF, DCF, IBP, MFN, FLU, KPF, MLX, TLF and PBZ were purchased from Sigma
(Sigma Aldrich, Ireland). FLU-OH was obtained as a gift from The Community
Reference Laboratory for

N~AIDs in the EU in Germany.

dlO-PBZ was obtained from

Cambridge Isotope Labs (Cambridge Isotope Labs, USA). dJ-MLX, dJ-IBP and dJ-DCF
Were obtained from CDN Isotopes (CDN Isotopes, Canada). dJ-FLU was obtained from
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Witega (Witega, Germany). d4- TLF was obtained as a gift from Stormont, (Stormont,
UK). Primary stock standard solutions (stable for 12 months) were prepared in ethanol at
a concentration of 1 mg mL-'. Intermediate single standard solutions (stable for 6 months)
1

Were prepared in methanol at a concentration of 10 flg mL- • CPF, DCF, IBP, MFN, FLU,
FLU-OH, KPF, TLF, MLX and PBZ standard fortification solution for plasma (stable for
1

6 months) was prepared in methanol at a concentration of 500 ng mL- from the 10 flg
mL- 1 intermediate stock solution. Internal standard fortification solution for milk or
plasma containing d3- MLX , d4- DCF , d3:"IBP d3-FLU, ~-TLF and dw- PBZ was prepared
at a concentration of 1.25 l1g mL- 1• CPF, DCF, IBP, MFN, KPF and PBZ standard
fortification solution for milk (NMRL) was prepared in methanol at a concentration of
500 ng mL- 1 from the 10 flg mL- 1 intermediate stock solution. MLX, FLU, FLU-OH and
TLF standard fortification solution for milk (MRL) was prepared in methanol at a
concentration of 1.5, 4, 4 and 5 ug mL- 1. All standards were stored at 4
Isol ute

TM

°c in the dark.

Evolute ABN 50 flm solid phase extraction cartridges (10 mL, 100 mg) were

obtained from Biotage (Biotage, UK). Methanol:water (10:90, v/v) and 10 mM ascorbic
acid

were

used

as

solid

phase

extraction

wash

solvents.

N-hexane:diethyl

ether:acetonitrile: methanol (45:45:7:3,v/v) was used as the solid phase extraction elution
.solvent. Injection solvent was water:acetonitrile (90: 10, v/v).

6.32
°
. Le con dOawns
The LC consisted of an Agilent 1200 Rapid Resolution LC equipped with a G1312B
'Binary pump, G 1316B-HiPALS SL autosampler and a G1316B-TCCSL column oven
(A.gilent Ireland). The NSAIDs were chromatographed on a 1.8 flm Agilent Eclipse Plus
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C l8 column (3.0 x 50 mm) (Agilent, Ireland) and the column temperature was maintained
at 55 QC. A gradient was applied with water containing 0.001 M acetic acid and
acetonitrile (90: 10, v/v + 0.001 M acetic acid) (A) and acetonitrile (B) (Table 6.1). The
total run time was 15 minutes. The injection volume was 15 JlL. The mass spectrometer
used was a QTRAP 4000 with a TurboIonSpray source from Applied Biosystems
(Applied Biosystems/MDS-Sciex, Canada). The MS was controlled by version 1.5 of
Analyst software. The described LC-MS/MS system was shown to be suitable for the
analysis ofNSAIDs in plasma (Figure 6.2-6.7) and milk (Figure 6.2-6.11).

6.3.3 MSIMS parameters
The analysis was performed using negative ion electrospray MSIMS in multiple reaction
·monitoring (MRM) mode. The collision voltages were optimised as shown (Table 6.2).
Each transition was performed with a 13 msec dwell time and a pause time of 3 msec.
The MS/MS detector conditions were as follows: Ion mode electrospray negative;
CUrtain gas 45 psi; ion spray voltage 4400 V; temperature 650 QC; ion source gas one 70
psi; ions source gas two 70 psi; Interface heater on; entrance potential 10 V; Resolution

QI unit; Resolution Q2 unit; CAD gas =high
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Table 6.1: LC gradient profile for determination of CPF, DCF, IBP, KPF, MFN, PBZ,
FLU, FLU-OH, TLF and MLX

Component A:
Component B:
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Component A: water containing 0.001 M acetic acid + acetonitrile
(90 + 10, v/v)
Acetonitrile

Table 6.2: MS/MS parameters for determination of CPF, DCF, IBP, KPF, MFN, PBZ,
FLU, FLU-OH, TLF and MLX
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Note: Matrix matched curves were used for quantification of all compounds
d3-lBp Was used as internal standard (1.S) for CPF, IBP and KPF, dJ-DCF was used as
I.S for DCF, dlO-PBZ was used as 1.S for PBZ, dJ - FLU was used as 1.S for FLU and
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FLU-OH. d4 - TLF was used as I.S for MFN and TLF. d3- MLX was used as I.S for
MLX.

6.3.4 Plasma/milk samples
Plasma/milk obtained for use as negative controls was separated into 50 mL aliquots and
stored at -200C. The plasma/milk was analysed in previous batches and plasma/milk
found to contain no detectable residues ofNSAIDs were used as negative controls.

6.3.5 Sample extraction and clean-up

6.3.5.1 Plasma E~traction .
Plasma samples (5 mL) were aliquoted into 50 mL polypropylene tubes. The plasma
aliquots (5 mL) were fortified with internal standard at levels corresponding to 15 ng mLI

by adding a 60 JlL portion of a 1.25 ug mL- mix solution of d3- MLX , d4-DCF, d3-IBP,
1

d3-FLU, ~-TLF and dw- PBZ . Samples were fortified at levels corresponding to 5, 7.5
1

·and 10 ng mL- 1 by adding 50, 75 and 100 JlL portions ofa 500 ng mL- solution ofCPF,

DCF, IBP, MFN, KPF and PBZ. After fortification, samples were held for 15 min prior
to extraction. Hydrochloric acid (500 JlL, 1 M) was added to the plasma samples and they
were left to stand at room temperature (10 min). Acetonitrile (5 mL) was added and the
samples were vortexed (30 sec), centrifuged (4500 rpm, 10 min, 4 QC) and the
SUpematant was transferred to a clean polypropylene tube. 10 mM ascorbic acid ( 15
IllL) was added and the samples were vortexed (30 sec) and the pH of the samples were
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checked to ensure they were ~t pH 3 before proceeding to the solid phase extraction
(SPE) stage.

6.3.5.2 Milk Extraction
Milk samples (5 mL) were aliquoted into 50 mL polypropylene tubes. The milk aliquots
(5 mL) were fortified with internal standard at levels corresponding to 15 ng mL-' by
adding a 60 IJ.L portion ofa 1.25 ug mL- 1 mix solution ofd3-MLX , d4-DCF, d3-IBP, d3FLU, ~-TLF and dw- PBZ . Samples were fortified at levels corresponding to 5, 7.5 and
1

10 ng mL- 1 by adding 50, 75 and 100 IJ.L portions ofa 500 ng mL- solution of CPF,
1

DCF, IBP, MFN, KPF and PBZ (NMRL solution) and at 7.5, 15 and 22.5 ng mL- with
MLX, at 20, 40 and 60 ng mL -I with FLU and FLU-OH and at 25, 50 and 75 ng mL

-I

with TLF by fortifying with 25, 50 and 75 f.lL portions of a 1.5,4,4 and 5 ug mL

of

-I

MLX, FLU, FLU-OH and TLF (MRL solution). After fortification, samples were held for
15 min prior to extraction. Acetonitrile (5 mL) was added and the samples were vortexed
(30 sec), centrifuged (3568 x g, 10 min, 4°C) and the supernatant was transferred to a
clean polypropylene tube. The sample pellet is re-extracted with 5 mL of acetonitrile and
the supernatants are combined. 10 mM ascorbic acid (20 mL) and 1 M hydrochloric acid

(0.2 mL) were added to the extracts and the pH of the samples were checked to ensure
they Were at pH 3 before proceeding to the solid phase extraction (SPE) stage.
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6.3.5.3 Solid phase extraction
The sample extracts were purified by SPE using Evolute ABN ™ SPE cartridges. Sample
extracts were loaded onto the cartridges (preconditioned with 3 mL of n-hexane:diethyl
ether (50:50, v/v) 3 mL of methanol and 5 mL of ascorbic acid. The samples were loaded
onto cartridges under gravity. The cartridges were washed with 3 mL ofmethanol:water
(10:90, v/v). The cartridges were dried under vacuum (15 min). The cartridges were
eluted with 2

x

1.5 mL of n-hexane:diethyl ether: acetonitrile: methanol (45:45:7:3, v/v).

The eluates were reduced to dryness under nitrogen without heat before re-dissolving in
150 J..I.L ofwater:acetonitrile (90:10, v/v) and vortexed (1 min). An aliquot (15 J..I.L) was

i .

l1jected on the LC column.

6.3.5.4 Matrix-Matched Calibration
Matrix matched calibration curves were prepared and used for quantification. Control
Plasma/milk previously tested and shown to contain no residues was prepared as above
,(6.3.4). One control plasma sample and one control milk was used for each calibration
standard level. Plasma samples (5 mL) or milk samples (5 mL) were aliquoted into 50
rnL Polypropylene tubes. Individual plasma or milk samples were fortified with internal
1

standard at levels corresponding to IS ng mL- by adding a 60 J..I.L portion of a 1.25 ug
rnL-' mix solution of d3- MLX , dt-DCF, d3-IBP, d3- FLU , dt-TLF and dlO-PBZ. Plasma
samples were fortified at levels corresponding to 0, 5, 7.5, 10 and 20 ng mL-] by adding
1

0,50,75, lOO and 200 J..I.L portions ofa 500 ng mL- standard solution ofCPF, DCF, IB,
I(PF, MFN and PBZ. After fortification, plasma samples were held for 15 min prior to
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the extraction procedure as described above (6.3.5). Milk samples were fortified at levels
corresponding to 0, 5, 7.5, 10 and 20 ng mL- 1 by adding 0, 50, 75, 100 and 200 ilL
portions of a 500 ng mL- 1 standard solution of CPF, DCF, IBP, MFN, KPF and PBZ
(NMRL solution) and at levels corresponding to 0, 7.5, 15, 22.5, 30, 60 ng mL-

1

of

MLX, 0,20,40,60,80 and 160 ng mL- 1 FLU and FLU-OH and 0.25, 50, 75, 100 and
200 ng mL- 1 of TLF by adding 0, 25, 50, 75, 100 and 200 ilL portions of a 1.5, 4, 4, 5
ug mC' standard solution of MLX, FLU, FLU-OH and TLF (MRL solution). After
fortification, milk samples were held for 15 min prior to the extraction procedure as
described above (6.3.5). Calibration curves of plasma or milk were prepared by plotting
the response factor as a function of analyte concentration (0 to 20 ng mL-

l
)

to quantify

samples.

6.3.6 Method validation

For estimation of accuracy, blank plasma samples were fortified with CPF, DCF, IBP,
MFN, KPF and PBZ at 5, 7.5 and 10 ng mL- I . For estimation of accuracy, blank milk
Samples were fortified with CPF, DCF, IBP, MFN, KPF and PBZ at 5, 7.5 and 10 ng mLI

and at 7.5, 15 and 22.5 ng mL-) with MLX, at 20, 40 and 60 ng mL-) with FLU and

FLU-OH and at 25, 50 and 75 ng mL-) with TLF. Six replicate test portions, at each of
the three fortification levels, were analysed. Analysis of the 18 test portions was carried
OUt On three separate occasions for each matrix. For the estimation of the precision of the
method, repeatability and within-laboratory reproducibility was calculated. For
'unauthorised substances the decision limit (CCa) of the method was calculated according
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to the calibration curve procedure using the intercept (value of the signal, y, where the
concentration, x is equal to zero) and 2.33 times the standard error of the intercept for a
set of data with 6 replicates at 3 levels. The detection capability (CCP) was calculated by
adding 1.64 times the standard error to the CCa. For authorised substances the decision
limit (CCa) of the method was calculated according to the ISO 11843 calibration curve
procedure by plotting the corresponding concentration at the permitted limit plus 1.64
times the standard deviation of the within laboratory reproducibility for a set of data with
six replicates at three levels. The detection capability (CCP) was calculated by adding
.1.64 times the standard deviation of the within laboratory reproducibility to the CCa.

6.4 ReSUlts and Discussion
6.4.1 Developmentl optomisation experiments

The ionization of all NSAIDs was studied in negative and positive mode. Most NSAIDs
can be detected by.ESI-MS both in negative and positive mode showing different
ionization efficiencies. The optimum parameters (polarity mode, decustering potential,
Collision energy, collision cell exit potential) were determined for each drug and the best
diagnostic ions for MSIMS analysis are shown in Table 6.2. Negative ion mode was
chOsen as the required sensitivity was obtained for all compounds and less baseline noise
\Vas obtained. The MSIMS method was developed to monitor one precursor ion (parent
mass) and two daughters (corresponding to strong and weak ion), which is a suitable
Confirmatory method yielding four identification points in accordance with 2002/657/EC.
Only one daughter ion could be obtained for KPF and IBP, but two daughter ions could
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be obtained for all other compounds investigated in the study. A previous method
developed at the authors laboratory utilising GC-MS/MS was capable of obtaining 2
daughter ions for these substances after derivatisation [Dowling et aI., 2008]. The LC
method developed in this study was based on a method developed at the author's
laboratory for the determination of eight banned non-steroidal anti-inflammatory drugs
but was not suitable for incorporation of the new range ofanalytes in this study.
[Dowling et aI., 2009]. Chromatographic tests were carried out to evaluate the suitability
of the 1.8 J..lm Agilent Eclipse Plus Clscolumn (3.0 x 50 mm) and the LC mobile phase
utilised in this study when additional NSAIDs were added. The tests showed that the
Internal standards of DCF and FLU overlapped in each internal standard transition when
I

the analytes were eluted with a flow rate of 750 J..lL min- and a run time of 6.5 min per
injection. A study was performed using the same composition of mobile phase A and B.
The times in the gradient were adjusted, the flow rate was reduced and the
Chromatographic runtime was extended to separate the internal standard of DCF and
FLU. This resulted in the analytes being eluted with good peak shape when using a
Illobile phase of water containing 0.001 M acetic acid and acetonitrile (90: 10, v/v +
1

0.001 M acetic acid) (A) and acetonitrile (B) with a flow rate of 0.5 J..lL.min- and a
l'Untime of 15 min. The internal standards c4-DCF and d3- FLU were completely
separated under these conditions. As a result a batch of 30 samples can be analysed using
the developed LC-MS/MS method for 10 NSAID residues in 7.5 hours allowing the
running of up to 3 batches of extracted samples within a 24 hour period. The extraction
of the NSAIDs from plasma was based on methods developed by Gowik et aI. (Gowik et
,aI., 1998) and by Vinci et al (Vinci et aI., 2006) but modified with the addition of
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acetonitrile. The extraction of NSAIDs in milk was based on a method previously
developed at the author's laboratory [Dowling et aI., 2009]. The extraction procedures
Were found to be satisfactory in the extraction of the NSAIDs from milk and plasma in
this study. The purification ofNSAIDs from the plasma and milk extracts was
Investigated initially using a solid phase extraction procedure previously developed at the
authors laboratory using Evolute ABN ™ cartridges but the original procedure was not
satisfactory for the additional range of new analytes in this study. The NSAID FLU-OH
was poorly recovered when the method previously developed at our laboratory was
utilised. Elution studies were perfonned to ascertain where losses were occurring. The
Cartridges were eluted with different compositions and volumes of solvents including, 3
mL diethyl ether:hexane:acetonitrile (45:45: 10, v/v/v), 3 mL diethyl ether:hexane,
acetonitrile:methanol (45:45:5:5, v/v/v/v), 1.5 mL diethyl ether: hexane (80:20, v/velution 1) and 1.5 mL acetonitrile:methanol (90: 10, v/v- elution 2), 1.5 mL
acetonitrile:methanol 90: 10, v/v-elution 1) and 1.5 mL diethyl ether: hexane 50:50, v/v.elution 2), 3 mL methanol and 3 mL diethyl ether:hexane:acetonitrile:methanol
(37.5:37.5:20:5 v/v/v/v). The results showed that elution of the cartridge with a solvent
composition containing n-hexane:diethyl ether: acetonitrile: methanol (45:45:7:3, v/v-2

x

1.5 mL) gave the best results for all the analytes tested in this study. This is the first time,
·to the best of our knowledge, that CPF, DCF, IBP, KPF, MFN and PBZ residues have
been purified from bovine plasma using Evolute ABN ™ solid-phase extraction
1

Cartridges. The methodology is capable of meeting the 5 ng mL- set for NSAIDs in
Plasma. Moreover the values detennined for the decision capability (CCa) in this study
were lower than those recorded for these substances in the literature in plasma by LC-
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MS/MS to date. This is the first time that FLU, TLF, FLU-OH, IBP, KPF and MLX have
been purified from milk using Evolute ABN™ solid phase extraction cartridges. The
method meets the target level of 5 ng mL') for IBP and KPF in milk for the first time.
There are no analytical methods that monitor for authorised and non-authorised NSAIDs
10 milk aswell as FLU and FLU-OH simultaneously in milk that meet the stringent

validation requirements according to Commission Decision 2002/657/EC. The primary
advantage of the developed analytical strategy in this study is that quantitation and
Confirmation can be carried out using a single analytical technique according to
Commission Decision 2002/657/EC (Commission Decision 2002), except for IBP and

KPP. Confirmation of these residues using a second analytical technique is described
elseWhere (Dowling et aI., 2008).
.After validation of this method, the EU changed the legislation for DCF and an MRL of
0.1 ng mL') was set in milk. Preliminary spiking studies at the new MRL for DCF were
carried out using the developed analytical strategy in this study. Results showed that this
analytical strategy was sensitive enough to detect DCF at this level. The same extract was
.also analysed on an Applied Biosystems 5500 triple quadrupole mass spectrometer and
.ratIo
' compared to the 4000
the response using this system gave a better sIgna
. I-to-nOIse

QTRAp. This analytical strategy with detection using the 4000 QTRAP or 5500 Applied
Biosystems LC-MS/MS technology shows, for the first time during initial studies, that
·the new MRL set for DCF in milk at 0.1 ng mL') could be achieved.
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6.4.2.2 Method Validation
Validation of the method in plasma and milk was according to procedures described in
Commission Decision 2002/657/EC [Commission Decision 2002] covering specificity,
calibration curve linearity, recovery (accuracy), precision, decision limit (CCa) and
detection capability (CC~).

6.4.2.1 Specificity
The technique of LC-MS/MS itself offers a high degree of selectivity and specificity. To
establish the selectivity/specificity of the method, a variety of plasma and milk samples
were fortified with analytes and internal standards and non-fortified samples were also
analysed. No interfering peaks were observed at the retention time of the analytes. To
further test specificity in plasma and milk, samples were also fortified with 5.0 ng mL-)
of naproxen (NAP), niflumic acid (NIFLU), oxyphenylbutazone (OXYPHEN) and
suxlbuzone
'
(SUXI). No interfering peaks were observed at the retention window of the
analYtes,

.6.4.2.2 Linearity
The linearity of the chromatographic response in plasma was tested with matrix matched
cUrves Using 5 calibration points in the concentration range of 0 to 20 ng mL-) when
fOn'fi
I led with CPF, DCF, IBP, KPF, MFN and PBZ.

The linearity of the

chrOI1l atographic response in milk was tested Wit' h matnx
.
t h d
.
ma c e curves usmg 6
calibration points in the concentration range of 0 to 20 ng mL-) when fortified with CPF,

DCF, IBP, KPF, MFN and PBZ (NMRL substances). For MRL substances the linearity
of the chromatographic response in milk was tested with matrix matched curves using 5
216

calibrati on pomts
.
. the concentration range of 0 to 30 ng mL- I for MLX, 0 to 160 ng
m
mL- 1 for FLU and FLU-OH and 0 to 100 ng mL- 1 for TLF. Overall the regression
coeffilClents
.
(r2) were ~ 0.98 except for FLU-OH.

6.4.2.3 Accuracy
The accuracy was determined using bovine plasma fortified at 5.0, 7.5 and 10.0 ng mC
with CPF, DCF, lBP, KPF, MFN and PBl.

I

Mean corrected recoveries (n = 18)

determ'me d'm three separate assays III
. plasma (Table 6.3) were between 99 and 109 %.
The accuracy was determined using bovine milk fortified at 5.0, 7.5 and 10.0 ng mLwith CPF, DCF, lBP, KPF, MFN and PBl and the mean corrected recoveries (n

=

1

18)

. mIlk
. (Table 6.4) were between 74 and 109 %. The
determ'med'm three separate assays III
aCCuracy was determined using bovine milk fortified at MRL levels of 7.5, 15 and 22.5
ng mL- 1 for MLX, at 20, 40 and 60 ng mL- 1 with FLU and FLU-OH and fortified at 25,
50 and 75 ng mL- 1 with TLF. and the mean corrected recovery (n

=

18) of the analytes,

determined in three separate assays in milk (Table 6.4) were between 73 and 102 %.

6.4.24
..
• PreClSlOn
The precision of the method, expressed as RSD values for the within-lab reproducibility
ofCPF, DCF, lBP, MFN and PBl in plasma was less than 16 % (Table 6.3). No
deuterated analogue was available for CPF, MFN, KPF an d FLU-OH'III our laboratory at
the time of carrying out this work. d3- lBP was used as 1.S for CPF and KPF, d3-TLF was
used as 1.S for MFN and d3-F~U was used as 1.S for FLU-OH. The precision of the
method, expressed as RSD values for the within-lab reproducibility ofCPF, DCF, lBP,
'I(PF, MFN and PBl when fortified into milk was less than 16 % (Table 6.4). The
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precision of the method, expressed as RSD values for the within-lab reproducibility of

MLX, FLU and TLF when fortified into milk was less than 10 % except for FLU-OH
which Was less 25 % (Table 6.4). A one way analysis of variance was carried out at each
of the fortification levels to separate out estimates for within run, between run and total
Variance of the method and the results are shown in Tables 6.3 and 6.4. Commission
Decision 2002/657/EC states that the precision for quantitative methods for mass
fractions lOwer than 100 ng mL- I , the application of the Horwitz Equation gives
unacceptable high values. Therefore, the RSD values for concentrations lower than 100
ng rnL-1

shall be as Iow as possible.

Table 6.3: Intra- and inter-assay variation for accuracy of CPF, DCF, IBP, KPF,

MFN, PBZ, in plasma

-

-

~Jy~

"'OftI(,c*J1l1l ievd (naml-')

Cpt.·

g~~ ••f~V-1IQl

5
7..S
10
5.7.5.10
5
7.5
10
j, 7.5, 10
5

1.5

i~~··~0iIIIll0nect "••_
f-"N

;~" ••1IQl
~V_1IQl

10
5, 7.5, 10
5
1.5
10
j, 7.S, 10
5
7.5
10
'.1.5.10

5
1.5
10
j, 1.S, 10

llct",_ Run

Accuncy

W.tlln Run

(~<.)

CV(~".'

cv (0,.)

lOt

1ll.8
7.1
11.0

92
9.6
6.6

99
101
106
102
101

.. .0

2.1

3.0

2.3
12

3.9

......

0.0

103
100

",3

....2

311

0.9

1/11

ll.A

lOt

5....
3.2

311
7.2
0.0

lOt

103

7.0

4,3
".0
3.0

T04IIJ

cv (...,
20.9
120
JZ.8
15.2
4.5
11.9
128
9.7

. ...

6.0
3.9
U
92
9.0

.l.2
7.1

103
103

..2

99

2,3

109
102
101

5..2

10,3

ll.6

".9

".5

O.ll

/lA
...6
112

6Jl

11.2
5..8
311
5.9

218

Table 6.4: Intra- and inter-assay variation for accuracy of CPF, DCF, IBP, KPF,
l\1FN, PBZ, FLU, FLU-OH, TLF and MLX in milk
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6.4.2.5 CCa and CCP

The decision limit (CCa) is defined as the limit above which it can be concluded with an
error probability of a, that a sample contains the analyte. In general, for non-MRL
SUbstances an a equal to 1 % is applied. The detection capability (CCp) is the smallest
COntent of the substance that may be detected, identified and quantified in a sample, with

a starIstIcal
. certainty of 1-13, were 13 = 5 %. In the case 0 f non MRL su bstances CCa is
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the concentratIOn
. corresponding to the intercept + 2.33 times the standard error of the
Intercept. CC~ is the concentration corresponding to the signal at CCa + 1.64 times the
standard error of the intercept (i.e the intercept + 3.97 times the standard error of the
Intercept). Blank plasma was fortified at 1, 1.5 and 2 times the minimum required
performance level of 5 ng mL- 1 set for CPF, DCF, !BP, KPF, MFN, PBZ, FLU, FLU-OH,
TLF and MLX. CCa and CC~ were calculated in plasma using the intercept (value of
the signal , y, were the concentratIOn,
.'
x IS equal to zero) an d the stand ard error of the
Intercept for a set of data with six replicates at three levels (5.0, 7.5 and 10.0 ng mL-

I
).

CCu values of 1.80,0.58,0.71,0.87,0.70 and 1.19 ng mL-' were determined for CPF,
DCF, mp, KPF, MFN, PBZ respectively. CC~ values of3.1, 0.99, 1.22 1.49, 1.20,2.02
ng mL- 1 were determined for CPF, DCF, !BP, KPF, MFN and PBZ respectively (Table

6.5). Non authorised substances in milk were fortified at 1, 1.5 and 2 times the minimum
reqUlred
.
performance level of 5 ng mL- 1 set for CPF, DCF, !BP, KPF, MFN and PBZ.
1

CCu values of2.11, 0.83, 0.47, 1.63,0.92 and 0.55 ng mL- were determined for CPF,
DCF, IBP, KPF, MFN and PBZ (Table 6.6). CC~ values of3.59, 1.41,0.80,2.77, 1.56
~d

.
0.94 ng mL- 1 were determined
for CPF, DCF, !BP, KPF, MFN and PBZ (Table 6.6).

,In the case of substances which have MRLs (MLX, FLU, FLU-OH and TLF) fortification

Was at 0.5, 1 and 1.5 times the corresponding MRL. The decision limit (CCa) is
calCUlated by analysing the 18 milk samples fortified at the MRL over three days, and
Using the concentr~tion at the 'permitted limit plus 1.64 times the standard deviation
,Obtained to yield CCa. The detection capability

(CC~) of the proposed method was

calculated from the CCa value plus 1.64 times the corresponding standard deviation.
1

CCu values of 17.6,42.89,55.76 and 54.45 ng mL- were determined and

CC~ values of
220

20.13 45 78
1
' . ,71.50 and 58.9 ng mL- were determined for MLX, FLU, FLU-OH and TLF
In

'lk

01]

when fortified at their associated maximum residue limits.

Table 6.5'.

Calculated CCa and CCf3 values for plasma
COr
(lit mrl)

CW
DCF
JAP
KW
MFN
Pia

Table 6.6:

CCJt

(IItml- l)

3111

1-1)

o.~

0.$8

U.
0.8'1
0.i'G
1.19

'.2'2

L49

•.»

2..02

Calculated CCa and CCf3 values for milk

co.

CPF
D(7
lAP

KIF

(1II1l11- 1)

2.1.
0.83
G.41

3-'9
U.

W

MFN

0.92

J>B:Z
FLU
FLU-oH
nF

G.55

MlJC

cc,

(111 __ ')

42.U

0...

2_11

'J&

U4
4$.18

$5.16

, • .,t)

54.45

'-.510

.,..51

20.13

6.4.2.6 Meas urement vTTncertamty
•
According to SANC0/2004/2726 rev 1 the within laboratory reproducibility can be
regarded as a good estimate of the combined measurement uncertainty of individual
lllethods [SANCO 2004]. For the calculation of the extended uncertainty a safety factor is
reqUired. The within laboratory reproducibility should be multiplied by a value of 2.33

and this should be used when determining the CCa, corresponding to a confidence level
Of99 %. As the only source ofvar~ation during the validation was the different days and
differe nt PIasma or milk sourced from different amma
. Is 'It was d'd
eCI ed to use a safety
factor of3.0 instead of2.33. The measurement uncertainty of the method in plasma was
est' 01
]

ated at 47, 12, 15, 23, 19 and 26 % for CPF, DCF, IBP, KPF, MFN and PBZ
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respectively. The measurement uncertainty of the method in milk was estimated at 50,
34,36,48,20,24, 16, 75,24 and 30 % for CPF, DCF, IBP, KPF, MFN, PBZ, FLU, FLUOH, TLF and MLX, respectively.
This Was determined by calculating the within laboratory reproducibility of the method,
followed by multiplication of the within laboratory reproducibility by the safety factor of
3.0.

6.4.2.7 Evaluation
The method developed in this study has been used to evaluate the presence of CPF,
DCF, IBP, KPF, MFN, PBZ, FLU, FLU-OH, TLF and MLX in bovine milk and CPF,
DCF, IBP, KPF, MFN and PBZ in plasma. In monitoring for these substances in either
lllatrix at our laboratory it was possible to detect the precursor ion and two daughter ions
(at 5 ng mL- 1) in mUltiple reaction monitoring mode except for IBP and KPF.
FUrthermore the product ion ratio requirement was also met. The method has been carried
OUt by different analysts under varying environmental conditions and the method was
shoWn to be robust. To

demo~strate the applicability ofthe method

milk samples taken

fro rn animals treated with MLX and FLU-OH obtained from the Community Reference
Laboratory in Berlin were tested. These samples had assigned values ranging from 5- 15
ng rnL -I. The samples were analysed by the method developed in this study and all
samples Were found to

contai~ 5 ng mL- 1 of FLU-OH and 15

1

ng mL- ofMLX.
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6.S Conclusions
A fast, simple, sensitive and selective LC-MS/MS method for the determination of CPF

,

DCF, IBP, KPF, MFN and PBZ in bovine plasma and CPF, DCF, IBP, KPF, MFN, PBZ,
FLU, FLU-OH, TLF and MLX in bovine milk has been developed. The LC-MS/MS
method provided quantitative confirmatory data for the analysis of bovine milk for CPF

,

DCF, MFN, PBZ, FLU, FLU-OH, TLF and MLX. The method developed allows for the
analysis of a wide variety of drugs from different NSAID sub-classes such as CPF, IBP
and KPF (arylpropionic acid derivatives), PBZ (pyrazolidinedione derivatives) DCF,
MFN and TLF (anthranilic derivatives) and FLU and FLU-OH (nicotinic acid
derivatives) and MLX (oxicam derivative). There is no published method available to the
best of our knowledge for the simultaneous determination of authorised and nonauthorised NSAIDs such as CPF, DCF, IBP, KPF, MFN, PBZ, FLU, FLU-OH, TLF and
MLX in bovine milk that purifies sample extracts using Evolute ™ ABN solid phase
extraction cartridge procedure described in this study which is an improvement on
previous work carried out utilising this cartridge chemistry. This is the first time that
FLU, TLF, FLU-OH IBP KPF and MLX have been purified from milk using Evolute

,

,

ABN™ solid phase extraction cartridges simultaneously with other NSAIDs. This is the
1

first time that a method is available that meets the minimum requirements of 5 ng mLfor IBp and KPF in milk. There is no published method available to the best of our
knowledge for the simultaneous determination of CPF, DCF, IBP, KPF, MFN and PBZ

In bovine plasma that purifies sample extracts using Evolute ™ ABN solid phase
extraction cartridges. This study describes the first such sensitive and selective
methodology. This is also the first time that a rapid multi-residue methodology for the
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above authorised and non-authorised NSAIDs has been validated according to
Commission Decision 2002/657IEC [Commission Decision 2002] and the measurement
uncertainty of the method has been described. This methodology shows that suitable
senSI'fIVlty
. was obtained and that the method performs very well in terms of accuracy and
within-laboratory reproducibility. The developed method was evaluated by comparison of
results when method was performed by different analysts under different environmental
conditions, using different batches of reagents and solid phase extraction cartridges. The
results (unpublished data) were highly acceptable providing evidence of the development
of a rugged analytical method in this study. Recently it was proposed by Community
Reference Laboratories (CRLs) in Europe that laboratories should be capable of
1

monitoring for NSAIDS at a level of 5 ng mL- in EU member states where no MRL
exists in plasma or milk and this study shows that these limits can be reached using the
developed analytical strategy' [SANCO 2004]. The objective of the work to anticipate the
reqUirements of the future where risks could occur due to the administration of NSAIDs
by developing a method to monitor for authorised and non-authorised NSAIDs
simultaneously has been achieved. The objective of the work to validate an analytical
strategy for these' residues 'in bovine plasma and milk that meet EU target levels
according to the requirements in Commission Decision 2002/657/EC therefore has also
been ac h'leved successfully.
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Chapter 7: A hybrid liquid chromatography mass
spectrometry strategy in a forensic laboratory for
opioid, cocaine and amphetamine classes in
human urine using a hybrid linear ion trap-triple
quadrupole mass spectrometer

Publ·Ished in Journal ojChromatography A, 1217,2010, Pages 6857-6866
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7.1 Abstract
A rapid method has been developed to analyse morphine, codeine, morphine-3glucuronide, 6-monoacetylmorphine, cocaine, benzoylegonine, buprenorphine,
dihYdrocodeine, cocaethylene, 3,4_methylenedioxyamphetamine, ketamine, 3,4methylenedioxymethamphetamine, pseudoephedrine, lignocaine, benzylpiperazine,
methamphetamine, amphetamine, 2-ethylidene-l ,5_dimethyl-3,3-diphenylpyrrolidine and
methadone in human urine. Urine samples were diluted with methanol:water (1: 1, v/v)
and sample aliquots were analysed by hybrid linear ion trap-triple quadrupole mass
Spectrometry with a runtime of 12.5 min. Multiple reaction monitoring (MRM) as survey
Scan and an enhanced product ion (EPI) scan as dependent scan were performed in an
infonnation-dependent acquisition (lDA) experiment. Finally, drug identification and
cOnfinnation was carried out by library search with a developed inhouse MS/MS library
based on EPI spectra at a collision energy spread of 35±15 in positive mode and MRM
ratios. The method was validated in urine, according to the criteria defined in

Co

' .
MRM tranSItIOns
..
~ each substance
lor
nun ISSlon Decision 2002/657/Ee. At least two

were monitored in addition to EPI spectra and deuterated analytes were used as internal
o

standards for quantitation. The reporting level was 0.05 J.lg mL for the range of analytes
\

01

tested. The regression coefficients

(r2)

for the calibration curves (0-4 J.lg mL

)

in the

stUdy Were 2: 0.98. The method proved to be simple and time efficient and was
Implemented as an analytical strategy for the illicit drug monitoring of opioids, cocaines
and amphetamines in criminal samples from crime offenders, abusers or victims in the
RepUblic of Ireland. To the best of our knowledge there are no hybrid Le-MS
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applications using MRM mode and product ion spectra in the linear ion trap mode for

oPlOlds,
.. cocaines or amphetamines with validation data in urine.

KeYWords: Drugs of Abuse; Human Urine; Liquid Chromatography Hybrid Triple
Quadrupole Linear Ion Trap (QTRAP) Liquid Chromatography Mass Spectrometry;
Method Validation

7.2 Introduction
The analysis of drugs of abuse such as morphine (MGR), codeine (COD), morphine-3glUcuronide (M-3-G), 6_monoacetylmorphine (6-MAM), cocaine (COC),
benzoylecgonine (BENZOYL), buprenorphine (BUPREN), dihydrocodeine (DHC),
COcaethylene (COCA) , 3,4_methylenedioxyamp hetamine (MDA) , ketamine, (KET) 3,4methylenedioxymethamphetamine (MDMA) pseudoephedrine (PSEUDOEPH),
lignocame
. (LIGNO), benzylpiperazine (BZP), methamphetamine (METHAMP),
amphetamine (AMP), 2-ethylidene-l ,5_dimethyl_3,3-diphenylpyrrolidine (EDDP) and
methadone (METH) in urine is highly important as their illicit use is widespread. The
molecular structure of these compounds is shown in Fig. 7.1. Acute intoxication of these
drugs either alone or in combination with other drugs is well documented. Urine is a
simple aqueous matrix that has been used frequently and is preferred for screening and
identification of illicit drugs because the concentrations of drugs and their metabolites
Can be reasonably high [Rivier 2000], urine can be easily sampled and testing is nonInvasive, the volume of sample is generally high and urine testing provides long detection
W
i for
ndrug
d 'use, from several days for opiates
.
.
OWs
an d cocames
up t 0 mont h s C:lor
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chronic cannabinoid use [Vandevenne et al., 2000J. The drawbacks of this matrix in
regulatory monitoring are that the drug concentrations can be affected due to diurnal
fluctuation and the effect of fluid intake, in post-mortem cases urine is not always
available and to detect the effect of a drug blood needs to be analysed. The use of drugs
analysed in this study alone or incombination with other drugs such as cannabis or
alcohol is increasingly popular. 6-MAM is the specific metabolite of heroin in urine
[Dams et al., 2003J. BZP has the reputation ofproducing amphetamine type effects
[Berndon et al., 1992, Schechter et al., 1988J and is banned in Ireland since March 2009.
BENZOYL an inactive metabolite of COC has a longer half life than COC [CapelloPeiro et aI., 2005J additional1y alcohol and COC are widely abused producing COCA
haVing a longer halflife [McCance-Katz et al., 1993, Harris et al., 2003J than COC.
Various adulterants can be added to COC [Shannon et al., 1988,Risser et al., 2007J or to
ectasy tablets [Smith et aI., 2002J but the type of drugs used for recreational use can
change rapidly [DiUion et aI., 2003, Jansen et aI., 1993J with substances like KET
becoming popular [Kohrs et al., 1998, Anis et al., 1983J.
In OUr laboratory in the Republic of Ireland, the analysis of opioids, amphetamines and
cOcaines was carried out using three separate analytical procedures using three fulltime
analYsts and three different GC-MS instruments.
The prOcedures were wel1 established and evaluated in a large number of external quality
COntrol schemes. GC-MS entails a great deal of sample preparation, requires longer
... ~
. d
chro
matographic runtimes and GC-MS can lack senSItIVIty lor certam rugs.
Work was undertaken in order to evaluate newer technology to improve overall analysis
time in the laboratory and expand the classes of drugs for analysis. Sample preparation
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procedures prior to analysis by LC-MS are generally more simplified. The aim of this
study was to develop a fast, simple and reliable sample preparation procedure in urine to
analyse 19 drugs representing drugs from the opioid, amphetamine and cocaine classes
Using a single sample preparation procedure and detection method that can be carried out
by a single laboratory analyst. To date the simplest sample preparation procedures in
urine in the literature for the determination of drugs included in this study such as AMP

,

MDA and MDMA [Andersson et aI., 2008], MOR, M-3-G, M-6-G, COD, COD-6glucuronide, ethyl morphine, M-6-G and 6-MAM [Gustavsson et aI., 2007] and MOR,
BENZOYL, 6-MAM, COC, COCA, METH and EDDP [Dams et aI., 2003] were
aCcomplished using direct injection. Alternatively KET has been filtered prior to direct
i~ eChon
. [Chen et aI., 2007] with subsequent LC-MS detectlOn.
. To date drugs of abuse in

'this study have been analysed in urine by LC-Ion TRAP MS [Chen et aI., 2007, Tsutsumi
et aI., 2005, Wu et aI., 2005, Cheng et aI., 2006, Katagi et aI., 1996], LC Tandem MS
[Andersson et aI., 2008, Gustavsso n et aI., 2007, Dams et aI., 2003, Cheze et aI., 2007,
Concheiro et aI., 2007, Kuwayama et aI., 2008, Berg et aI., 2009, Gergov et aI., 2009,
'Musshoff et aI., 2004, Concheiro et aI., 2007] and hybrid LC-MS [Mueller et aI., 2005].
Chromatographic runtimes were between 8 and 35 min, respectively. The LC-MS
Chromatography methods cover only a few analytes usually with long chromatographic
run-times. There was a paucity of studies that used hybrid LC-MS technology in the
literature as the majority of studies use LC- tandem MS. One such hybrid LC-MS
technology is the 4000 QTRAP LC-MS from Applied Biosystems. This study evaluated
'"
. I
' tec hn'lque t0 rep Iace three
the posslblhty
of using this technology as a smg
e d
etectlOn
separate GC-MS detection techniques. In the 4000 hybrid linear ion trap- triple
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quadrupole mass spectrometer, Q3 can be utilized as a quadrupole or a linear ion trap
with axial ion InjectIOn
"
. [Hager et aI., 2002]. OperatIOn
.as.
a trIp1e quadrupole mass
spectrometer is useful when high sensitivity and selectivity of MRM transitions is needed
for example'In quantItatIve
"
'
0 peratIOn
. as a l'mear ion trap
analysis or targeted
screenmg.
1llass spectrometer is necessary when higher sensitivity in fullscan experiments is
reqUired. In EPI mode, Q 1 is used to filter the precursor ions. Q2 acts as a collision cell
to generate fragments while Q3 working in ion trap mode is used to scan product ions.
This results in triple quadrupole MS like fragmentation pattern but with higher
sensitivity. The QTRAP has a built in collision energy spread (CES) feature which allows
Collection of data at the different collision energies in one EPI spectrum.
A 1llethod by Mueller et al (2005) analyses 301 drugs qualitatively in blood and urine by
3200 QTRAp hybrid LC-MS with a chromatographic runtime of 30 min. Urine although
1llentioned in the manuscript data or validation results were not given. In addition one

MRM transition was monitored in the study therefore MRM ratio's cannot be calculated
'if a situation arises and an EPI scan does not trigger successfully and re-injection of the
sample would be necessary. Three EPI scans were also utilised in the study at three
separate collision energies (CE) which increases the duty cycle. The advantage of the
study by Mueller et aI., [2005] is the capability to monitor a large number of compounds
Si1llultaneously in urine and blood however substances such as COCA, EDDP, BNZY
and LIGNO were not analysed. The consumption of alcohol and COC is extremely
POPUlar and the detection of COCA is important in forensic toxicology because COCA

has a longer detection window than COC [McCance-Katz et aI.,

1993, Harris et aI.,

2003]. This study describes the first hybrid triple quadrupole linear ion trap method with
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MRM as survey scan and IDA and EPI scan as dependent scan for the determination of
COCA, EDDP, BNZY and LIGNO. Furthermore this is the first time that the 19
forensically important drugs have been analysed simultaneously running two MRM's and
a single EPI experiment in positive mode in urine providing information on high and low
mass fragments in a single injection to the best of our knowledge. Drug identification was
carried out by library searching with an in-house developed MS/MS library based on EPI
Spectra at a single CES of 35 ± 15 in positive mode. Validation of the method was based
on Commission Decision 2002/657/EC [Commission Decision 2002], a validation
protocol used in the field of veterinary drug residue monitoring. The decision states
Criteria on the agreement of retention times, base peak and diagnostic ions and relative
abundances between the standards and the samples is essential. The decisions are based
On the calculation of identification points (lPs) which depend on the analytical technique.
In the case of banned substances the minimum number of IPs for a methodology to be
Considered reliable has to be equal to 4 or higher. This is achieved by monitoring a
minimum of 4 selected ions per compound when working with single MS and a minimum
of two selected reaction monitoring (SRM) transitions per compound in tandem MS.
Thus running two MRM transitions ~ives 4 IPs and also obtaining an EPI spectra gives
additional confirmatory information in this study. In this paper a fast, simple and reliable
Illethod is described for the simultaneous analysis of the 19 analytes in urine.
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Structure a: EDDP

Structure b: Codeine

,,

\

HO'

Structure c: Dihydrocodeine

,,\
HO'
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Structure d: Methadone

Structure e: Morphine
HO

\

,\

HO'

Structure f: Cocaine

o
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Structure g:6-MAM

Structure h: Buprenorphine
HO

N~
H0:CCH ,
-

H C
3

:

CH 3

CH~

Structure i: Benzoylego nine

o
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Structure j: MDA

Structure k: MDMA
H

I

N,

CH 3

o

Structure I: Ketamine

Structure m: Amphetamine
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Structure n: Pseudoephedrine

Structure 0: Methamphetamine
H

I

N"

CH 3

Structure p: Cocaethylene

o

o
Structure q: Lignocaine
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Structure r: Benzylpiperazine

N~
~NH

F'19. 7.1 Structures of the opiate, cocaine and amphetamine classes of drugs

7.3 Ex peramental
'
7.3.1 M a t erlals
' and methods
LC-MS grad e water, methanol, propan-2-o1 (HPLC) were obtained from Reagecon and
fonn'IC aCId
. was obtained from BDH (Merck, UK). Ammonium acetate was obtained
from S·Igma-Aldrich. MOR, M-3-G, COCA, COD, DHC, 6-MAM, METH, BUPREN,
EOOP, COC, BENZOYL, LIGNO, MOR-d6, COD-d6, DHC-d6, METH-d9, M-3-G-d),
BENZOYL-ds, COC-d), METHAMP, KET, MDA, MDMA, PSEUDOEPH, BZP, AMP,
METHAMP-d

,
I4

MDA-d , MDMA-ds, AMP-dll were purchased from LGC Standards
s

(LGC, UK). Commercially prepared primary stock standards in solution were purchased

from LGC standards available in concentratIOns
.
. firom 100-1000 Ilg mL- I except
rangmg
for BZP . A stock solution of BZP standard was prepared m
. methanol at a concentration
6

of 1000 Ilg mL-I. A working internal standard solution of MOR-d6, COD-d6, DHC-d ,
s
s
J
METH -d9, M-3-G-d), BENZOYL-ds, COC-d), METHAMP-d 4, MDA-d , MDMA-d ,
was prepared at a concentration of 2 Ilg mL-1(stable for 6 months). A

A.Mp-d
J1

Intennediate standard solution (stable for 6 months) of MOR, M-3-G, COD, DHC, 6MAM, METH, EDDP,

BUPREN, COC, BENZOYL, COCA, BZP, PSEUDOEPH,

MOMA, MDA, AMP, KET, METHAMP and LIGNO was prepared at a concentration of
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10 J,.tg mL- 1 (stable for 6 months). Standard fortification solutions (stable for 6 months)
Were prepare d m
. methanol at a concentration of 2.5 J..lg mL- I from the 10 J..lg mL"
1

1

Interm ed'late stock solution and at a concentration of 0.25 J..lg mL- from the 2.5 J..lg mLstock.

All standards were stored at 4 °C in the dark.

Injection solvent was

water:methanol (1: 1, v/v).

7.3.2 Le con dOItIons
°
The LC consisted of an Agilent 1200 Rapid Resolution LC equipped with a G1312B
.Binary pump, G1316B-HiPALS SL autosampler and a G1316B-TCCSL column oven
(A gl'1 ent Ireland). The drugs were chromatographed on a 5 J..lm Phenomenex HYPURITY

C
'
8 co umn (4.6 x 100 mm) (~GB, Ireland) and l
the column temperature
was mamtained
at 30 ° C. A gradient was applied with water and methanol (95:5, v/v + 25 mM
amrnonium acetate) (A) and methanol :propan-2-01 (97.95:2, v/v + 0.05 mM % formic
acid (B) (Table 7.1). The total run time was 12.5 minutes with a flow rate of 0.8 mL minI

. The injection volume was 20 J..lL. The mass spectrometer used was a QTRAP ™ 4000

With a TurboIonSpray source from Applied Biosystems (Applied Biosystems/MDSSciex, Canada). The MS was controlled by version 1.5 of Analyst software.

7.3.3 MS/MSIEPI
The analysis was performed using positive ion electrospray MS/MS in multiple reaction
monitoring (MRM) mode. Two transitions were used and the collision energy was
oPtirnised as shown (Table 7.2). The MRM MS/MS detector conditions were as follows:
IOn rnode electrospray positive; curtain gas 25 psi; ion spray voltage 5000 V; temperature
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650 QC; ion source gas 1 50 psi; ion source gas 2 50 psi; interface heater on; entrance
potential 10 V; resolution Q 1 unit; resolution Q2 unit; collision -activated dissociation
CAD gas =medium
The strongest MRM transition and the CES spectra at 35 ± 15 for each substance were
chosen from the enhanced product ion spectra (EPI mode) to set up the libary. The IDA
threshold was set at 500 counts per second (cps). The dependent scan was
scan mtensity
.

an EPI scan which was carried out at the CES conditions before switching back to MRM
.mode. The resulting EPI spectra was then searched against the mass spectrallibary. The
Set up of the libary was achieved as follows; the LC parameters described above were
utilised and the injection volume was 20 J.lL: concentration of each substances was 0.1 J.lg
tnL- I . Turbo Ion spray source in EPI scan mode with 60 V declustering potential. Ql

Resolution was unit. Dynamic fill time of the trap (Q3) was set. Curtain gas 25 psi; ion
Spray voltage 5000 V; temperature 650 QC; ion source gas 1 50 psi; ion source gas 250
psi; CAD medium; CES 35±15 V.

7.34
•
• uTTrme
samples
Urine obtained for use as negative controls were separated into 50 mL aliquots and stored
at -20 0C. The urine was analysed in previous batches and urine found to contain no
deteCtab le residues of opioids, cocaines and amphetammes
.
.
were used as negative
·controls.
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Table 7-1: LC gradient profile for determination of MOR, M-3-G, COD, DHC, 6MAM, METH, EDDP, BUPREN COC, BENZOYL, COCA, BZP, PSEUDOEPH,
MDMA, MDA, AMP, )(ET, METHAMP and LIGNO

0.0
1.5
6.0
8.0
8.1
10.0
10.5
12.5

Component A:
Component B:

D5
D5
5

o
o
o
D5
D5

5
5

D5
lOO
lOO
lOO
5
5

water:methanol (95:5, v/v + 25 mM ammonium acetate)
methanol:propan-2-o1 (97.95:2, v/v + 0.05 mM % formic acid)
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Table 7-2: MSIMS parameters for determination of MOR, M-3-G, COD, DHC, 6-

MAM, METH, EDDP, BUPREN COC, BENZOYL, COCA, BZP, PSEUDOEPH,
MDMA, MDA, AMP, KET, METHAMP and LIGNO
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Note.. M atnx
. matched curves .were used for quantI·fi·
.
I
IcatlOn an d deutrated mtema
standards were used as internal standards for all compounds

7.35
. Sample Preparation
Drine samples (

10

9 ~I) were aliquoted into 15 ml polypropylene tubes. The urine aliquots

were fortified with internal standard at levels corresponding to 0.1
100 /o-tL portion ofa 2

~g mL-

1

by adding a

~g mL- 1 mix solution of MOR-d6' COD-d6, DHC-d6, METH-d9, M241

l
s
3-G _d3, BENZOYL-dg, COC-d3, METHAMP-dI4, MDA-d s, MDMA-d and AMP-d !.

1

Samples were fortified at levels corresponding to 0.1, 0.5 and 1 Jlg mL- by adding 40 JlL
1

of a 0.25 Jlg mL- 1 fortification solution and 20 and 40 JlL portions of a 2.5 Jlg mLI IcatlOn
florffi
. solution. After fortification, samples were held for 15 min prior to the next
analyt'lcal step. Methanol:water (1: 1, v/v) (1800 JlL) was added to the urine samples and
VOrtexed (30 sec), centrifuged (3568 g, 5 min, 4 DC) and the supernatant was transferred
to an autosampler vial. An aliquot (20 JlL) was injected on the LC column.

7.3.6 Matrix-Matched Calibration
Matrix matched calibration curves were prepared and used for quantification. Control
Urine previously tested and shown to contain no residues was prepared as above (7.3.4).
COntrol urine sample (10 mL) was diluted with methanol:water (1:1, v/v) to 200 mL. A
single urine sample was used for each calibration standard level. Urine samples (mL)
Were aliquoted into 50 mL polypropylene tubes and samples were fortified with internal
1

standard at levels corresponding to 0.1 Jlg mL- by adding a 100 JlL portion of a 2 Jlg mLI

, solution of MOR-d6, COD-d6, DHC-d6, METH-d9, M-3-G- d 3, BENZOYL-dg,
mIX

COC-d , METHAMP-d 4, MDA-ds, MDMA-ds and AMP-dll' Calibration standard levels
I
3
1
were fortified at levels corresponding to 0, 0.05, 0.1, 0.25, 0.5, 1.0,2.0 and 4.0 Jlg mL1

by adding 0, 20, 40, 100 JlL portions of a 0.25 Jlg mL- fortification solution and 20, 40,
80 and 160 JlL portions ofa 2',5 J.Lg mL- 1 standard solution of MOR, M-3-G, COD, DHC,
6-MAM, METH, EDDP, BUPREN, COC, BENZOYL, COCA, BZP, PSEUDOEPH,
MDMA, MDA, AMP, KET, METHAMP and LlGNO. After fortification, samples were
held for 15 min prior to the vortexing and centrifugation procedure as described above
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(7.3.5). The concentration of the drugs (!J.g mL -I) were determined from the matrix
matched calibration curves. The calibration curves were calculated by linear regression,
standard peak area of the strong
plotting the response factor (peak area analyte/mternal
.
tran SItIon
.. as a function of analyte concentration).

7.3.7 Method validation
For estimation of accuracy, blank urine samples were fortified with MaR, M-3-G, COD,

DHc, 6-MAM, METH, EDDP,

BUPREN, COC, BENZOYL, COCA, BZP,

PSEUDOEPH, MDMA, MDA, AMP, KET, METHAMP and LIGNa at 0.1, 0.5 and 1.0

~g

mL-I. Six replicate test portions, at each of the three fortification levels, were

analysed. Analysis of the 18 test portions was carried out on three separate occasions. For
of the precision of the method, repeatability and within-laboratory
the estimatIOn
.
.
reproducibility was calculated. The decision limit (CCa) of the method was calculated
aCCording to the ISO 11843 calibration curve procedure using the intercept (value of the
signal, y, where the concentration, x is equal to zero) and 2.33 times the standard error of
the intercept for a set of data with 6 replicates at 3 levels. The detection capability

(CC~)

\Vas calculated by adding 1.64 times the standard error to the CCa. Carryover was
InVestigated by analysing a blank solvent before and after each injection during validation
and routinely in each analytical batch. The stability of standard solutions was evaluated

by quantifying levels in an external quality control material over a six month period as a

Qc is ran with every batch routinely. Short-term stability of extracts was performed by
analYsing extracts held at 4

0c for 48 hours. Matrix effects were investigated by infusion
1

Of all

analytes (2.5 "g mL-'j by an external syringe pump to a tee-connector at 10 "I mL243

between the electrospray probe and the outlet of the analytical column with simultaneous
blank matrices diluted in
.
injecrIOn of methanol:water (1: 1, v/v). Subsequently 5 different
methanol:water (1: 1, v/v) were injected on the analytical column. The specific ion
transitions of the analytes in different blank matrices were recorded and any signal
decreasing or increasing at the retention time of the investigated analyte was compared
with the methanol:water (1:1, v/v) injection.

7.4 Results and Discussion
7.41
,
experiments
. p re )'Immary
fufu'IS study an analytical strategy was developed to analyse unne
. samples to detect

drugs of abuse. The LC-MS/MS method using MRM mode and product ion spectra in the

I co nfimnatory data for
linear'IOn trap mode (Q3) was developed to pro vl'd e uneqUlvoca
.
the analysis of MOR, M-3-G, COD, DHC, 6-MAM, METH, EDDP, BUPREN, COC,
BENZOYL, COCA, BZP, PSEUDOEPH, MDMA, MDA, AMP, KET, METHAMP and
LIGNO. The ionization of all drugs was studied in positive mode. The optimum
.conditions (declustering potential, collision energy, collision cell exit potential) were
determined for each drug and the best diagnostic ions for MS/MS analysis were obtained
and can be seen in Table 7.2. For a method to be deemed confirmatory 4 identification
Points must be obtained. In MRM (multiple reaction monitoring) mode this is achieved
by monitoring one precursor ion (parent mass) and two daughter ions (corresponding to
stron g and weak ion) which is a suitable confirmatory meth0 d'In accordance Wl'th

20 02/657/EC [Commission Decision 2002]. Precursor and product ions for each analyte
of interest were determined by direct infusion of single analyte solutions (1
.lOethanol:water 1: 1 v/v). Chromatographic tests were carried out using a 5

~g mL-

1

in

~m
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HYPURITY Cs column (4.6 x 100 mm). All analytes were eluted at a flow rate of 800 ilL
• -I

rnlO and a runtime of 12.5 min per injection with good peak shape when using a mobile
phase of water:methanol (95:5, v/v + 25 mM ammonium acetate) (A) and
rnethanol:propan_2_01 (97.95:2, v/v + 0.05 mM % formic Acid) (B). The formic acid was
used to assist the ionisation of the analytes in positive mode and improve peak shape by
reducing peak taI'1'mg. The ammonium acetate assIsts
. Wit. h separatIon
. 0f the analytes. In
the in'f I
I la stages of development carryover was observed but a wash program was set up
10 the autosampler. No carryover problem was noted during validation and during routine

use of the method when solvent blanks are analysed before and after samples. In MRM
rnode the possibility of cross talk of analytes with internal standards was evaluated after
tuning by injection of standards on column singularly. Crosstalk occurs if two
cornpounds co-eluting have similar fragment ions in two successive transitions in an

MRM method. The degree of the problem depends on the instrument speed as the
fragment ions pass through the collision cell rapidly enough to exit the cell before the
same fragments of the next compound come in. However this can cause dead time
making the scan cycle time significantly longer leading to fewer datapoints across the
Chromatographic peak. No issue with crosstalk was identified during the evaluation. A
BPI experiment was set up in the Analyst 1.5 software. The strong MRM transition was
chOse

.
. hr h I
n upon completion of tuning in MRM mode. The IDA scan mtensIty t es 0 d was

Set at 500 cps (counts per second) in the instrument method. The dependent scan was an
BPI sCan set at 35 CES ± 15. One drawback of the Analyst 1.5 software in data dependent
lllode is that the software only allows a single preselected CE or CES for all analytes in

an BPI experiment. It would be better if the software manufacturers in the future would
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allow individual DP and CE settings per compound in EPI dependent scan mode. The
result'mg EP I spectra was searched against a mass spectra library. In Figure 7.2
chromatogram of COCA is shown. In Figure 7.3 the library spectrum of COCA and also
lIbrary
spectrum of COCA at a CES of 35 ± 15 including the library search
the acqUlred
.
.
fit values is shown. The fit value (Fit) gives information about the resemblance ofthe
those
signals'm t h e reference spectrum With
.
'm the unknown spectrum. The reverse fit
(Reverse Fit) gives information on the resemblance of the signals in an unknown
Spectrum with those in the reference spectrum. The purity (Purity) is a combination of
both other values. For COCA in Figure 7.3 the purity value was greater than 94%. The
stability of the solution standards was evaluated by quantifying levels in an external QC
material over a six month period as the QC material was analysed with every batch
routinely and is within specification. The short term stability of sample extracts was
aCceptable when extracts were stored at 4°C for 48 hours. In the initial stages of method
development matrix suppression was witnessed at the beginning of the chromatographic
runtime and as a result the eluent was diverted to waste initially to reduce the bulk of
matrix components. To further reduce any possible matrix effects deuterated internal
standards were used. During the evaluation period 233 samples were analysed by this
Le-MS procedure and an established GC-MS procedure and results were in good
agreement. Often in forensic toxicology cases it can be difficult for the pathologist to
obtain large sample sizes. Preconcentration of urine during method development was not
req'
h
.
Ulred based on the sensitivity achieved by the QTRAP met hdh
0 t us t e urme samples

(loo ~L) were diluted 20 fold in methanol:water (1:1, v/v) and a good peak shape was
achi eved. It was envisaged that urine samples wou Id not reqmre
. extenSlve
. c Iean-up due
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to its 10w protem
. and high aqueous content. The first advantage of the sample preparation
procedure is a small sample volume is required. The second advantage is that the 19
drugs can be analysed rapidly and simultaneously using simple dilution with
methanol:water (1: 1, v/v). The third advantage is that the sample preparation procedure
reduces the workload in monitoring for these substances in any laboratory and as a result
a single analyst is capable of preparing a matrix matched curve and 50 samples in a single
day. A fourth advantage is the savings in cost as there is no need to purchase costly
hYdrolysis reagents for the detection of drugs that are extensively metabolised. The first
advantage of the hybrid Le-MS detection method developed in this study is the fast runtime of 12.5 min per injection allowing detection of 19 forensically important drugs. The
seCond advantage of is that high and low concentrations of the drugs in urine samples can
be identified, quantified and confirmed simultaneously in a single injection using EPI
sPectra. High levels of drugs can be detected routinely using EPI spectra and the samples
do not need to be re-injected as EPI spectra can be used to unambiguously confirm
OVerdose cases in a straightforward manner. The disadvantage of using MRM ratio's only
IS that the sample will require dilution as a result of detector saturation and re-injection.
The method has been used since 2009 to replace three other analytical strategies in our
labo t
.
h' d
.
.
I dd"
ra ory for detection of opioid, cocame and amp etamme rugs m urme. n a ItlOn

full l
b
"
iytlcal
'
a oratory information
management system
(LlMs) connectIvity 0 f th
e ana
strate gy has been achieved using Analyst 1.5 software as part 0 f rout'me momtonng
., 0f
fO ren .
SIC toxicology samples.
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7.4.2 Validation study
Validation of the method was according to procedures described in Commission Decision
2002/657/EC [Commission Decision 2002] covering specificity, calibration curve

rlnearity, accuracy, precision, decision limit (CCa) and detection capability (CC~).

7.421
.. S pecl°fiIClty
0

The technique of liquid chromatography hybrid triple quadrupole linear ion trap
(QTRAP) mass spectrometry itself offers a very high degree of selectivity and specificity.
To establish the selectivity/ specificity of the method, urine samples (30) were fortified
with the above drugs and also non-fortified samples were analysed. Interfering peaks
Were observed at the retention time of some of the analytes in the chromatograms of the
non-fortified samples but the response was negligible when compared to the reporting
level

7.4.22
. LolDearIty of the response
0

The linearity of the chromatographic response was tested with matrix matched curves
1

Using 8 calibration points in the concentration range of 0 to 4.0 J.!g mL- • In routine
2

monitoring 25 analytical batches were analysed and the regression coefficients (r

)

for all

the ca rb
I ration curves were ~ 0.98.

7.4.2.3 Accuracy

lQ accuracy (n~ 18) of the method was determined using human urine samples fortified
e

at 0.1,0.5 and 1.0 J.!g mL-1for in three separate assays was 84-113%.
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7.4.2.4 Precision
The precision, expressed as RSD values for the within-lab reproducibility at the three
1

levels of fortification (0.1, 0.5 and 1.0 ug mL- ) was less than 12 % (Table 7-3).

~~ble 7-3: Intra- and inter-assay variation for accuracy of MOR, M-3-G, COD,
Ps C, 6-MAM, METH, EDDP, BUPREN COC, BENZOYL, COCA, BZP,
EUDOEPH, MDMA, MDA, AMP, KET, METHAMP and LIGNO
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7.4.2.5 CCaand CCp
The decision limit (CCa) is defined as the limit above which it can be concluded with an
error probability of a, that a sample contains the analyte. In general, for non-MRL
substances an a equal to 1 % is applied. The detection capability (CCP) is the smallest
Content of the substance that may be detected, identified and quantified in a sample, with
a statistical certainty of

1-P,

were

P== 5 %. CCa

and CCp were calculated using the

Intercept (value of the signal, y, were the concentration, x is equal to zero) and the
standard error of the intercept for a set of data with 6 replicates at 3 levels (0.1, 0.5 and

1.0 J..Lg mrl). CCa is the concentration corresponding to the intercept + 2.33 times the
standard error of the intercept. CCp is the concentration corresponding to the signal at

eea + 1.64 times the standard error of the intercept (i.e the intercept + 3.97 times that
standard error of the intercept). The full list of CCa and CCp values are shown in Table

7·4 . In our methodology CCa values of 0.03-0.05 J..Lg mL- I and CCp values of 0.04-0.09
J..Lg mL-1 were obtained. Although CCa and CCp values are widely adopted in the field
drug residues. The use of these parameters was 10vestIgated
as an
of Vetennary
.
.
.
. . 0 f quanti'fi"
.alternat'Ive approach to limit of detection and lImIt
IcatlOn m th'IS study. Based

On the calculated CCa level in this validation study samples were analysed to verify that
the method can detect the calculated CCa level. In our methodology CCa values of 0.030.05 J..Lg mL- 1 were obtained' during validation. The lowest level in our matrix matched
'calibration curve standard is 0.05 J.!g mL-I. This standard give acceptable signal-to-noise
•
. Ieve I.
ratio' s l':tor each compound and is used rout1Oely
as the report1Og
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7.4.2.6 Measurement Uncertainty

According to SANC012004/2726 rev 1 the within laboratory reproducibility can be
regarded as a good estimate of the combined measurement uncertainty of individual
methods [SANCO 2004]. For the calculation of the extended uncertainty a safety factor is
The within laboratory reproducibility should be multiplied by a value of2.33
reqUlred.
.
and this should be used when determining the CCa, corresponding to a confidence level
of 99 %. As the only source of variation during the validation was the difTerent days and
eCI ed to use a saiety
factor of3.0
different unne
. sourced from different humans It. was d·d
J"
Instead of2.33. The measurement uncertainty of the method was estimated at 32, 26, 29,
27,18,16,35,30,19,28,16,20,30,18,25,17,13,31, and 20 % for MaR, COD, M-3G, 6-MAM, COC, BENZOYL, BUPREN, DHC, COC, MDA, KET, MDMA,

PSEUDOEPH, LIGNO, BZP, METHAMP, AMP, EDDP and METH. This was

detennined by calculating the within laboratory reproducibility of the method, followed

by multiplication of the within laboratory reproducibility by the safety factor of3.0.

7.4.2.7 Evaluation

The method developed in this study has been used to evaluate the presence ofMOR,

COD, M-3-G, 6-MAM, COC, BENZOYL, BUPREN, DHC, COC, MDA, KET, MDMA,
PSEUDOEPH, LlGNO, BZP, METHAMP, AMP, EDDP and METH in human urine in
the Republic ofIreland in 2009. In monitoring for these substances at our laboratory drug
identification was carried out by libary search with a developed inhouse MS/MS libary
based on EPl spectra at a collision energy spread (CES) of35 ± 15. Additionally
rOuti ne Iy it was possible to detect the precursor ion and twO daughter IOns
.
(.
With"III a
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reaction monitoring mode asweH as generating an EPI
single in'~ec f Ion)'ill multiple
.
The method has been carried out using
spectra und er co H'ISlon
. energy spread conditIOns.
',
I ferent batches of urine, different QC material, by different analysts, using different
d'f

batches of reagents, under varying environmental conditions and the method was shown
to be robust. To demonstrate the applicability of the method incurred urine samples taken
from sub'~ects treated with MOR, COD and BENZOYL from the QC Reference Material
1

Were tested. These QC samples had values ranging from 0.25- 0.37 I-lg mL- for MOR,
1

0.23- 0.35 I-lg mL- 1 for COD and 0.13- 0,19 I-lg mL- for BENZOYL. The QC for MOR,

COD and BENZOYL were found to be non-compliant as they contained levels above
CCa. and the calculated concentrations were within the specified range of the QC
Ihatenal.
' Furthermore the EPI spectra confirmed unambiguously the presence of MOR,

COD and BENZOYL as spectra matched the corresponding spectra in the libary
developed in-house. To further demonstrate the method applicability the method has been
used to analyse a number of urine proficiency testing (PT) samples in which subjects
were treated with MOR, BENZOYL, BUPREN, AMP, EDDP, METH and KET. The PT
samples were analysed by the' method developed in this study and were found to be nonas they contained levels above the calculated CCa . The EPI spectra matched
cOm plant
I'
the Corresponding spectra in the libary developed in-house in Analyst 1,5 software and
satisfactory Z-scores of below 1.4 were obtained for PT samples, Furthermore a PT
sample negative for cocaines, opiates and amphetamines was analysed by this analytical
strategy and was reported as being negative thus further ensunng
' that an accurate
analytical strategy was developed. The method was also stringently evaluated in-house by
COmparison with established GC methods (3 xGC-Ion Trap methods for opiates, cocaines
252

and amphetamines) and running all incoming samples simultaneously with old and new
analyt'Ical methods. The results (unpublished data) were acceptable. The developed
analytical strategy performs very well in termS of accuracy and within-laboratory
reproducibility.

7.4.2.8 Case Study
The described methodology has been applied in the laboratory since 2009 and positive
drugs of abuse were identified in forensic criminal samples from crime offenders, abusers
Or victims using this method. The method has been used to analyse 233 samples from
01/03/2009 until 14/12/2009. The following substances were confirmed to be present in

samples during this time period.
The presence of 6-MAM was confirmed in 110 samples. The presence of BENZOYL was
confirmed in 91 samples, LIGNO was found in 78 samples, COC was found in 67
samples, METH was found in 65 samples, EDDP was found in 63 samples, AMP was

m 45 samples, COCA was found in 43 samples, MOR was found in 25 samples,
found'

BNZY was found in 21 samples, MDA was found in 17 samples, PSEUDOEPH and
COD was found in 12 samples, MDMA was found in 7 samples, METHAMP was found
In 6 samples and DHC was found in 3 samples during this time period. BENZOYL is the
main metabolite of COC in urine and LlGNO is often used as an adulterant in COC.

h can be concluded that 6-MAM which is a marker for heroin and COC dominates the
picture during this time period. The results obtained using the analytical strategy
developed in this study were reported in forensic cases in the Republic of Ireland.
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Table 7.4: Calculated CCa. and
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~ig. ~-2: Chromatogram of Negative Control Urine fortified with 0.1 ug.mL"

of dJ"
. ocame (A) and fortified with 0.1 ug.mL" of Cocaethylene and at 0.1 ug.mL" with
Internal standard d3-Cocaine (B)

.9__

Ul-_,

•

,"J

r. ... _

~- ...1

';' ... ,
,ut

""_"~
,~

..
J
,"'"

.-"c. . . t-~'"

-

>•

J

, ..

.....-4...u.,.....

""

.

~--

-

.-

F'Ig, 7-3: Spectra of Cocaethylene
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7.5 Conclusions
The developed strategy has been carried out using different batches of urine, different QC
material, by different analysts, using different batches of reagents, under varying
environmental conditions. The developed method shows good agreement with reference
GC-MS methods (not shown). The advantage of a small sample size and the ability to
confirm the identity of a wide variety of drugs in a single injection has important
advantages for high sample throughput in a regulatory laboratory. Matrix effects studies
Were carried out and results have shown that utilizing a labelled internal standard

,

dilution of samples and a diverter valve minimised the effects. The accuracy of the
method has been further certified as acceptable results were obtained by method
comparison with PT samples and reference GC-MS methods. In conclusion the method
Shows that simple dilution ofiJrine and analysis by hybrid LC-MS technology can present
a rugged analytical strategy. There are no methods in the literature to the best of our
knOwledge that analyse the 19 drugs simultaneously in this study in urine representing
opioids, cocaines or amphetamines by simple dilution and hybrid LC-MS using a hybrid

linear ion trap-triple quadrupole mass spectrometer in MRM mode and product ion
spectra in the linear ion trap mode. Therefore the aim of developing a fast, simple and

reliable sample preparation and hybrid Le-MS strategy for opioids, cocaines and
amPhetamines in this study has been achieved successfully.
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Chapter 8: A new mixed mode solid phase
extraction strategy for opioids, cocaines,
amphetamines and adulterants in human blood
with hybrid liquid chromatography tandem mass
spectrometry detection

~blished in Journal ofPharmaceutical and Biomedical Analysis, Volume 54, Issue 5,
U, Pages 1136-1145
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8.1 Abstract

A rapid method has been developed to analyse morphine, codeine, 6monoacetylmorphine, cocaine, benzoylegonine, dihydrocodeine, cocaethylene, 3,4methylenedioxyamphetamine, ketamine, 3,4- methylenedioxymethamphetamine,
pseudoephedrine, lignocaine, benzylpiperazine, methamphetamine, amphetamine,
methadone, phenethylamine and levamisole in human blood. Blood samples were cleaned
up Using mixed mode solid phase extraction using Evolute CX ™ solid phase extraction
Cartridges and the sample aliquots were analysed by hybrid triple quadrupole linear ion
trap (QTRAP) mass spectrometry with a runtime of 12.5 min. Multiple reaction
I ormg (MRM) as survey scan and an enhanced product ion (EPI) scan as dependent
mon·t .

Scan were performed in an information-dependent acquisition (lDA) experiment. Finally,
drug identification and confirmation was carried out by library search with a developed
inhouse MSIMS library based on EPI spectra at a collision energy spread of 35±15 in
Positive mode and MRM ratios. The method was validated in blood, according to the
criteria defined in Commission Decision 2002/657lEe. At least two MRM transitions for
each substance were monitored in addition to EPI spectra and deuterated analogues of
analytes were used as internal standards for quantitation where possible. The method
Proved to be simple and time efficient and was implemented as an analytical strategy for

. drug monitoring of opioids, cocalOes,
.
· eS and ad u1terants In
. .orensic
c:
the ill.lClt
amp h
etarnlO
cases of crime offenders abusers or victims in the Republic of Ireland.

,
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KeYWords: Drugs of Abuse; Human Blood; Liquid Chromatography Hybrid Triple
Quadrupole Linear Ion Trap (QTRAP) Mass Spectrometry; Method Validation; Solid
Phase Extraction

8.2 Introduction
Acute intoxication of drugs either alone or in combination with other drugs is well
documented. In 2009 the veterinary drug LEV which is a veterinary anthelmintic drug
has come into recent attention in the public health and medical communities as an alleged
new cutting agent in adulterated cocaine. There have been a few cases first in Canada and
then in the United States of patients with life-threatening cases of
neutropenia/agranulocytosis as a result of LEV_adulterated cocaine [Zhu et al., 2009,
Kinzie et al., 2009]. PHEN is a substance that can cause false positive results for
amphetamines when immunoassay is used [Eichorst et al., 1991].
The molecular structure of these compounds are shown in Fig.8.1.

Structure 1: Levamisol e

Structure 2: Phenethylamine

Fi gure 8.1 Structures of Levamiso1e and Phenet h
I·
YamIDe
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The analysis of these and drugs such as morphine (MaR), codeine (COD), 6monoacetylmorphine (6-MAM), cocaine (COC), benzoylecgonine (BENZOYL),
y p
dihydrocodeine (DHC), cocaethylene (COCA) ,3,4_methylenediox am hetamine
(MDA), ketamine, (KET) 3,4_methylenediOXymethamphetamine (MDMA)
pseudoephedrine (PSEUDOEPH), lignocaine (LIGNa), benzylpiperazine (BZP),
methamphetamine (METHAMP), amphetamine (AMP) and methadone (METH) in blood
IS

of vital importance in forensic toxicology. Blood is an important matrix as provides a

sample screen of toxic substances present in the body at the time of collection. In our

laboratory in the Republic of Ireland, the analySis of opioids, amphetamines and cocaines
in blood was carried out using three separate sample preparation procedures and three
different GC-MS instruments with additional derivatisation procedures. LEV was not

monitored previously but tbe procedures were well established in blood but time
consuming. The aim of this work was to develop a single fast, simple and reliable sample
preparation procedure in blood to analyse the 18 drugs in this study. A study carried out
by Juhascik et al [2009] investigated whether switching from an established liquid liquid
Partitioning (LLE) sample preparation procedure in blood to a solid phase extraction
(SPE) sample preparation procedure was feasible for drugs of abuse. The study found that
SPE had lower limits of detection for a wider range of drugs, was capable of detecting
drugs that were previously not detectable by LLE and was shown to be a faster technique
than LLE. Further benefits ofthe technique of SPE include reduction of matrix effects,
the ability to automate the sample preparation procedure, dual retention mechanisms,

Im proved sorbent chemistries for rigorOUS wash and eIuuon
.
.
protoco Is, Improved
sensitiVity and decreases exposure and costs due to hazardoUS solvents. The main
260

challenge of SPE is the large number of parameters that need to be adjusted to optimise
the sorbent chemistry performance. To date sample preparation procedures in whole
blood in the literature using LC coupled to various detection systems for the
determination of drugs included in this study was achieved by solvent extraction
[Juhascik et aI., 2009, Shima et aI., 2008J, liquid/liquid extraction [Juhascik et aI., 2009,
GergoV et aI., 2009, Mueller et aI., 2005, Gergov et aI., 2003, Logan et aI., ]987J and SPE
[Mueller et aI., 2005 Johansen et aI., Bogusz et aI., ]997, Dams et aI., 2002, Decaestecker
et aI., 2003, Chen et aI., 1993, Gerostamoulos et aI., ]995]. SPE sorbent chemistries
Ufr
1 lzed were reverse phase [Decaestecker et aI., 2003, Bogusz et aI., ] 997,

Gerostarnoulos et aI., ] 995J, cation exchange [Decaestecker et aI., 2003, Johansen et aI.,
2007, Darns et aI., 2002J strong/weak mixed mode cation exchange sorbents [Dams et aI.,
2002, Decaestecker et aI., 2003, Chen et aI., ]993J and polymeric sorbents utilizing Oasis
l-ILB [Decaestecker et aI., 2003]. A new mixed mode SPE sorbent chemistry technology
was developed by Biotage ™ with an optimised pore size and was evaluated as a single
PUrification strategy for the] 8 drugs in blood. To date drugs in our study have been
analysed using LC coupled to different detectors including LC-diode array and
flUorescence detectors [Dams et aI., 2002J, LC-e1ectrochemical detector [ Logan et aI.,
19

87, Chen et aI., ] 993, Gerostamoulos et aI., ] 995J, LC-MS [Gergov et aI., 2009,

Bogusz et aI., ] 997J, LC-MS/MS [Shima et aI., 2008, Gergov et aI., 2003, Johansen et
aI., 2007, Decaestecker et aI., 2003, Che'ze et aI., 2007J and hybrid LC-MS [Mueller et
aI., 2005J. The benefits of the technique of LC-MS are that it does not require
derivatisation, can analyse both free and conjugated drugs simultaneously, can analyse
thermolabile drugs directly, short chromatographic runtimes, easy online coupling to SPE
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and sample preparation procedures prior to analysis by LC-MS are generally more
simplified. The disadvantage is the possibility of matrix effects. Evaluation of the
l'Iterature showed the majority of studies in blood analysed blood by tandem LC-MS with

chromatographic runtimes varying from 10 to 30 min. There are limited studies using
hYbrid LC-MS technology such as the 4000 QTRAP LC-MS system available from
Applied Biosystems. The hybrid LC-MS method in this study was based on work
1
undertaken at our laboratory for drugs of abuse in urine [Dowling et al., 20 0]. The
second aim of this study was to extend the method to include LEV and PHEN. In the
4000 QTRAP hybrid triple quadrupole ion trap mass spectrometer, Q3 can be operated as
a quadrupole or as a linear ion trap with axial ion injection [Hager et al., 2002]. The
Instrument also has the capability to perform a large number of survey scans because it
has a linear acceleration collision cell (LINAC) [Sasaki et al., 2007] that enables ions to
be t r
an
'
. fiormatlOn
. reIatmg
' to th'IS type ofLCsported
through
the system rapidly. Furlher m

deseribed [Dowling et aI., 20 I0]. A method developed by MueHer et al
MS'IS prevIously
.
[2005] analyses 301 drugs qualitativelY iu blood and urine by 3200 QTRAP hybrid LC-

MS with a chromatographic runtime of 30 min. Blood was mentioned in the manuscript
but no validation results were given and results were qualitative only. A disadvantage

.was that only one MRM transition is monitored and if a situation arises where the EPI
scan does not trigger re-injection of samples would be necessary. Three EP! scans in
addition are utilised at three separate collision energies (CE) which increases the duty

Cycle in the study and substances such as COCA, BNZY, LEV and PHEN were not
analYsed in blood. This study describes a neW single solid phase extraction sample
preparation procedure using Evolule ABN ™ CX in blood for the analysis of COCA,
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BNZY, LEV and PHEN and the 14 other drugs with detection by hybrid LC-MS running
two MRMs and a single CES at ± 15 in positive mode. Validation was based on
Commission Decision 2002/657/EC [Commission Decision 2002] and in-house
procedure and drug identification was achieved by library searching based on EPI spectra
at a single CES of 35 ± 15 in positive mode. The method is being used as an analytical
strategy in the Republic of Ireland in forensic cases.

8.3 Experimental
8.3.1 Mt'
a erIa Is and Reagents

LC-MS grade water, ethyl acetate, methanol, propan-2-01 (HPLC) were obtained from
Reagecon and formic acid was obtained from BDH (Merck, UK). Ammonium acetate
and ammonium hydroxide were obtained from Sigma Aldrich. Evolute ™ ABN CX solid

phase extraction cartridges were obtained from Biotag e (Biotage, UK).
MOR, COCA, COD, DHC, 6-MAM, METH, BUPREN, EDDP, COC, BENZOYL,
LIGNO, LEV, PHEN, MOR-d" COD-d" DHC-d" METH-d" M-3-G-d" BENZOYL-d"
COC-d" KET-

<4, PSEUDOEPH- d" 6-MAM- d" EDDP- d" BNZY- d" METHAMP,

!<ET, MDA, MDMA, PSEUDOEPH, BZP, AMP, METHAMP-d14, MDA-d" MDMA-d"
AMP-d" were purchased from LGC Standards (LGC, UK). Commercially prepared
Primary stock standards in solution were purchased from LGC standards available in
concentrations ranging from 100-1000 flg mL" except for BZP. A stock solution ofBZP
standard was prepared in methanol at a concentration of 1000 flg mL".
Internal standard solution of MOR-d"
IlENZOYL_d" COC-d" KET-

COD-d"

DHC-d"

METH-d"

A working
M-3-G-d"

<4, PSEUDOEPH-d" 6-MAM- d" EDDP- d" BNZY- d"
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METHAMP-d

,
I4

MDA-d , MDMA-ds, AMP-dll was prepared at a concentration of2
s

~g

mL-1 (stable for 6 months). A intermediate standard solution (stable for 6 months) of
MOR, COD, DHC, 6-MAM, METH, EDDP, BUPREN, COC, BENZOYL, COCA, BZP,
PSEUDOEPH, MDMA, MDA, AMP, KET, METHAMP, LIGNO, LEV and PHEN was
prepared at a concentration of 10 jlg mL- 1 (stable for 6 months). Standard fortification
solutions (stable for 6 months) were prepared in methanol at a concentration of 1.25 jlg
mL-1 and 5

~g mL- 1 from the 10 jlg mL- 1 intermediate stock solution.

All standards were

stored at 4 QC in the dark. Injection solvent was water:methanol (50:50, v/v). 50 mM
ammonium acetate, 2% formic acid and 100 % methanol were used as solid phase
extraction wash solvents. 5% ammonium hydroxide in ethyl acetate (70:30, v/v) was used
as the solid phase extraction elution solvent. Injection solvent was water: methanol
(50:50, v/v).

Generic manufacturer's SPE procedure (Procedure A) involved dilution of blood 1:5
With 50 mM ammonium acetate buffer at pH 6.0 , sonication of the samples (l

0

min),

centrifugation (3000 rpm, 10 min) and passing the supernatant under gravity through an

SPE Cartridge preconditioned with methanol (3 mL) and ammonium acetate buffer (3
tnL). The cartridges were washed with ammonium acetate buffer (2 mL), methanol (2
mL) and eluted with 5% ammonium hydroxide: methanol (3 mL). Mod(fied Generic

"'an/ifacturer's SPE procedure (Procedure B) consisted of an acid wash step using 2 %

fOnnic acid being introdUced prior to tbe methanol wash step to ensure that all drugs were
Ionised and retained on the cartridge prior to the high organic wash step. Wash solvent
volUtnes were increased from 2 to 3 mLs. A drying step of 20 minutes was introduced
also. Elution solvent study (Procedure C) involved using procedure B but elution with
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ethyl acetate:methanol:ammonium hydroxide (68:25:2, v/v/v) or (70:25:5, v/v/v). Ethyl
acetate:ammonium

hydroxide

(98:2,

v/v)

or

(95:5,

v/v).

Methylene

hydroxide
chloride".Isopropanol:ammomum
.
' (78:15:2, v/v/v) or (80:15;5, v/v/v). Elution
vOlum es 0f3 x 2 mL were used.

8.32
.
. Le con d'ItIons

The LC consisted of an Agilent 1200 Rapid Resolution LC equipped with a G1312B
Binar

y pump, G1316B-HiPALS SL autosampler and a G1316B-TCCSL column oven

(Agl'1 ent Ireland). The drugs were chromatogniphed on a 5 j.1m Phenomenex HYPURITY

Cs column (4.6 x 100 mm) (AGB, Ireland) and the column temperature was maintained
at 30 0 C. A gradient was applied with water and methanol (95:5, v/v + 25 mM
ammonium acetate) (A) and methanol:propan-2-01 (97.95:2, v/v + 0.05 mM % formic
acid (B) (Table 8.1). The total run time was 12.5 minutes with a flow rate of 0.8 mL minI.

The injection volume was 20 j.1L. The mass spectrometer used was a QTRAP 4000

with a TurboIonSpray source from Applied Biosystems (Applied Biosystems/MDSSciex, Canada). The MS was controlled by version 1.5 of Analyst software.

8.3.3 MS/M SIEPI parameters
.

lb analysis was performed using positive ion electeospray MSIMS in multiple reaction
e

1ll0nitoring (MRM) mode. TwO transitions were used and the collision energy was
Optimised as shown (Table 8.2). The MRM MS/MS detector conditions were as follows:
Ion mode electrospray positive; curtain gas 25 psi; ion spray voltage 5000 V; temperature
650 'C; ion source gas I 50 psi; ion source gas 2 50 psi; interface heater on; entrance
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Potential 10 V; resolution Q1 unit; resolution Q2 unit; collision -activated dissociation
CAD gas ==medium. The strongest MRM transition and the CES spectra at 35 ± 15 for
each SUbstance were chosen from the enhanced product ion spectra (EPI mode) to set up
the libary. The dependent scan was an EPI scan which was carried out at the CES
Conditions before switching back to MRM mode. The resulting EPI spectra was then
searched against the mass spectrallibary. The set up of the libary was achieved as

fOllow s; th e L C parameters described above were UtI'1'Ised an d the lnJectlOn
"
. volume was
20 "
· · of each substances was 0. 1 Jlg m L- .
,... . L
concentratlOn
'
Table 8.1: Gradient profile for determination of MOR, COD, DHC, 6-MAM,

METlI, COC, BENZOYL, COCA, BZP, METHAMP, LIGNO, PSEVDOEPH,
AMP, }(ET, MDA, MDMA, LEV and PHEN

TIme (II'1n I

CDmpone/t A. 1

0.0
1.5
6.0

115
115

8.0
8.1

o
o
o

10.0
10.5
12.5

COlllponent A'
C
.
Olllponent B:

5

liS
liS

CDmpone/t 81 )

5
S
liS

100
100
100
5
S

water:methanol (95:5, v/v + 25 mM ammonium acetate)
methanol:propan-2-o1 (97.95:2, v/v + 0.05 mM % formic acid)
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Table 8.2: MS/MS parameters for determination of MOR, COD, DHC, 6-MAM,
METH, COC, BENZOYL, COCA, BZP, METHAMP, LIGNO, PSEUDOEPH

,

AMP, KET, MDA, MDMA, LEVand PHEN
Tb.sUlon

COo
OHC
6·M....

COc

COCA

UCHo

"eII.06
CO0-46
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~
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~

I
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~

"DIU.
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N
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J2I2-2113
121
J 10.0- 265.0
51
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51
31142 _ 1 1 2 . 1 ) i
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36
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46
311.0-12.0
to
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150.0-01.0
ll:)
150D-iSD
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11
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1114.1- I Q . O ] 1
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•
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ote: Matrix matched curves were used for quantification of all compounds

8.3.4 Blood samples
Blood obtained for use as negative controls were separated into 50 mL aliquots and
stored at -20 QC. The blood was analysed by the methodology described in this paper to
enl)ure it was negative before being used in validation studies.
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8.3.5 Sample preparation

Blood samples (500 ilL) were aliquoted into 50 mL polypropylene tubes. Samples were
. Ilg mL-I by addIng
fortified WI'th'Internal standard at levels correspondIng
. to 02
. a 100 ilL
portion ofa 21lg mL- 1 mix solution of MOR-d6' COD-d6, DHC- d6, METH-d9, M-3-G-d],
BENZOYL-dg, COC-d], KET- d4, PSEUDOEPH- dJ, 6-MAM- d6, EDDP- dJ,
METHAMP-d , MDA-ds, MDMA-ds and AMP-dll. Samples were fortified at levels
I4
1

corresponding to 0.05, 0.075 and 0.1 Ilg mL- by adding 20, 30 and 40 ilL of a 1.25 Ilg
InL- 1 fortification solution. After fortification, samples were held for 15 min prior to
extraction. Ammonium acetate (50 mM,S mL)buffer pH 6 (adjusted with concentrated
formic acid) was added and the samples were sonicated (l0 min). The samples were
Centrifuged (3568 g, 10 min, 4 DC) and the supematant was transferred to a clean
JlOlypropylene tube. The sample extracts were further purified by mixed mode cation
exchange solid phase extraction using Evolute ™ CX SPE cartridges. Sample extracts
were loaded onto the cartridges (preconditioned with methanol (3 mL)) and ammonium
acetate buffer (50 mM, 3 mL). The cartridges were washed with ammonium acetate
bUffer (3 mL), 2% formic acid (3 mL), methanol (3 mL) and then dried using a vacuum
Pump (20 min). The cartridges were eluted with 5 % ammonium hydroxide in ethyl
acetate: methanol: 70:25, v/v (3 x 2 mL). The eluates were reduced to dryness under
nitrogen at 40.C before re-dissolving in 500 ilL ofmethanol:water (50:50, v/v). An

arIquot (20 Ill) was injected onto the LC column.
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8.3.6 Matrix -Matched Calibration
Matrix matched calibration curves were prepared and used for quantification. Control
reSl ues was prepared as above (8.3.4).
· no
·d
blood p revlOUS
.
Iy tested and shown to contam
Control blood samples (500 ilL) were weighed into 50 mL polypropylene tubes. Samples
1

Were fortified with internal standard at levels corresponding to 0.2 Ilg mL- by adding a
9
6
100 fJL portion of a 2 fJg mL- 1 mix solution of MOR-d6' COD-d6, DHC-d , METH-d , M-

3
3-G-d , BENZOYL-dg, COC-d3, KET- d4' PSEUDOEPH- d3, 6-MAM- d6, EDDP- d ,
3
METHAMP-d 4, MDA-ds, MDMA-ds and AMP-dll.
I

Samples were fortified at levels corresponding to 0, 0.025, 0.05, 0.1 and 0.0.25 J.1g mL"
1

by adding 0, 10, 20, 40 and 100 III portions of a 1.25 Ilg mL- standard solution. Samples
Were fortified at the 0.5, 1.0 and 2.0 Ilg mL- 1 calibration levels by adding 50, 100 and 200

III portions of a 5 Ilg mL-1 standard solution. After fortification, samples were held for 15
ruin prior to extraction procedure as above (8.3.5), The concentration of the drugs (J.1g mL
-I )

Were determined from the matrix matched calibration curves.

8.3.7 Method validation
For estimation of accuracy, blank blood samples were fortified with MOR, COD, DHC,
6-MAM, METH, COC, BENZOYL, COCA, BZP, PSEUDOEPH, MDMA, MDA, AMP,
KET, METHAMP, LlGNO, LEV and PHEN at 0.05, 0.075 and 0.1 J.1g mL". Six
replicate test portions, at each of the three fortification levels, were analysed. Analysis of
the 18 test portions was carried out on three separate occasions. For the estimation of the
Precision of the method, repeatability and within-laboratory reproducibility was
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calculated. The decision limit (CCa) of the method was calculated according to the ISO
11843 calibration curve procedure using the intercept (value of the signal, y, where the
concentration, x is equal to zero) and 2.33 times the standard error of the intercept for a
set of data with 6 replicates at 3 levels. The detection capability (CCP) was calculated by
adding 1.64 times the standard error to the CCa. Matrix effects were investigated by
pump to a tee-connector at
innUSlon
. of all analytes (2.5 J.lg mL- 1) by an external synnge
.

10 J.lI mL-1 between the electrospray probe and the outlet of the analytical column with
simUltaneous injection of methanol:water (l: I, v/v) only and subsequently with blank
matrix diluted in methanol:water (1: 1, v/v) onto the analytical column. The specific ion
transitions of the analytes were recorded and any signal decreasing or increasing at the
11
retention time of the investigated analyte was compared with the methanol:water ( : ,
v/v) injection.

8.4 Results and Discussion
8.4.1 Development and optomisatio n experiments

In this study a methodology was developed as a tool for the analysis ofdrugs in forensic
cases in the Republic of Ireland using a new solid pbase extraction sorbent technology
and the drugs were detected by hybrid LC-MS. The hybrid LC-MSiMS method was
based on previous method developed in the author's laboratory for urine analysis
(DowIing et aI., 2010) using MRM mode and product ion spectra in the linear ion trap
Illode (Q3) however in addition LEV and PHEN were monitored allowing the analysis of
18 drugs simultaneously in a single injection. The ionisation oflhe drugs was studied in
Positive mode. The optimum conditions (declustering potential, collision energy,
270

collision cell exit potential) were determined and the best diagnostic ions for MS/MS
anal YSIS
. were obtained (Table 8.2). For a method to be deemed confirmatory 4
identification points must be obtained. In MRM (multiple reaction monitoring) mode this
IS

achieved by monitoring one precursor ion (parent mass) and two daughter ions

(corresponding to strong and weak ion) in accordance with 2002/657/EC [Commission
Decision]. Precursor and product ions were determined by direct infusion of single
analyte solutions (I

~g mL- 1 in methanol:water (50:50,v/v)). Chromatography conditions

Were described in section 8.3.2. An EPI experiment was set up in the Analyst 1.5
software. The strong MRM transition was chosen upon completion of tuning in MRM
mode. The dependent scan was an EPI scan. One of the drawbacks ofthe Analyst 1.5
software in data dependent mode was that the software only allows a single preselected
CE or CES for all analytes in an EPI experiment. It would be more advantageous if
DP and CE settings per compound could be set. The dependent scan was an
ind'IVldual
.
EPI scan and experiments to evaluate the optimum CES conditions for each analyte

showed that using simultaneously different settings improved fragmentation pattems. The
CES conditions for amphetamine, cocaine classes and adulterants was 35±15
oPtImum
.

however for certain opioids a 50 CES ± 15 gave improved fragmentation. Due to the
I

lIy ofthe software to only set one CES value. A value of35±15 was chosen and the

ab')'

spectra generated under these conditions were utilisable for opioids. Evaluation ofEPI
speetra of a sample peak and spectra obtained from analysis of reference standards in a
mass spectrallibary was subsequently carried out.

A new mixed mode solid phase extraction technology was launched hy Biotage called
Evolute TM ABN CX. The cartridge is a mixed mode resin based cation exchange SPE
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sorbent with an optimised pore size that minimises retention of high molecular weight
matrix components. In this study a sample size of 500 J.lL was chosen based on the
sensitivity required. Preliminary studies were carried out using the generic solid phase
extraction protocol (Procedure A) obtained from the sorbent manufacturer using ultra
pure water spiked with target compounds at a concentration of 0.25 J.lg mL

-I.

The results

showed that poor recoveries were obtained for KET, BENZOYL and LIDO. Collection of
Wash solvents in the generic procedure and analysis showed that KET, BENZOYL and
LIDO were recovered at a high percentage in methanol. The generic manufacturer's
procedure was modified as described (Procedure B). Studies showed that the methanol
Wash solvent contained no analytes upon addition of acid wash step. The addition ofthe
drying procedure is important when elution solvents are non-polar to maintain a good
recovery. Subsequent work was carried out to evaluate the best elution solvent
(Procedure C) for the range of drugs tested. The results of the elution study showed that
the best recoveries were obtained when a solution of ethyl acetate:methanol:ammonium
hYdrOXide (70:25:5, v/v/v) was used.
The blood purification procedure developed as described in the experimental section has
the following advantages as reduces the workload in monitoring for these substances at
OUr laboratory replacing three separate sample preparation methodologies, the ability to
automate the SPE procedure, the option to collect the methanol wash fraction for the
analysis of neutral and acidic compounds or to fractionate using different types of elution
Solvent thus widening the potential number of analytes that can be detected in a single

i'\iection, very stringent procedure and the strategy can he adopted for additional
matrices such as vitreous humo , muscle and urine (unpublished data) and strategy can be
r
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used with other detection techniques. The new purification strategy produces extremely
clean extracts and the optimised pore size of the cartridges ensures the whole blood
samples passed unhindered through the cartridges making the method very fast.
Furthermore the matrix of blood alone is a very complicated matrix so a thorough sample
purification procedure is essential and a 100% methanol wash step ensures clean sample
extracts.
A hybrid LC-MS detection method developed as described has advantages such as
replacing three separate detection technologies for opioid, cocaine and amphetamine
classes in blood using GC-MS, a fast run-time of 12.5 min per injection and the ability to
analyse LEV and PHEN and 16 important drugs simultaneously in blood, high and low
concentrations of drugs in blood samples can be identified, quantified and confirmed

sirnultaneously in a single injection with no need for re-injection as EP! spectra can be
Used to unambiguously confinn overdose cases in a straightforward manner, analysis of
PHEN and the amphetamine class simultaneously allows identification of false positive
results for amphetamines reducing significant time spent on sample re-analysis to identify
this and the elimination of derivatisation steps. The disadvantage of using MRM ratios
only instead of MRM-to-EPI experiments is that the sample will require dilution as a
result of detector saturation and re-injection. The method developed has been used in

2010 for detection of opioid,

~ocaine, amphetamine and adulterant drugs in blood in

forensic cases in the Republic of Ireland. In addition full laboratory information

rnanagement system (L1Ms) connectivity ofthe analytical strategy has been achieved
Using Analyst 1. 5 software as part of routine monitoring of blood forensic toxicology
Samples at our laboratory.
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8.4.2 Validation study
Validation of the method was according to procedures described in Commission Decision
2002/657/EC [Commision Decision 2002] covering specificity, calibration curve
linearity, accuracy, precision, decision limit (CCa) and detection capability (CCP)·

8.4.2.1 Specificity
The technique of liquid chromatography hybrid triple quadrupole linear ion trap
(QTRAP) mass spectrometry itself offers a very high degree of selectivity and specificity.
To establish the selectivity/ specificity of the method, blood samples were fortified with
the above drugs and also non-fortified samples were analysed. No interfering peaks were
observed at the retention time of some of the analytes in the chromatograms of the nonI led samples when compared to the reporting level.
forffi

8.4.2.2 Linearity of the response
The linearity of the chromatographic response was tested with matrix matched curves

llSing 8 calibration points in the concentration range of 0 to 2.0 l'g mL·'. The regression
Coefficients (/) for all the calibration curves used in this study were

~ 0.99.

8.4.2.3 Accuracy

lbe accuracy (n~18) of the method was determined using human blood samples fortified
at 0.05,0.075 and 0.10 Jlg mL- 1 in three separate assays was 80-103%.
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8.4.2.4 Precision
The precision of the method, expressed as RSD values for the within-lab reproducibility
1

at the three levels of fortification (0.05, 0.075 and 0.10 J.lg mL- ) was less than 16 %
(Table 8.3).
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Table 8.3: Intra- and inter-assay variation for accuracy MOR, COD, DHC, 6-MAM,
METH, COC, BENZOYL, COCA, BZP, METHAMP, LIGNO, PSEUDOEPH,
AMP, KET, MDA, MDMA, LEVand PHEN
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8.4.2.5 CCa and CC~
The decision limit (CCa) is defined as the limit above which it can be concluded with an
error probability of a, that a sample contains the analyte. In general, for non-MRL
sUbstances an a equal to 1 % is applied. The detection capability

(CC~) is the

smallest

Content of the substance that may be detected, identified and quantified in a sample, with
a statistical certainty of

I_~, were ~ == 5 %. CCa and CC~ values obtained were shown in

Table 8.4 and calculated using the intercept (value of the signal, y, were the
Concentration, x is equal to zero) and the standard error of the intercept for a set of data
l

with 6 replicates at 3 levels (0.05, 0.075 and 0.1 J.!g mr

).

CCa is the concentration

corresponding to the intercept + 2.33 times the standard error of the intercept.

CC~ is the

concentration corresponding to the signal at CCa + 1.64 times the standard error of the
Intercept (i.e the intercept + 3.97 times that standard error of the intercept).

Table 8.4: Calculated CCa and
l\1AM,

METH,

COC,

CC~

values in blood for MOR, COD, DHC, 6-

BENZOYL,

COCA,

BZP,

METHAMP,

LIGNO,

PSEUDOEPH, AMP, ](ET, MDA, MDMA, LEV and PHEN
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8.4.2.6 Measurement Uncertainty
According to SANC0/2004/2726 rev 1 the within laboratory reproducibility can be
regarded as a good estimate of the combined measurement uncertainty of individual
methods [SANCO 2004]. For the calculation of the extended uncertainty a safety factor is
required. The within laboratory reproducibility should be multiplied by a value of2.33
and this should be used when determining the CCa, corresponding to a confidence level
of99 %. As the only source of variation during the validation was the different days and
different blood sourced from different humans it was decided to use a safety factor of 3.0
Instead of2.33. The values are shown in Table 8.5 and were determined by calculating
the within laboratory reproducibility of the method, followed by multiplication of the
Within laboratory reproducibility by the safety factor of 3.0.

Table 8.5: Calculated measurement uncertainty values in blood for MOR, COD,

onc, 6-MAM, METR, coC, BENZOYL, COCA, BZP, METRAMP, L1GNO,
PSEUnOEPH, AMP, KET, MDA, MDMA, LEV and PHEN
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8.4.2.7 Evaluation
The analytical strategy in this study has been used to evaluate the presence of MaR

,

COD, DHC, 6-MAM, METH, COC, BENZOYL, COCA, BZP, METHAMP, LIGNa,
PSEUDOEPH, AMP, KET, MDA, MDMA, LEV and PHEN in human blood in the
Republic ofIreland in 2010. In monitoring for these substances at our laboratory drug
Identification was carried out by libary search with a developed inhouse MS/MS libary
based on EPI spectra at a collision energy spread (CES) of 35 ± 15. Additionally
routinely it was possible to detect the precursor ion and two daughter ions (within a
single injection) in multiple reaction monitoring mode aswell as generating an EPI
Spectra under collision energy spread conditions. The method has been carried out using
different batches of blood, different QC material, using different batches of reagents,
under varying environmental conditions and the method was shown to be robust. To
demonstrate the applicability of the method incurred blood samples taken from subjects
treated with AMP, MDA, MDMA, METHAMP, COC, BENZOYL, MaR, COD and
DHC from the QC Reference Material were tested. The QC for AMP, MDA, MDMA,
METHAMP, COC, BENZOYL, MOR, COD and DHC were found to be positive as they
Contained levels above CCa. and the calculated concentrations were within the specified

range ofthe QC material. Furthermore the EPI spectra confirmed unambiguously the
presence of AMP, MDA, MDMA, METHAMP, COC, BENZOYL, MaR, COD and

DHC as spectra matched the corresponding spectra in the libary developed in-house. To
further demonstrate the method applicability the method has been used to analyse a
number of PT schemes. In addition the method was also stringently evaluated in-house by
comparison with established GC methods (3 x GC-Ion Trap methods for opiates,
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cocaines and amphetamines) and running all incoming samples simultaneously with old
established methods and this new analytical strategy. The developed analytical strategy
performs very well in terms of accuracy and within-laboratory reproducibility.

8.5 Case study

The described methodology has been applied in the laboratory since 2010 and positive
drugs of abuse were identified in forensic cases from drug overdoses, suicidal or
accidental poisonings using this method. The method has been used to analyse 40 blood
samples received for toxicological analysis. The following substances were confirmed to
be present in these samples. The presence ofMETH and MaR was confirmed in 9
samples. The presence of BENZOYL and LIGNa was confirmed in 6 samples, COD was

found in 5 samples, PHEN was found in 4 samples, COC was found in 3 samples, 6MAM, DHC, MDMA and LEV were found in 2 samples and COCA, PSEUDOEPH and
MDA were each found once. It can be noted during the evaluation period that the
adulterants LEV and LIGNa were identified. In 2009 the veterinary drug LEV which is a

veterinary antihelminthic was being used as an alleged new cutting agent in adulterated
COCaine. Figure 8.2 shows the EPI libarY spectrum of the veterinary drug and adulterant
LEV which was found in a positive sample also with cocaine in Ireland. Information on
fit, reverse fit and purity is previously described [Dowling et aI., 2010]. It can be
COncluded that METH and MOR were the most prevalent subslances in the 40 samples
stUdied.
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8.6 Conclusions

The present investigation confirms that the sample preparation procedure using Evolute
ABN CX™

so I'd
1
phase extractIOn
cartn'd ges and d
etectIOn
using hybrid triple
'
'

quadrupole/linear ion trap mass spectrometer in blood can be used for the confirmation of
opioids, cocaines, amphetamines and adulterants simultaneously,
There are no quantitative confirmatory methods in the literature to the best of our
knowledge that analyse 18 drugs simultaneously in this study using this sample
preparation procedure and hybrid LC-MS using 4000 QTRAP in MRM mode and
product ion spectra in the linear ion trap mode ~nd this study is the first. The sample
preparation procedure produces extremely clean extracts and the volume of sample

required is only 500

~L. The advantage ofthe analytical strategy at our lahoratory is that

it replaces 3 separate sample preparation procedures utilising 3 different GC instruments

and that the sample preparation is dramatically simplified omitting extraction, hydrolysis,
derivitisation steps and sample analysis time is reduced. The method has been carried out
Using different hatches of blood, different QC material using different batches of
reagents, under varying environmental conditions and the method was shown to be
rugged. The developed method showS good agreement with well established reference
GC-MS methods (not shown) at our laboratory· The advantage of a small sample size and
the ability to confirm the identity of a wide variety of drugs in a single injection has
Important advantages for high sample throughput in a regulatory laboratory. Matrix
effects studies were carried out and no suppression effects were evident. The accuracy of
the method has been further certified as the quantitative and qualitative results were
obtained by method comparison with PT samples and reference GC-MS methods. The
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primary advantage of the developed analytical methodology is the quantitation and
Confirmation of a wide range of forensically important drugs can be carried out using a
single analytical strategy and a single analyst with a short analysis time.
Therefore a reliable and fast sample preparation and detection strategy for opioids,
cocaines, amphetamines and adulterants has been achieved successfully.
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CHAPTER 9

CONCLUSIONS AND FUTURE WORK
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9.1

Overview

,
ust an unequivocal confirmatory LC-MS methods were developed for the
Fast rob
d
.
determination of drugs in animal and human matrices.
The research in the veterinary drug residue field on non-steroidal anti-inflammatory
drugs covered a wide range ofNSAIDs in milk and plasma matrices. The research in the
post-mortem forensic toxicology field covered a wide range of drugs including opioid
drugs, cocaine, amphetamines and adulterant drugs in human blood and urine. Multi-

residue analytical protocols in each matrix for the analysis of a wide range of forensically
Important drugs were developed.
AIJ methods in the veterinary drug residue field and the post-mortem forensic toxicology
field were validated in accordance with commission Decision 2002/657/EC.

Some of the analytical protocol s in the veterinary drug residue section ofthe thesis have
been implemented for routine use in the Veterinary Toxicology section at the State
Laboratory and also in the National Residue Control program in Ireland for residue
monitoring ofNSAlDs. They have been accredited for use as such in accordance with
the IS017025 standard. All of the analytical protocols in the post-mortem Forensic
Toxicology section ofthe thesis have been implemented for routine use in the Human
TOXicology Section at the State Laboratory and also in the post-Mortem Forensic
Toxicology Monitoring program in Ireland. The drugs ofabuse methods are used to
provide toxicological results to the coroners of Ireland and also to the State Pathologist
and results have been utilised in court in forensic cases. In addition the analytical
strategies have been rigorously tested in international proficiency testing programs. Also
285

as part of this research in the post-mortem forensic toxicology work of the laboratory, a
survey was carried out in chapters 7 and 8 to investigate the prevalence of a number of
drugs of abuse in a variety of post-mortem urine and blood samples in Ireland.
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9.1.1 NSAIDS in Bovine Milk

• This investigation focused on the development of a fast, simple and selective
analytical protocol for four NSAIDs in bovine milk using GC-MS/MS.
•

It was proposed by Community Reference Laboratories (CRLs) in Europe that

laboratories monitoring for NSAIDs should be capable of monitoring for KPF,
l

DCF and PBZ in bovine milk at a level of 5 ng mr and IBP at a level of lOng mr
I·In

EU member states[SANCO 2007]. No analytical
.
methods were available for

the determination of these substances at the legislative levels set and the research
was undertaken in order to detect the proposed levels in milk.
•

The method developed in this study was based on a method developed by Vinci et

al., [2006] but adapted to include deuterated analogues oflBP, DCF and PBZ and
the LC-MS detection was replaced with GC-MS/MS coupled with a derivatisation
step for detection of (BP, KPF and DCF. The advantage ofthe additional

derivatisation step was the ability to produce two daughter ions for the
determination of IBP whereas by LC-MS only precursor (parent) and one
daughter ion for these compounds could be obtained [Vinci et aI., 2006].
•

The developed method had also been adopted by the National Reference
Laboratory in Ireland for the confirmatory analysis ofNSAIDs in samples taken
by veterinary inspectors for the Department of Agriculture and used by a number
of analysts. The method was accredited according to the ISO17025 standard [ISO

17025].
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9.1.2 Firocoxib in Bovine Milk

•

This investigation focused on the development of a fast, simple and selective
analytical protocol for one NSAID in bovine milk using RRLC-MS/MS.

•

This study was concerned with the development of a confirmatory method for
firocoxib (FIRO) which is a newly licensed NSAID in horses [MRL Opinion
38346206] and has become available on the market under the trade name
Previcox since 2007 [EMEA 082] and Equiox x since 2008 [EMEA V-142-enl].
FIRO cannot be used in mares in which milk is intended for human consumption.
FIRO has no MRL established in bovine species. It is anticipated that due to the
large increase in NSAID use in recent years that this substance may be used to
treat food producing animals otber tban equines. Off label application of a
veterinary drug compound to cows tbat produce milk for buman consumption in
the Republic of Ireland and the European Union is illegal. F1RO has been shown
to be comparable in efficacy to meloxicam and carprofen [EMEA 082] and also
been shown to be comparable in efficacy to phenylbutazone [Doucet et aI., 2008].
In the case of carprofen and meloxicam these substances are licensed for use in
horses and cattle therefore it cannot be excluded that FIRO would not be used in

,

•

cattle.
The developed method involves the addition of acetonitrile to bovine milk
followed by clean-uP using EvoluteTM ABN solid phase extraction (SPE)
cartridges and analysis by RRLC-MSiM S. There were no methods available for

the determination of FIRO in bovine milk prior to this research.
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•

The method performs very well in termS of accuracy and within-laboratory
reproducibility.
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9.1.3 Non-authorised NSAIDs in Milk

•

This investigation focuses on the analysis of non-authorised NSAIDs at the time
of publication (except carprofen) in milk. The development of a rapid analytical
method at the National Reference Laboratory for NSAIDs in Ireland was
undertaken to provide an analytical tool to monitor for non-authorised substances
in bovine milk.
The NSAIDs selected in this study were chosen to allow a method to be
developed for the analysis of a wide variety of non-authorised drugs from
different NSAID sub-classes.

•

A newly developed water wettable polymer based Evolute™ ABN (acidic basic
neutral) solid phase extraction (SPE) sorbent was investigated in the research and
a new procedure was developed using this sorbent for the purification of CPF,
DCF, MFN, NIFLU, NAP, OXYPHEN, PBZ and SUXI from milk.

•

Rapid Resolution Liquid Chromatography (RRLC, trade name given by Agilent
Technologies) was selected as the separation technique and a new protocol for
detennination of NSAIDs using RRLC-MS in the study was developed. The
technology allowed for rapid analytical results, increased speed of method

development times and utilised less solvent.
•

The developed method in this research was the most sensitive available to the best
of our knowledge and the theoretical values calculated for the CC" according to
ISO 11843 [ISO 11843] calibration curve procedure were shown experimentally
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to be valid by spiking milk at levels below the CCu values calculated to illustrate
the sensitivity.

•

It was proposed by Community Reference Laboratories (CRLs) in Europe that
1

laboratories should be capable of monitoring for NSAIDs at a level of 5 ng mLin EU member states where no MRL exists in milk. The objective of this work
was to develop a method that is capable of the determination of NSAIDs residues
in bovine milk below 5 ng mL
•

-I

were no MRL exists.

To demonstrate the applicability of the method milk samples taken from animals
treated with CPF, DCF and PBZ from the Community Reference Laboratory in

Berlin were tested. These samples had values ranging from about 4-13 ng mL·'.
The samples were analysed by the method developed in this study and all samples
were found to be non-compliant as they contained levels above the calculated
CCa and also met the confirmatory criteria for both ion ratio and relative

retention time.
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of Authorsled
NSAIDs in Milk
9.1.4 Si mu Itaneous AnalysIs
.
' and Non-Authorised
.

• This investigation focuses on the analysis of authorised and non-authorised
NSAIDs simultaneously in milk and non-authorised NSAIDs in bovine plasma.
• The extraction of the NSAIDs from plasma was based on methods developed by
Gowik et aI., (1998) and by Vinci et aI., (2006) but modified with the addition of
acetonitrile. The extraction ofNSAIDs in milk was based on a method previously
developed at the author's laboratory [Dowling et aI., 2009].
•

In this study an improved purification procedure was developed using Evolute
ABN TM solid phase extraetion cartridges for the analysis of a wider range of

NSAIDs including authorised and non-authorised NSAIDs in bovine milk. The
purification of NSAIDs from the plasma and milk extracts was investigated
initially using a solid phase extraction procedure previously developed at the
author's laboratory using Evolute ABN

TM

cartridges (chapter 5 methodology)

hut the original procedure was not satisfactory for the additional range of new
analytes in this study. The NSAID FLU-OH was poorly recovered when the
method previously developed at our laboratory was utilised. Elution studies were
performed to ascertain where losses were occurring. The cartridges were eluted
with different compositions and volumes of solvents including, 3 mL diethyl
3

ether:hexane:acetonitrile

(45: 45 :10,

diethyl

v/v/v),

ether:hexane:acetonitrile:methanol (45:45:5:5, vIvIv/v),
hexane (80:20, vIv -clution 1)

mL

1.5 mL diethyI ether:

and 1.5 mL acetonitrile:methanol (90: I0, vIv-

elution 2), 1.5 mL acetonitrile:methanol 90: 10, vlv-elution I) and 1.5 mL diethyl
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ether: hexane

50 :50 , v/v-e Iut·IOn

2) , 3 mL methano I an d

3 mL diethyl

ether:hexane:acetonitrile:methanol (37.5:37.5:20:5 v/v/v/v). The results showed
that elution of the cartridge with a solvent composition containing nhexane:diethyl ether: acetonitrile: methanol (45:45:7:3, v/v/v/v,2 x 1.5 mL) gave
the best results for all the analytes tested in this study.
• The developed solid phase extraction procedure was suitable for the purification
of six NSAIDs in bovine plasma.
•

An improved liquid chromatography tandem mass spectrometry detection
technique was developed to analyse ten NSAIDs simultaneously with a run-time
of 15 min. Chromatographic tests were carried out to evaluate the suitability of
x

the 1.8 J.lm Agilent Eclipse Plus CI8 column (3.0 50 mm) and the LC mobile
phase utilised in this study wben additional NSAIDs were added. The tests

showed that the internal standards of DCF and FLU overlapped in each internal
standard transition when the analytes were eluted with a flow rate of 750 J.lL min-'

and a run time of 6.5 min per injection. A study was performed using the same
composition of mobile phase A and B. The times in the gradient were adjusted,
the flow rate was reduced and the chromatographic runtime was extended to
separate the internal standard ofDCF and FLU. This resulted in the analytes being
eluted withgood peak shape wben using a mobile phase of water containing 0.001
M acetic acid and acetonitrile (90: 10, vIv + 0.001 M acetic acid) (A) and
acetonitrile (B) with a flow rate of 0.5 J.lL.min-' and a runtime of 15 min. The
internal standards d!-DCF and d,-FLU were completely separated under these

conditions.
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1

• The methodology is capable of meeting the 5 ng mL- set for NSAIDs in plasma
set by the EU. Moreover the values determined for the decision capability (CCa)
in this study were lower than those previously reported for CPF, DCF, IBP, KPF,
MFN and PBZ substances in plasma by LC-MS/MS.
•

FLU, TLF, FLU-OH, IBP, KPF and MLX were extracted from milk using
Evolute ABN TM solid phase extraction cartridges. The method meets the target
level of 5 ng mL- 1 for IBP and KPF in milk for the first time. There are no other
analytical methods that monitor for authorised and non-authorised NSAIDs in

milk as well as FLU and FLU-OH simultaneously in milk that meet the stringent
validation requirements according to Commission Decision 2002/657/EC.
[Commission Decision 2002/657/EC]
•

After validation of this method, the EU changed the legislation for DCF and an
MRL of 0.1 ng mL- 1 was set in milk. Preliminary spiking studies at the new MRL
for DCF were carried out using the developed analytical strategy in this study.
Results showed that this analytical strategy was sensitive enough to detect DCF at

•

this level.
The applicability of the method for use on a variety of types of milk samples was
demonstrated. To demonstrate the app!icabil ity of the method milk samples taken
from animals treated with MLX and FLU-OH obtained from the Community
Reference Laboratory in Berlin were tested- These samples had assigned values
ranging from 5- 15 ng mL- 1• The samples were analysed by the method developed
1

in this study and all samples were found to contain 5 ng mL- of FLU-OH and 15

ng mL- 1 ofMLX.
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• The methods were implemented into the National Monitoring Programme in
Ireland for the determination of CPF, DCF, !BP, KPF, MFN and PBZ in bovine
plasma and CPF, DCF, !BP, KPF, MFN, PBZ, FLU, FLU-OH, TLF and MLX in
bovine milk at the National Reference Laboratory for NSAIDs and accreditated
according to IS017025 Standard [IS017025].
• The method developed allows for the analysis of a wide variety of drugs from
different NSAID sub-classes such as CPF, !BP and KPF (arylpropionic acid
derivatives), PBZ (pyrazolidinedione derivatives) DCF, MFN and TLF
(anthranilic derivatives) and FLU and FLU-OH (nicotinic acid derivatives) and

MLX (oxicam derivatives).
•

Additionally the method published in 2010 in Food Additives and Contaminants
has been adopted in an inter-laboratory study by the Community Reference
Laboratory (CRL) in Gennany for NSAIDs. The cRL recommend the analytical
methodology be implemented by EU National Reference Laboratories for
NSAIDs. A training workshop on the method was held in 2010 at the CRL
headquarters in Gennany and regulatory laboratories within EU member states
were trained on the NSAID methodology which became available as a result of

this research.
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9.1.5 Drugs of Abuse in Urine

•

This study focused on the development of a hybrid liquid chromatography-mass
spectrometry strategy in a forensic laboratory for opioid, cocaine and
amphetamine classes in human unne using a hybrid linear ion trap-triple
quadrupole mass spectrometer.

•

The analysis of drugs of abuse such as

morphine (MaR), codeine (COD),

morphine-3-glucuronide (M-3-G), 6_monoacetylmorphine (6-MAM), cocaine
(COC),

benzoylecgonine

(BENZOYL),

buprenorphine

(BUPREN),

dihydrocodeine (DHC), cocaethylene (COCA) , 3,4_methylenedioxyamphetamine
p
(MDA) , ketamine, (KET) 3,4_methylenediox ymetham hetamine (MDMA),
pseudoephedrine (PSEUDOEPH), lignocaine (LlGNO), benzylpiperazine (BZP),
methamphetamine

(METHAMP),

amphetamine

(AMP),

2-ethylidene-I,5-

dimethyl_3,3-diphenylpyrrolidine (EDDP) and methadone (METH) in urine is
highly important as their iIlicit use is widespread and the aim of this study was to
develop a fast, simple and reliable sample preparation procedure in urine to
analyse 19 drugs from the opioid, amphetamine and cocaine classes using a single
sample preparation procedure and detection method that can be carried out by a

•

single laboratory analyst.
There was a paucity of studies that used hybrid LC-MS technology in the
literature as the majority of studies

use LC- tandem MS. One such hybrid LC-MS

technology is the 4000 QTRAP LC-MS from Applied Biosystems.
•

This is the first time that the 19 forensicaIly important drugs have been analysed
simultaneously running twO MRM's and a single EPl experiment in positive
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mode in urine providing information on high and low mass fragments in a single
injection to the best of our knowledge. Drug identification was carried out by
library searching with an in-house developed MS/MS library based on EPI spectra
at a single CES of 35

±

15 in positive mode. Validation of the method was based

on Commission Decision 2002/657/EC [Commission Decision 2002], a validation
protocol used in the field of veterinary drug residue monitoring.
• The LC-MS/MS method using MRM mode and product ion spectra in the linear

Ion trap mode (Q3) was developed to provide unequivocal confirmatory data for
,

the analysis of MOR, M-3-G, COD, DHC, 6-MAM, METH, EDDP, BUPREN
COc, BENZOYL, COCA, BZP, PSEUDOEPH, MDMA, MDA, AMP, KET,
METHAMP and LIGNO.

•

Often in forensic toxicology cases it can be difficult for the pathologist to obtain
large sample sizes. preconcentration of urine during method development was not
required based on the sensitivity acbieved by the QTRAP method thus the urine
1
samples (100 JlL) were diluted 20 fold in methanol:water (I: , vIv) and a good
peak shape was achieved.

• The first advantage ofthe sample preparation procedure is that a small sample
volume is required. The second advantage is that the 19 drugs can be analysed
1
rapidly and simultaneously using simple dilution with metbanol:water (I: , v/v).
The third advantage is that the sample preparation procedure reduces the
workload in monitoring for these substanCes in any laboratory and as a result a
single analyst is capable of preparing a matrix matched curve and 50 samples in a
single day. A fourth advantage is the savings in cost as there is no need to
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purchase costly hydrolysis reagents for the detection of drugs that are extensively
metabolised.
• The first advantage of the hybrid Le-MS detection method developed in this
study is the fast run-time of 12.5 min per injection allowing detection of 19
forensically important drugs. The second advantage of is that high and low
concentrations of the drugs in urine samples can be identified, quantified and
confirmed simultaneously in a single injection using EPI spectra. High levels of
drugs can be detected routinely using EPI spectra and the samples do not need to

be re-injected as EPI spectra can be used to unambiguously confirm overdose
cases in a straightforward manner. The disadvantage of using MRM ratio's only is
that the sample will require dilution as a result of detector saturation and re-

•

injection.
In addition full laboratol}' information management system (L1MS) connectivity
of the analytical strategy was achieved using Analyst 1.5 software as part of

routine monitoring of forensic toxicology samples.
•

To demonstrate the applicability of the method incurred urine samples taken from
subjects treated with MOR, COD and BENZOYL from the QC Reference
Material were tested. These QC samples had values ranging from 0.25- 0.37
mL- for MOR, 0.23- 0.35
1

~g mC'

for COD and 0.13- 0.19

~g

~g

mL-' for

BENZOYL. The QC for MOR, COO and BENZOYL were found to be present as
samples contained levels above CCa and the calculated concentrations were
within the specified range of the QC material. Furthermore the EPI spectra
confirmed unambiguously the presence ofMOR, COD and BENZOYL as spectra
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matched the corresponding spectra in the library developed in-house. To further
demonstrate the method applicability the method has been used to analyse a
number of urine proficiency testing (PT) samples in which subjects were treated
with MOR, BENZOYL, BUPREN, AMP, EDDP, METH and KET. The PT
samples were analysed by the method developed in this study and were found to
be non-compliant as they contained levels above the calculated CCa . The EPI
spectra matched the corresponding spectra in the library developed in-house in
Analyst 1.5 software and satisfactory Z-scores of below 1.4 were obtained for PT
samples. Furthermore a PT sample negative for cocaines, opiates and
amphetamines was analysed by this analytical strategy and was reported as being
negative thus further ensuring that an accurate analytical strategy was developed.

•

The method was also stringently evaluated in-house

by comparison with

established GC methods (3 xGC-Ion Trap methods for opiates, cocaines and
amphetamines) and running all incoming samples simultaneously with old and
new analytical methods. The results (unpublished data) were acceptable. The
developed analytical strategy performs very well in termS of accuracy and within-

laboratory reproducibility.
•

The described methodology has been applied in the laboratory since 2009 and
positive drugs of abuse were identified in forensic criminal samples from crime
offenders, abusers or victimS using this method. The method has been used to

analyse 233 samples at the time of publication.
•

The developed strategy has been carried out using different batches of urine,
different QC material, by different analysts, using different batches of reagents,
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under varying environmental conditions and 1000's of samples have been
analysed using the strategy and replaced the analysis of all urine samples in
Ireland for drugs of abuse.
•

The advantage of a small sample size and the ability to confirm the identity of a

wide variety of drugs in a single injection has important advantages for high
sample throughput in a regulatory laboratory. Matrix effects studies were carried
out and results have shown that utilizing a labelled internal standard, dilution of
samples and a diverter valve minimised the effects. The accuracy of the method
has been further certified as acceptable results were obtained by method
comparison with PT samples and reference GC-MS methods. In conclusion the
method shows that simple dilution of urine and analysis by hybrid LC-MS
technology can present a rugged analytical strategy.

9.16
. D rugs of Abuse in Blood

• This chapter describes a multi-residue hybrid LC-MS strategy for the
determination of opioid, cocaine, amphetamines and adulterants in hurnan blood.
• A new mixed mode SPE sorbent chemistry technology was developed by Biotage
TM

with an optimised pore size and was evaluated as a single purification strategy.

The 18 drugs in blood included morphine (MOR), codeine (COD), 6monoacetylmorphine (6-MAM), cocaine (COC), benzoylecgonine (BENZOYL),
dihydrocodeine (DHC), cocaethylene (COCA), 3,4_methylenedioxyamphetamine
(MDA), ketamine, (KET) 3,4_methylenediOXymethamPhetamine (MDMA)
ine
pseudoephedrine (PSEUDOEPH), lignocaine (L1GNO), beozylpiperaz (BZP),
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methamphetamine (METHAMP), amphetamine (AMP) and methadone (METH)
and are of vital importance in forensic toxicology.
•

Evaluation of the literature showed the majority of studies in blood were using
tandem LC-MS with chromatographic runtimes varying from 10 to 30 min. There
are limited studies using hybrid LC-MS technology such as the 4000 QTRAP LCMS system available from Applied Biosystems. The hybrid LC-MS method in
this study was based on work undertaken at our laboratory for drugs of abuse in
urine [section 9.1.5]. The second aim ofthis study was to extend the method to

include levamisole (LEV) and phenethylamine PHEN.
•

Collision Energy Spread (CES) conditions for each analyte were investigated and
showed that using simultaneously different settings improved fragmentation
patterns. The optimum CES conditions for amphetamine, cocaine classes and
adulterants was 35±15 however for certain opioids a 50 CES ±15 gave improved
fragmentation. Due to the ability of the software to only set one CES value a
value of 35±15 was chosen and the spectra generated under these conditions were

usable for opioids.
•

The developed method was capable of detecting the presence of 18 drugs within a

runtime of 12.5 minutes in a single injection.
•

Validation was based on commission Decision 2002/657iEC [Commission
Decision 2002] and in-house procedure and drug identification was achieved by
library searching based on enhanced product ion (EP!) spectra at a single CES of

35 ± 15 in positive mode.
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•

Preliminary studies were carried out using the generic solid phase extraction
protocol (Procedure A-chapter 8) obtained from the sorbent manufacturer using
ultra pure water spiked with target compounds at a concentration of 0.25 f.lg mL I.

The results showed that poor recoveries were obtained for KET, BENZOYL

and LIDO. Collection of wash solvents in the generic procedure and analysis
showed that KET, BENZOYL and LIDO were recovered at a high percentage in
methanol. The generic manufacturer's procedure was modified as described
(Procedure B-chapter 8). Studies showed that the methanol wash solvent
contained no analytes upon addition of an acid wash step. The addition of the
drying procedure is important when elution solvents are non-polar to maintain a

good recovery.
•

Work was carried out to evaluate the best elution solvent (Procedure C-chapter 8)
for the range of drugs tested. The results of the elution study showed that the best
recoveries were obtained wben a solution of ethyl acetate:methanol: ammonium

hydroxide (70:25:5, v/v/v) was used.
•

The blood sample preparation procedure has the advantages of reducing the
workload in monitoring for tbese substances at our laboratory replacing three
separate sample preparation methodologies, the ability to automate the SPE
procedure, the option to collect the methanol wash fraction for the analysis of
neutral and acidic compounds or to fractionate using different types of elution
solvent thus widening the potential number of analytes that can be detected in a
single injection. The procedure is very stringent and the strategy can be adopted
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for additional matrices such as vitreous humor, muscle and urine (unpublished
data) and strategy can be used with other detection techniques.
•

The hybrid LC-MS procedure has advantages such as replacing three separate
detection technologies for opioid, cocaine and amphetamine classes in blood
using GC-MS at our laboratory, a fast run-time of 12.5 min per injection and the
ability to analyse LEV and PHEN and 16 important drugs simultaneously in

blood. Other advantages include high and low concentrations of drugs in blood
samples can be identified, quantified and confirmed simultaneously in a single
injection with no need for re-injection as EPI spectra can be used to
unambiguously confinn overdose cases in a straightforward manner. In addition
the analysis of PHEN and the amphetamine class simultaneously allows
identification of false positive results for amphetamines reducing siguificant time
spent on sample re-analysis to identify this and the elimination of derivatisation
steps. The disadvantage of using MRM ratios only instead of MRM-to-EPI
experiments is that the sample will require dilution as a result of detector

saturation and re-injection.
•

In addition full laboratory infonnation management system (L1MS) connectivity
of the analytical strategy has been achieved using Analyst 1.5 software as part of
routine monitoring of blood forensic toxicology samples and has been

implemented into our regulatory laboratory.
To demonstrate the applicability of the method incurred blood samples taken from
subjects treated with AMP, MDA, MDMA, METHAMP, COC, BENZOYL,
MOR, COD and DHC from the QC Reference Material were tested. The QC for
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AMP, MDA, MDMA, METHAMP, COC, BENZOYL, MaR, COD and DHC
were found to be positive as they contained levels above CCa and the calculated
concentrations were within the specified range of the QC material. Furthermore
the EPI spectra confirmed unambiguously the presence of AMP, MDA, MDMA,
METHAMP, COC, BENZOYL, MaR, COD and DHC as spectra matched the
corresponding spectra in the library developed in-house. To further demonstrate
the method applicability the method has been used in a number of PT schemes. In

addition the method was also stringently evaluated in-house by comparison with
established GC methods (3 x GC-Ion Trap methods for opiates, cocaines and
amphetamines) and running all incoming samples simultaneously with old
estahlished methods and this neW analytical strategy. The developed analytical
strategy performs very well in termS of accuracy and within-laboratory

•

reproducibility.
A case study was performed and the described methodology has heen applied in
the laboratory since 2010 and positive drugs of abuse were identified in forensic
cases from drug overdoses, suicidal or accidental poisonings using this method.
The method had been used to analyse 40 hlood samples received for toxicological
analysis at the time of publication and has subsequently replaced all other drugs
of abuse methods for analysis of blood in Ireland in The State Laboratory.

•

The developed strategy has been carried out using different batches of blood,
different QC

material~ by different analysts, using different batches of reagents,

under varying environmental conditions.
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•

The present investigation confirms that the sample preparation procedure using
Evolute ABN CX™ solid phase extraction cartridges and detection using hybrid
triple quadrupole/linear ion trap mass spectrometer in blood can be used for the
confirmation of opioids, cocaines, amphetamines and adulterants simultaneously.

•

There were no quantitative confirmatory methods in the literature for the 18 drugs

analysed simultaneously in this study using this sample preparation procedure and
hybrid LC-MS in MRM mode and product ion spectra in the linear ion trap mode.
• This research developed the first such strategy for incorporation into a forensic
toxicology laboratory. The described metbodology has been applied in the
laboratory since 20 I0 and positive drugs of abUse were identified in forensic
criminal samples from crime offenders, abusers or victims using this method.

9.2 Recommendations and Future Work

In the veterinary drug monitoring focusing on NSAIDs there is on-going public interest
In relation to these drug residues in food worldwide. A study published by Azzouz et aI.,
[2011] in milk showed that NSAIDs were identified in raw, whole, semi-skimmed and
skimmed bovine milk products in combination with other drugs. The study in 2011 found
7
KPF and PBl in raw bovine milk detected with estrone and I p-estradiol. In whole
bovine milk NIFLU, NAP, FLU, KPF, DCF, PBl, MFN were detected with florfenicol,
estrone, 17p-estradiol, 17a_ethinylestradiol. In semi-skimmed bovine milk NIFLU and
Pal were found with triclosan, estrone and I7P-estradiol. In skimmed bovine milk
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KPF, PBZ and DCF were found with
NIFLU , NAP ,LU,
F
. pynmethamme,
.
. estrone, 17Pestradiol, florfenicol and 17a_ethinylestradiol.
that there this is an on-going problem in SAIDs in milk and other
Th'IS study Identifies
.
veterinary drug residues in edible matrices and more methodologies are required. The

papers published in this thesis and in the literature focUS primarily on acidic NSAIDs but
n
there is very I"Imlted methodology available ~tor the determmatlO
. ' of basic NSAIDs.

SUbsequently further work upon completion of papers published for this thesis was
undertaken focusing, in particular, on the basic NSAIDs in milk and a new methodology
Was published by Dowling et aI., [2011]. There is a need to extend regulatory analyses to

Include basic NSAIDs in muscle and other matrices outlined in EU legislation.

Development of a multi-residue method for the determination of acidic and basic
NSAIDs simultaneously in a variety of matrices offood producing animals would be
highly beneficial as there are no methodologies available yet to the best of our
knowledge.

There is also a concern over the environmental impact of the agricultural practices and
Use ofNSAIDs in food producing animals. Since the 1990's the Gyps vulture population
has significantly dropped across the Indian subcontinent [Gilbert et aI., 2002; Prakash et
aI., 2003; The Peregrine Fund, 2004]. Three species in particular Gyps bengalensis, G.
mdicus and G. tenoirostris have been known to be affected. Diclofenac has shown a
04
direct correlation with renal failure by Oaks et aI., [20 ] in Gyps bengalensis. The
nUmbers ofthese species have declined by more than 97% since 2002 [prakash et aI.,
2003, Green et aI., 2004]. All three of these species are now on the critically endangered
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list by the World Conservation Union. This is quite significant given that G. bengalensis
Was ten

years previously one of the commonest large raptor's in the world. There is a
.

showmg
vulture'
declme IS
huge amou nt 0 f eVI'ence
d
' that the catastrophic
.
. caused by the
NSAID diclofenac which was widely used to treat livestock across the subcontinent
[Green et al., 2004, Oaks et al., 2004, Schultz et al., 2004]. As a result of the problems
contammants
a manuscnpt
was'
wntten on "Potential
with NSAID sas envlronmenta
.
I
'
.
application and future monitoring of unconventional wildlife specimens in wildlife
forens"IC and regulatory iovestigatioOs" by NgOla
. et aI., and the work on NSAIDs,

veterinary drug monitoring by Dowling et aI., was incorporated (under review). The
article discusses wildlife forensics and the need to evaluate alternative matrices for

NSAIDs and the need for a legislative framework similar to veterinary drug residues
monitoring in the European Union for wildlife forensic monitoring in the future. Naidoo
et al., [2009] has stated that dic10fenac has been largely regarded as the most devastating

toxicant in recent times. Future work needs to be undertaken in order to
en vlfonmental
.
set up NSAIDs methodologies in these alternative matrices and set up target levels for
legisl at"Ion In
. these matrices.

Further work completed as a result of the NSAIDs research published in this thesis has
been in the availability intemationally of the NSAIDs methodologies for use in other
veterinary drug residue laboratories. Additionally the method published in 2010 in Food
Additives and Contaminants had been adopted in an inter-laboratory study by the
Community Reference Laboratory (CRI.) in Germany for NSAIDs. The CRI. recommend
the analytical methodology be implemented by EU National Reference Laboratories for
0

NSAIDs in EU member states. A training workshop on the method was held in 20 1 at
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the CRL headquarters in Germany and regulatory laboratories within EU member states
ramed on the NSAID methodology developed as a result of the work described in
Were t .
th'IS thesis. Future work will involve helping other regulatory laboratories to set up
analyt'Ica I methods for these substances.

As a result of the published methodology in this thesis Dubreil et aI., [2011] has

completed and published further work. This groUP utilised the methodology published in
2010 in Food Additives and Contaminants. They carried out studies on mobile phase and
their results showed the best option for their research were the conditions developed in

article published in 2010 in Food Additives and Contaminants as part ofthis thesis.
DubreiI et aI., [2011] incorporated thi s into their NSAID analysis performed at Veterinary
Drug Residues Unit, Laboratory of Fougeres, ANSES (National Agency for Food
EnVironment and Occupational Health Safety), France.

In 2012 work is being undertaken by the United States Food and Drug Agency (USFDA)
utilising the NSAIDs paper published in 1. Chrom A in 2009 as a basis for developing a
NSAIDs method in milk at their site in colorado.

!here are very few studies available for licensed drugs to evaluate the effect of
processing on residues and there is a need to develop such methodologies for the
detennination ofNSAIDs. As mentioned earlier it is necessary to obtain more accurate
estimates of consumer exposure to residues or possible breakdown products. The effects
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of cooking and processing procedures on NSAID drug residues should be evaluated in
the future.
There has been very little research on NSAIDs in edible products although NSAID are
Widely used in veterinary medicine. The reason for requiring such experiments is that
residues in animal food products at the retail level and sampling in import/exports is
restricted to muscular tissue, milk, eggs and honey and more research is required in this
area in the future. Edible product analysis is important as it also allows quantification in
the consumable part of the animal below the maximum residue limit (MRL).

Methods developed in edible matrices in order to achieve reliable quantitation should
create the calibration curves in matrix and adequate internal standards should be used to

correct for ESI response. Detection ofNSAIDs using Le-MS particularly in food
analysis is still quite limited. There are even more limited studies utilising high resolution
rnass spectrometry. Further research for the future could focus on identifying new
rnetabolites ofNSAIDs drugs in different food animal products (e.g metabolomic
stUdies).

The main objectives ofthe research work and for the future on NSAIDs should be to
address the food safety issues conceruing NSAIDS and edible matrices by developing
new analytIcal
. strategies and apply tbese to ascertam
. answers to k
'
In
ey quesllons.

addition, the effect ofNSAIDs in the environment which is a new emerging difficulty
due to use of these substances in food producing animals needs to be addressed.
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Furthermore the evaluation of the presence of these substances in the aquatic
environment requires study.

In the post-mortem forensic toxicology monitoring field detection systems utilising
hYPhenation of a gas chromatograph and mass spectrometer had become the gold
standard for analysis in the post-mortem forensic toxicology area. In the post-mortem
forensic toxicology discipline liquid chromatography mass spectrometry has become
Increasingly valuable and rapidly methodologies are transferring from LC-UV or GC-

MS. LC-MS is helping to close the gaps in knowledge with respect to hydrophilic,
thennolabile and non-volatile analytes that previously could not be analysed by the most

Widely used technique of GC-MS. In forensic laboratories LC-MS is advantageous
because direct analysis of aqueous solutions containing thermolabile, non-volatile and

hYdrophilic compounds can be performed. In the future the use of LC-MS and GC-MS in
POst-mortem forensic toxicology field will however still be complementary in the

regulatory laboratory. In post-mortem forensic toxicological analysis the drugs are
generally unknown. Therefore in the future the analytical methods utilised should cover a

Wide range of compounds and their metabolites and in addition allow for unequivocal
identification. The papers published in this thesis and in the literature focus on traditional
drugS of abuse and adulterants in blood and urine. There has been an explosion of new
alternative designer drugs being utilised and the numbers and types are always rapidly
Changing. It is a difficult challenge to set up analytical methodologies to ascertain
deSigner drug presence in post-mortem samples and in the future work should be done to
InCorporate these.
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Another general problem in the analysis of new designer drugs is the lack of quality
Controlled analytical reference standards making it impossible to record mass spectra for

these drugs to incorporate into the database/libaries. It will be necessary to synthesise
new designer drugs within forensic laboratories in order to respond quickly.

New drugs of abuse also cause a problem in post-mortem forensic toxicology as often
there is little known about the met~bolism and toxicity of these substances and whether

they can contribute to the cause of death. It will be necessary to perform metabolism
studies and toxicity studies in order to understand their effects in the future.

It would also be useful if there was a more proactive approach within the forensic
tOXicology field for scientists to set up protocols in order to develop incurred quality
COntrol material for these substances for distribution between regulatory laboratories in
order to test new analytical strategies that are developed.

Further work carried out subsequent to that reported in this thesis focused in particular on

the designer cannibinoid CP47, 497. A dilute and shoot methodology in human urine was
PUblished by Dowling et aI., [2011] detailing the limitations of developing methodologies
for designer drugs. CP47, 497 is a synthetic cannibinoid and is functionally similar to
cannabis. The synthetic cannabinoids are considerably more potent than cannabis and

Were never intended for human use. However certain manufacturers were marketing these
SUb stances for human consumption under the IdentIty
.
. 0 f'Incense wh
l ' f yIng
. the
I e'satls
auth 0fItles
'. by writing in very small print "not lor
l'.
h uman consump t'IOn " on th e pack
'
agIng
initially so they could not be banned. These herbal products were sold under trade names
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SUch as "Spice Gold", "Spice Diamond" and "Spice Silver" to name but a few. CP47, 497
has been banned in the Republic of Ireland. The analysis of new designer drugs is a new
area and difficulties in their analysis include the availability of incurred material,
reference standards, appropriate isotopically labelled reference standards, lack of
knowledge of measurement ranges in human tissues and lack of validation protocols. In
the future it will be necessary to ra~idlY develop methods for the determination of new
designer drugs to address the gaps in knowledge due to lack of analytical protocols.

There is also a need to monitor traditional drugs of abuse and new designer drugs
Simultaneously to identitY their mis-use as there are very few analytical protocols
available that can do this. In 20 I I research was presented at a joint meeting of the
Society of Forensic Toxicologists and The International Society of Forensic
TOXiCologists. The work focused on the new designer cannibinoids analysed
Simultaneously with cannabis and its metabolites in human blood. There is a need to use
SUch protocols to iilclude the most up-to-date information on changes in drug patterns
from traditional to new designer drugs in the future.

In the analysis of drugs of abuse there is a need to include drugs in the analytical
Protocols that are known to cause false positives or negatives in order to be in a position
to interpret immunoassay results more effectively. Work should be undertaken to obtain
knOWledge of the main problematic compounds and these should be included in
Confirmatory procedures.
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There is a need to improve interpretation of urine test results for opiates as test results for
semi-synthetic opioids can be difficult because of complex biotransformation of parent

drug to metabolites that are also commercially available that can be abused. It would be
useful in the future if normetabolites such as norcodeine, norhydrocodone and

noroxycodone, which are unique metabolites that are not commercially available, are
mcorporated simultaneously in drug detection strategies. As a result detection of
nOrmetabolites in specimens not containing parent drug provides final evidence that the
)larent drug was consumed and will reduce the potential for false negatives that would
lOUt tests for these Unique
metabohtes.
Occur w'th
.
'

0 fpOSItIve
negatIve
There IS
. a need to perform surveys of the inCIdence
.
"
/
' sampIes for

IInmunoassay with new designer drugs in order to identify if there is an epidemic of use
that is occurring but not been identified in forensic cases or if these new drugs are
procedures.
affect'109 the Immunoassay/Le-MS
.

There IS
. a need for forensic laboratories to have stronger I'n!<
I s WIt. h emergency room
Illed'Ical personnel in order to analyse samples that present m
. accI'd ent and emergency to
ascert'
. designer drugs give clinical symptoms th
Id
. .daI or
am If
at may
ea t 0 b'lzarre, SUlCI

Criminal hehaviour in order to alert the general public to the potential dangers of use of
sUch substances or new substances.
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The above are issues related specifically to classes of drugs studied in this thesis. In the
veterinary drug residue monitoring field and post-mortem forensic toxicology field there
are COrn

mon areas that need to be addressed for the future.

There have been many applications in the use ofLC-MS in both fields however the

lll~ority of applications use LC-MS or LC- tandem MS/MS. There are two main LC-MS
protocols that are being utilised. The first approach is the development of multi-residue
procedures using quadrupole, ion trap or hybrid mass spectrometers which generate
product ion spectra that are subsequently searched against libraries of reference mass
SPectra recorded on the same apparatus. A major drawback of this approach at present is
that the LC-MS reference libraries generally cannot be used on different LC-MS
apparatus due to insufficient reproducibility of LC-MS/MS spectra obtained with
different instruments. In the future it would be advantageous if manufacturers could

develop transferable libraries.

Another drawback in both fields in LC-MS analysis is the lack of information on

ll1etabolite spectra for comparison in libraries. It would be better if more information on
llletabolites was available in commercial libraries obtained from instrument
lllanufacturer's.

Some manufacturer's have set up a software feature labelled as "scheduled MRM" which
allows for the setting of time windows for transitions in the survey scan. This allows for
Increasing the number of transitions in the survey scan allowing for detection of a wider
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number of drugs while minimising the cycle time of the MS method. In the future it

would be d '
.
a vantageous If vendor software manufacturers would Improve software
allOWing fo r an Increased
.
..
number of tranSItIOns
thus a11'
oWing the development of wide
ranging

I'
.
mu tI-resIdue LC-MS detection methods in both fields.

It Was noted in research carried out in this thesis focusing on the detection of drugs of
abUse utilising hybrid LC-MS systems that monitoring of peaks did not trigger
information dependent acquisition (IDA) mode or the quality of the enhanced product ion
(EPI) S
. poIanty
' SWltC
. h'Ing, I'f reqUIre
. d,could not be
pec ra was not t
sufficient.·
In addItIOn
performed because the software was too slow and separate injections would be necessary.
In the future the LC-MS hardware and software available for analytical laboratories from
various manufacturers needs to be continually improved thus allowing regulatory
. the possibility to develop rapId
. targeted
laboratones
' . mu Itl-resl
.
'd ue methods for a
senSItIve

Wide number of compounds and improving capabilities for positive/negative switching in
a single injection when running MRM to EPI experiments.

Another LC-MS approach is based on high resolution mass spectrometry. Compounds
are 'd .
f .
I enhfied by comparison with accurate mass. The advantage 0 uSing this approach is
that in theory searching of samples for compounds where no reference standard is
POssible. It is important to note that utilising accurate mass and isotopic patterns alone is
nOt enOugh for unequivocal confirmation. It is better to set up reference mass database
Using theoretical mass data and retention time data. Additionally it is useful to generate
fragments of compounds thus providing additional structural information. A difficulty of
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SUch databases using theoretical mass data and retention time data is that information is

only available for a limited set of data. There is also a difficulty in differentiating
betw'
.
een Isomenc compounds. Another drawback of such databases in relation to new
designer drugs is often it is not possible to have knowledge of the metabolic pathway

utilised and knowledge of metabolites is limited.
At present software manufacturers are developing metabolite prediction software. This
would allow the predicted compounds to be added to the database. Other software tools
are in development for the prediction of fragmentation patterns for which no reference
standards are available. In the future it would be useful if dependable software tools for

1l1etabolite and fragmentation patterns could be developed to help with drug analysis and
to SUpport accurate mass based compound identification in both fields.

There is also a need for studies to be performed to evaluate how reliable these software
prediction tools are in real samples without reference standards in regulatory laboratories.
In databases that have been developed at present there is a wide range of compounds and

it·

IS

not uncommon for a large number of compounds to have the same molecular

formUlae giving rise to a large hit list being formed. It is recommended that software
tOols need to be developed in order to shorten the hit lists and perhaps this might be
achieved by identifying the presence of metabolites.

S01l1e Work has begun using a metabolomic approach where a predefined set of

functional groups can be calculated for each candidate compound. In addition mass shifts
frOm mctior biotransformation reactions can be calculated and the peaks with respective
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masses can b
h'
e searc ed In the data files of real samples. In the future metabolomic

Protocols will need stringent testing in real samples in both fields in order to ascertain the
validity 0 f such an approach.

In some laboratories, work has been carried out developing screening procedures using
accurate mass and in addition retention time information in the search protocol and

recordi

I
.
ng at east two spectra. One spectrum leaves the Intact pseudomolecular ion and

One spectrum which contains a unique pattern or fingerprint thus allowing for

unequivocal confirmation. This approach appears worthwhile. The difficulties arise as
usin d'f::

.
g lIferent voltages to collect spectra increases the MS cycle time. It will be

ImPOrtant to slow the chromatography in order to achieve a sufficient amount of data
Points across the peak. This results in longer run-times for analysis which reduces the
resPonse in emergency toxicology situations. It would be advantageous if instrument
Vendors could improve the hardware and software in high resolution LC-MS technologies
In the

. '
areas above so the next generation LC-MS Instruments can Improve sample

throughput. Although the use of high resolution mass spectrometry has been more limited
In the field than tandem LC-MS it is envisaged that in the future this approach will
becom e much more prevalent as an analytIcal
. too1.In regu latory
Ib
.
a oratones.

The above issues are difficulties e~countered with the analytical detection tools provided

by manUfacturers of the detection technology to provide reliable LC-MS results.
Validation Protocols to be utilised with these detection systems and the particular sample
pre.treatment steps are crucial. In the sample preparation area analytical protocols that
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focus on generic extraction procedures allowing for the concurrent detection of large
numbers of compounds from a wide variety of classes is expected to rapidly expand.

Sample preparation methodologies traditionally involved liquid/liquid extraction, protein
precipitation and solid phase extraction in the vast majority of methods independent of
the sample matrix. Newer approaches utilising dilute-and-shoot preparation should be
used for the urine matrix for the future. Blood samples are usually analysed using protein
precipitation or a combination of precipitation and centrifugation. In the future sample
preparation methods will reduce the volume of sample required, minimise the number of
steps thus reducing the analytical time and solvent consumption and eliminating the need
for chlorinated organic solvents. Sample preparation SPE or other sorbent technology
formats could be reduced to 96 well-plate format. In addition automated SPE or newer
sorbent technologies e.g supported liquid extraction (SLE) or online SPE approaches
,could be utilised. The number of sorbent technologies is rapidly expanding and newer
sorbent technologies such as molecular imprinted polymers and SLE to name but a few
are becoming available allowing for clean extracts while lowering limits of detection.

The aim is the development of generic extraction protocols for a wide variety of drugs.
The drawback of generic extraction is that unavoidably more matrix components are
extracted which lead to matrix effects.
Matrix effects refer to "the direct or indirect alteration or interference in response due to
the presence of unintended analytes or other interfering substances in the sample" The
Presence of a matrix effect can have two consequences within the sample. The signal can
be enhanced (ion enhancement) due to matrix effect or the signal can be reduced (ion
suppression) this increases the probability that a sample could be false compliant or false
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non-compliant. Currently there is no consensus as to how matrix effects experiments

should be performed and it is important for the future that the matrix effect experimental
protocol be established in both fields. In addition setting of widely accepted criteria for

this parameter needs to be addressed. No criteria exist within the validation framework of
Commission Decision 2002/657/EC for matrix effects in veterinary drug residue
monitoring.

The validation criteria for maSS spectrometry in Commission Decision ZOOZI657IEC were
adopted in this thesis for veterinary drug residues and post-mortem forensic toxicology
research. The criteria within Commission Decision ZOOZI657IEC does not include TOFMS, medium to high resolution of approximately 10,000 FWHM. Due to high resolution
mass spectrometry approach becoming a valuable analytical tool in regulatory
laboratories it will be necessary to include criteria within Commission Decision
2002/657/EC .

In addition it would be helpful at a national level if laboratories could add spectra of new
designer drugs to a database that other regulatory laboratories could have access to.
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